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Type-I iodothyronine deiodinase (ID-I) is a selenoenzyme which converts thyroxine (T4) to
tri-iodothyronine (T3), and is found predominantly in liver, kidney and thyroid tissue. The
aims of this thesis were : a) to investigate the species variation in thyroidal ID -I expression,
b) to study the contribution of ID-I to T3 production in primary cultures of human and
sheep thyrocytes, c) to examine the regulation of ID-I expression by the different 2nd
messenger pathways, and d) to study the selenium dependence of ID-I expression, using
in vitro and in vivo models.
Thyroidal ID-I activity varied greatly between species, with the highest activities
found in omnivores (rat, man, guinea-pig and mouse), whiie ir; heruivuitsa (uatiie, sheep,
goat, rabbit, pig, llama and deer) thyroidal ID-I was < 0.3% of the activity found in the rat.
The livers of all species studied showed similar, and relatively high levels of hepatic ID-I
activity.
Primary cultures of sheep and human thyrocytes were established and were shown
to produce T3 in a dose-dependent fashion with respect to thyrotropin (TSH). Using
various inhibitors of ID-I activity and de novo synthesis, sheep thyrocytes were found to
produce T3 by de novo synthesis only. In contrast, human thyrocytes produced T3 solely
by deiodination of endogenous thyroxine (T4), catalysed by ID-I. In addition, T3 production
was demonstrated to be dependent on iodine supply in sheep but not human thyrocytes.
Incorporation of 125l into T3 and T4 was only observed with TSH stimulated sheep
thyrocytes.
Using human thyrocytes in primary culture I have confirmed that stimulation of ID-I
expression by TSH occurred via the cyclic-AMP second messenger cascade. Stimulation
of ID-I activity was observed when TSH (0.5 -1.0 U/L) or 8-Bromo-cAMP (10 4 mol/L) was
added to the cell medium (3 to 15 fold increase). Addition of TSH at concentrations in
excess of 5 U/L or the addition of the phorbol ester, PMA, in conjunction with the calcium
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ionophore, A23187 resulted in a decrease in the ID-I activity. Affinity labelling of ID-I with
bromoacetyl-[125l]-rT3 and in vitro labelling of ID-I with [75Se]-selenite showed that the
reduction in ID-I activity followed a reduction in the amount of the protein, and not a
change in the specific activity of ID-I. Addition of PMA/A23187 also prevented the
appearance of the TSH-induced "follicles" that were usually observed in monolayer culture.
In human thyrocytes grown in selenium free medium, a small but significant
increase in ID-I activity was observed as the extracellular selenium concentration was
increased (0 to 1 pM), but this only occurred in the presence of TSH. In the absence of
selenium, TSH was still able to induce an increase in ID-I activity. Human thyrocytes were
also found to take up and retain [75Se]-selenite in a temperature-dependent manner,
suggesting that this is an energy-dependent process. The uptake could not be stimulated
by TSH.
The effects of dietary selenium and/or iodine deficiency in rats was also studied.
Selenium deficiency caused a decrease in hepatic ID-I activity to approximately 15% of the
control value. Iodine deficiency had no significant effect on hepatic ID-I activity. Total
thyroidal ID-I activity did not decrease in selenium deficiency, and infact increased in both
/ r
iodine and combined iodine and selenium deficiencies, with this rise most probably
resulting from increased ID-I expression signalled by elevated plasma TSH.
These studies show that : a) thyroidal ID-I expression varies greatly between
spocifeo, b) human thyrocytes in primary culture utilize ID-I for T3 production, while sheep
thyrocytes rely on de novo synthesis, c) thyroidal ID-i expression is under the control of
both the cAMP (+) and PI (-) second messenger pathways, and that d) thyroidal ID-I is
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Section 1 : INTRODUCTION
1.01 : Anatomy and structure of the thyroid gland
The thyroid gland is a "butterfly" shaped organ located in front of the upper trachea, and
consists of two lobes joined together by a small piece of tissue known as the isthmus.
The primary role of the thyroid is tosynthesise store and subsequently secrete the thyroid
hormones, thyroxine (T4) and 3,3',5-triiodothyronine (T3) into the bloodstream. The thyroid
gland develops in the human embryo from an invagination in the floor of the primitive
pharynx at the level of the first and second branchial arches. This invagination grows
downwards from the back of the tongue in front of the primitive pharynx, to form a flask¬
like vesicle with a narrow neck. This vesicle slowly bifurcates as it continues to grow
downwards to its final position in front of the upper trachea. During the descent, the
vesicle becomes a solid mass of epithelial cells and loses its connection to the pharyngeal
cavity. During atrophy of this connection, small pockets of thyroid epithelial cells can be
left along the path taken by the descending thyroid, and hence give rise to functional
ectopic thyroid tissue, Before reorganisation of the epithelial cells into follicles, the
ultimobranchial body which develops from the fourth branchial pouch, transports
calcitonin-producing C cells to the thyroid (Ericson and Fredriksson, 1990).
The basic functional unit of the thyroid is the follicle. The follicle is a spherical,
cyst-like structure consisting of a single layer of epithelial cells which encloses the lumen.
The lumen contains colloid secreted by the epithelial cells and consists of a glycoprotein-
rich solution which is involved in the synthesis and storage of thyroid hormones. The
follicles are surrounded by a thin basal lamina, with the extrafollicular spaces containing
capillaries, lymph ducts, nerves and C cells. The intercellular spaces in the wall of the
follicle are sealed by tight junctions which bind the follicular cells together and form a
barrier between the extrafollicular space and the lumen. In addition, the tight junctions
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maintain the distinct composition and properties of the apical and the basolateral
membranes. The apical membrane has been shown to have microvilli present on its
surface, and the presence of peroxidase, aminopeptidase and hydrogen peroxide
generating enzymes which are involved in thyroid hormone synthesis. In contrast, the
basolateral membrane lacks microvilli and the enzymes involved in thyroid hormone
synthesis, but unlike the apical membrane, it contains high levels of Na+-K+-ATPase
activity and is believed to have Na+-I" cotransporter proteins associated with it (Elkholm
and Bjorkman, 1990). The differences between the apical and basolateral membranes
reflect the differing functions of these membranes in thyroid hormone synthesis and
secretion, and will be explained later in this chapter.
In addition to the follicular cells or thyrocytes which are the predominant type of
epithelial cells in the thyroid, this organ also contains a small number of C cells. These
cells are not involved in thyroid hormone synthesis or secretion but instead produce and
secrete calcitonin, a hormone involved in calcium homeostasis.
1.02 : Structure of thyroid hormones
The thyroid is the sole source of thyroxine (TJ which is the predominant hormone
secreted by this endocrine gland. Although T4 is the most abundant thyroid hormone, the
biological actions of thyroid hormones are mediated through 3,3',5-triiodothyronine (T3),
as described below. In addition to T3 and T4, there is a further thyroid hormone 3,3',5'-
triiodothyronine (rT3) which has very low biological activity, and is predominantly formed
by catabolism of T4. All three thyroid hormones are iodinated derivatives of two tyrosine
residues coupled together by an ether bond, and are also knows as iodothyronines (figure
1 a). The phenolic ring of the iodothyronines is regarded as the outer ring, and the iodine
positions on this ring are described as either 3' or 5'. The other ring with an alanine side
group is regarded as the inner ring, and its iodine positions are designated as 3 or 5.
2
Figure 1a : Structure of iodothyronines.
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The numbering of the iodine positions within iodothyronines allows for easier description
of the various reactions which thyroid hormones can undergo.
1.03 : Synthesis and secretion of thyroid hormones
The first step in the pathway leading to thyroid hormone secretion is the trapping of iodide
within the thyrocyte (figure 1 b). Although the basic biochemical mechanism for transport
of iodide across the basolateral membrane has not been fully elucidated, the mechanism
is believed to be an active process (Wolff, 1964), involving a cotransporter of Na+ and I"
which transports one I" ion against its concentration and electrical gradient. This transport
is driven by the cotransport of two Na+ ions into the thyrocyte down the electrochemical
gradient of Na+ (Nakamura etal, 1988). Maintenance of this Na+ electrochemical gradient
is provided by the activity of a Na+- K+-ATPase and hence the energy to transport iodide
is provided indirectly by ATP hydrolysis. Transport of iodide is inhibited by a very large
range of compounds which either reduce intracellular ATP concentrations (metabolic
inhibitors), inhibit Na+- K+-ATPase (cardiac glycosides) or are anions competing for the
transporter binding site (halides, pseudohalides, complex anions). Once inside the
thyrocyte iodide is not metabolised, but instead leaks across the apical membrane,
possibly through iodide channels, to the lumen (Nakamura et al, 1988).
The second step in thyroid hormone production is the oxidation of iodide and
subsequent iodination of the tyrosyl residues found on thyroglobuiin. Thyrogobulin is a
very large glycoprotein (molecular weight = 660 kDa) secreted by the thyrocyte into the
follicle lumen. During the vesicle mediated secretion of this protein, thyroglobuiin is
glycosylated, phosphorylated and sulphonated on its passage through the rough
endoplasmic reticulum and Golgi apparatus (Elkholm and Bjorkman, 1990). Thyroglobulin
comprises approximately 80% of the soluble protein fraction in the thyroid, and its tyrosyl
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Figure 1 b : Diagrammatic representation of the steps in thyroid hormone biosynthesis
and secretion.
membrane is oxidized by the haem containing, membrane bound enzyme, thyroperoxidase
(TPO) which has a molecular weight of approximately 100 kDa. Oxidation of iodide to the
higher oxidation state required for iodination of tyrosine can only be performed by
hydrogen peroxide (H202) or molecular oxygen, as these are the only compounds which
have sufficiently high redox potentials to allow this reaction to occur. H202 has been
shown to be produced by the thyroid and hence TPO is believed to use H202 to oxidize
iodide. There has been a great deal of speculation as to the exact mechanism
responsible for the production of H202, with the NADPH-cytochrome c reductase,
monoamine oxidase, xanthine oxidase and NADH/NADPH-cytochrome b5 reductase
enzyme systems all being implicated at some time or other (DeGroot and Niepomniszcze,
1977; Yamamoto and DeGroot, 1975; Ohtaki et al, 1981; Ohtaki etal, 1982). The process
is now known to be NADPH-dependent (Virion et al, 1984) with two possible mechanisms
used. Nakamura etal have postulated that an NADPH oxidase produces superoxide (02")
which is then used by superoxide dismutase to generate H202 (Nakamura et al, 1987).
Other workers have proposed that the NADPH oxidase is auto-oxidized by molecular
oxygen to form an active species which is capable of producing H202 (Dupuy etal, 1990).
The mechanism by which TPO catalyses oxidation of iodide and subsequently the
iodination of tyrosyl residues is also unclear at present. Many alternative mechanisms
have been proposed for this iodination, with three proposals receiving the most attention.
These involve either free radicals, iodinium ions (l+) or a hypoiodite intermediate (Nunez
and Pommier, 1982; Ohtaki etal, 1981; Magnusson etal, 1984), and each makes use of
H202 to raise the oxidation state of the free enzyme to form an activated complex
(compound I), which is then reduced back to the native state on oxidation of iodide
(Bjorkman and Elkholm, 1990; Taurog, 1992). Irrespective of the mechanism used by
TPO, tyrosyl residues in thyroglobulin are iodinated using I" and H202 to form mono- and
diiodotyrosyl residues. These residues are then coupled by TPO within thyroglobulin via
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a 3 step reaction, to produce iodothyronines. The iodotyrosyl residues are first oxidized
by TP0/H202 to activated forms which can then couple spontaneously within the same
thyroglobulin molecule to produce a quinol ether intermediate. This intermediate then
undergoes a structural rearrangement to form an iodothyronine residue and
dehydroalanine (Taurog, 1992). The iodothyronine residue formed depends on the two
iodotyrosyl residues coupled. Two diiodotyrosyl (DIT) residues when coupled will yield
a T4 residue, while one DIT residue and one monoiodotyrosyl (MIT) residue will couple to
yield a T3 or rT3 residue, with the MIT residue forming the phenolic or outer ring.
The third step in T3 and T4 synthesis is the recovery of iodinated thyroglobulin from
the follicle lumen and its subsequent hydrolysis, lodinated thyroglobulin is believed to be
taken back into the thyrocyte by macropinocytosis and micropinocytosis. There is some
evidence to suggest that normally iodinated thyrogobulin is selectivity taken up by both
of these types of endocytosis in preference to low-iodinated thyroglobulin (Elkholm and
Bjorkman, 1990). The thyroglobulin-containing vesicles migrate towards the basolateral
membrane, and en route fuse with lysosomes. These lysosomes contain a complex
mixture of enzymes (phosphatases, nucleases, proteases, glucoside hydrolases and
lipases) generically termed, acid hydrolases since they require an acidic environment for
optimum catalytic activity (pH 5). Evidence has been found for an ATP-driven H+ pump
for maintenance of this optimum pH (Fouchier et at, 1984). Hydrolysis of thyroglobulin
yields iodothyronines (T4, T3, rT3), iodotyrosines (MIT, DIT) and small peptide fragments.
Almost all of the MIT and DIT released from thyroglobulin is deiodinated by iodotyrosine
deiodinase, an enzyme distinct from ID-I, and the products are then recycled. The
iodotyrosine deiodinase has been shown to be a flavoprotein which is capable of
deiodinating DIT and MIT, but not T4 (Rosenberg and Goswami, 1979). This enzyme is
found in the mitochondria and microsomes of the thyroid and several peripheral tissues
and is NADPH-dependent.
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It was originally thought that 5'-deiodination of T4 to T3 did not occur in the thyroid,
however it is now clear that significant levels of deiodination can occur (Erickson et al,
1981; Taurog, 1992). The enzyme responsible for this deiodination of T4 is the same as
that found in liver and kidney, but unlike the liver and kidney forms of ID-I, thyroidal ID-I
can be stimulated by the activation of the TSH-receptor (Erickson et al, 1982; Ishii et al,
1981; Ishii etal, 1983; Pazos-Moura et al, 1991). This enzyme will be described in detail
in a later chapter.
The iodothyronine hormones are believed to passively diffuse out of the thyrocyte,
though there may also be a carrier protein involved in this process (Bjorkman and
Elkholm, 1990). Once through the basolateral membrane, the iodothyronines enter the
genera! circulation via the capillary blood vessels found in the extrafollicular spaces.
1.04 : Control of thyroid function
Control of thyroid function is exerted by the hypothalamic-pituitary-thyroid axis and has
been well described (Reichlin, 1986). In summary, the hypothalamus secretes three
neurohormones which are involved in the regulation of thyrotropin (TSH) release from the
anterior pituitary. Thyrotropin-releasing hormone (TRH) which is a tripeptide
(pyroglutamyl-histidyl-prolinamide) stimulates TSH release from the anterior pituitary, while
release of TSH is inhibited by somatostatin (a 14 amino acid peptide) and by dopamine
(a monoamine) (figure 1c). As a result of TRH stimulation, the anterior pituitary releases
TSH, a 28 kDa glycoprotein consisting of two dissimilar, noncovalently linked subunits (a
and p). The a subunit is structurally homologous to the a subunits of follicle stimulating
hormone (FSH), luteinizing hormone and human chorionic gonadotrophin (hCG), while the
P subunit confers biological activity on TSH when associated with the a subunit.
Furthermore, TSH is believed to exist in many different isoforms, which have different
relative biological activities. Using a rat thyroid cell line (FRTL-5), acidic forms of TSH
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TSH
Figure 1c : The hypothalmic-pituitary-thyroid axis (N.B. the action of somatostatin
within the diagram is also true of dopamine).
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were shown to accumulate more cAMP than alkaline forms, whereas opposite potencies
were observed with respect to stimulation of iodide and thymidine uptake (Pickles et al,
1992).
TSH release is also influenced by a thyroid hormone feedback mechanism. High
concentrations of pituitary T3 have been shown to reduce both the release and synthesis
of TSH, possibly mediated by the increased production or release of an inhibitory factor.
This increase in pituitary T3 can be caused by increased pituitary 5'-monodeiodination of
T4 by type-ll 5'-iodothyronine deiodinase or by high plasma T3 levels. Feedback regulation
of TSH release by high levels of thyroid hormones has also been shown to occur at the
level of the hypothalamus. High levels of thyroid hormones are thought to induce the
release of somatostatin, with no evidence for the inhibition of TRH release (Berelowitz et
al, 1980).
Historically, TSH was believed to be the sole regulator of thyroid function, with its
activity mediated by the cyclic-AMP second messenger cascade (Dumont, 1971).
However, it is now thought that the thyroid is also under the control of a rather
complicated network of agents including TRH, ATP, ibradykinin , dopamine and serotonin,
in addition to TSH which is the main regulator of thyroid function (Raspe and Dumont,
1992). TSH and these other regulatory compounds are thought to mediate their effects
by activation of specific receptors, which in turn activate one or more of the second
messenger systems found in the thyrocyte. Three second messenger systems have been
identified in the thyrocyte. These are the cAMP, Ca2+-phosphatidylinositol (Ca2+-PI) and
tyrosine kinase cascades. The activation of these cascades will now be summarized
The generation of cAMP as a result of hormone action was first described over 25
years ago (Butcher et al, 1967) and since than has been well characterised (Birnbaumer
/
et al, 1990). The cascade in the thyrocyte is activated when a ligand, typically TSH in
vivo, binds to and activates its receptor. The activated receptor associates with a
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stimulatory GTP-binding transduction protein (Gs) causing the exchange of GDP for GTP,
and hence the dissociation and activation of the a subunit of this protein. The activated
a subunit activates the catalytic subunit (adenylate cyclase) leading to the production of
cAMP from intracellular ATP. Subsequently the activated a subunit returns to its inactive
state when the GTP is hydrolysed to GDP by the intrinsic GTPase activity of the a subunit.
As a result of adenylate cyclase activation, an accumulation of intracellular cAMP
occurs and this activates the phosphorylation of specific target proteins by protein kinase
A, which exists in a number of isoforms. The activity of the cAMP cascade is highly
regulated and cAMP is hydrolysed by specific phosphodiesterases which terminate the
cAMP signal (Beavo and Reipsynder, 1990). Activation of the cAMP cascade is believed
to increase expression of TPO and thyroglobulin (Pratt et al, 1989; Pohl et al, 1990), with
cAMP also stimulating basolateral iodide uptake via a protein synthesis-dependent
process (Collison et al, 1989). In addition;this cascade is also believed to control
secretion of thyroid hormones, most probably by increasing endocytosis of thyroglobulin
(Dumont et al, 1971).
The existence of the Ca2+-PI second messenger cascade was more recently
discovered and described by numerous workers (Michell, 1975; Berridge and Irvine, 1984;
Nishizuka, 1984). The initial biochemical reaction of the Ca2+-PI cascade is the hydrolysis
of a minor membrane component, phosphatidylinositol 4,5-bisphosphate (PIP2) to yield
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). This hydrolysis is catalysed
by phospholipase C (PLC) which is stimulated by the a subunit of a stimulatory GTP-
binding transduction protein (Gq) in much the same way as for adenylate cyclase which
is described above. Both DAG and IP3 can be regarded as second messengers which
mediate the effects of the Ca2+-PI cascade. DAG brings about activation of a
multifunctional protein kinase (protein kinase C) when in the presence of intracellular Ca2+.
IP3 is known to increase the intracellular Ca2+ ion concentration ([Ca2+];) though release
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of Ca2+ from an intracellular store which is non-mitochondrial in origin. Increased [Ca2*],,
via activation of calmodulin and other Ca2+-binding proteins and enzymes, elicits a wide
range of cellular responses. Activation of the Ca2+-PI cascade is believed to increase
apical membrane permeability to iodide (Okajima etal, 1988), increase the generation of
H202 (Bjorkman and Ekholm, 1991) and antagonize the cAMP cascade (Decoster et al,
1980; Raspe and Dumont, 1992).
Tyrosine kinase activity in cells was first shownIO years ago (Hunter and Sefton,
1980) and it is now known that the receptors of several growth factors possess tyrosine
kinase activity (Ullrich and Schlessinger, 1990). Activation of the tyrosine kinase cascade
is initiated when two ligand activated receptors with tyrosine kinase activity form a dimer.
This receptor dimer undergoes autophosphorylation of specific tyrosine residues allowing
the recognition and phosphorylation of specific substrates to occur (Ptdlns 3-kinase,
phospholipase Cy or ras-GAP) (Ullrich and Schiessinger, 1990; Cantley et al, 1991).
These proteins all have intracellular signalling capacity which may account for the
pleiotropic action of receptors with tyrosine kinase activity.
A number of compounds have be shown to effect the function, growth and
differentiation of thyrocytes. TSH, PGE,, PGE2, histamine, dopamine, noradrenaline,
serotonin and VIP all stimulate the cAMP cascade (Raspe and Dumont, 1992). In contrast,
somatostatin causes a reduction in the intracellular concentration of cAMP, presumably
by activation of the inhibitory Grtransduction protein. TRH, bradykinin, ATP and TSH (at
approximately a 10-fold higher concentration than required for a maximum cAMP
response) have all been shown to stimulate the Ca2+-PI cascade (Chanoine et al, 1993;
Raspe et al, 1991). Although direct evidence has proved elusive, various workers have
postulated that EGF, IGF, and insulin modulate thyrocyte growth via the intrinsic tyrosine
kinase activity of their receptors (Contor et al, 1988; Formisano et al, 1991; Takahashi et
al, 1991). In a recent review, Raspe and Dumont summarized data from several workers
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and postulated the function of each cascade in thyrocyte regulation (Raspe and Dumont,
1992). It was argued that cAMP, which is mainly activated by TSH, controls the
differentiation, proliferation and the secretion of thyroid hormones. In contrast, activation
of the Ca2+-PI cascade by neurotransmitters and high levels of TSH was argued to control
thyroid hormone synthesis by regulating of the supply of H2Oa and I" to TPO. Activation
of the Ca2+-PI cascade also reduces intracellular cAMP levels, thereby antagonizing the
action of agents which elevate intracellular cAMP concentration. Finally, the action of
EGF, IGF, and insulin, which can be classified as growth factors, and was postulated to
occur via the tyrosine kinase cascade, thereby modulating thyrocyte growth while causing
dedifferentiation.
1.05 : Transport and the biological role of thyroid hormones
Transport of thyroid hormones from the thyroid to the target organs in plasma
predominantly involves their binding to a number of plasma transport proteins. These
transport proteins vary widely in their plasma concentration and affinity for the thyroid
hormones. The main advantage of having the bulk of thyroid hormones bound to plasma
proteins is to prevent excessive loss into the urine, while the hormones are still readily
available if required. There are three plasma proteins which are responsible for binding
thyroid hormones. The first of these proteins is thyroxine-binding globulin (TBG) which
has a molecular weight of 54 kDa. This a2 globulin binds 70% of plasma T4, 80% of
plasma T3 and consists of a single polypeptide chain with 4 complex polysaccharide units
on its surface. TBG is present in the plasma at a concentration of approximately 3.6 x 10"7
mol/L, and has one binding site per molecule. In contrast thyroxine-binding prealbumin
(TBPA) is tetrameric, with 2 binding sites and a plasma concentration of approximately 4.6
x 10~6 mol/L. TBPA also has a molecular weight of 54 kDa, and binds 20% of T4 and 10%
of T3. Finally, the monomeric protein albumin, with its 7 binding sites and molecular
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weight of 66 kDa, binds approximately 10% of both T4 and T3. These three proteins bind
virtually all the T4 and T3 found in the plasma, leaving less than 0.05% of T4 and 0.5% of
T3 circulating as free hormones (Robbins and Edelhoch, 1986).
Entry of thyroid hormones into cells has previously been regarded as a passive
diffusion process. However, there is considerable evidence for the active transport of
thyroid hormones, with endocytosis and a Na+ ion facilitated transporter both implicated.
Once inside the target cell both T4 and T3 can bind to a number of soluble proteins, the
identity of which varies between tissues. Of the cytosol thyronine-binding proteins (CTBP)
which have been found, so far only a few have been identified, and these include
haemoglobin, myoglobin, glutathione-S-transferases (GSTs) and pyruvate kinase (Davis,
1992). The effect of T4 and T3 on these proteins is not fully characterized, though the
activities of both pyruvate kinase and the GSTs are inhibited by these thyroid hormones.
Intracellular T4 has also been shown to cause an increased degradation of type-ll
iodothyronine deiodinase via the rearrangement of f-actin, a major component of the
cytoskeleton (Safran et al, 1993).
The main sites of T3 action are the mitochondria and the nucleus. There is
considerable evidence to support an effect of T3 on the mitochondria, with 3 possible site
of action implicated (Davis, 1992). The first of these is the inner mitochondrial membrane
protein, ADP - ATP translocase. This protein has been shown to bind a significant amount
of T3, and is known to transport ADP into the mitochondria in exchange for ATP.
Regulation of ATP synthase is also believed to be under the control of T3, with T3
increasing the activity of this ATP generating enzyme. Finally, the expression of various
components of the electron transport chain are also increased by T3. By stimulation of
these 3 components, T3 can bring about increased ATP production by increasing oxidative
phosphorylation.
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The ability of T3 to bind to a nuclear receptor has been known for some time.
However in the last 10 years the nature of this interaction has been described in more
detail. The current state of knowledge has been summarised in a recent review
(Oppenheimer, 1992). To simplify this further, the main elements which confer the actions
of T3 are coded for by two genes of the c-erb A superfamily of genes, which are classified
as c-erb A-a and c-erb A-p. As a result of alternate splicing, the c-erb A-a gene gives rise
to mRNA for 3 distinct proteins (a,, a2 and rev-erb A). The a, product is known to bind T3
and exhibit similar binding characteristics as T3 receptors isolated from nuclei. The a2 and
rev-erb A products do not bind T3 and are believed to be involved in the regulation of
gene expression by competing with the active receptors for the sites of receptor-DNA
interaction. The c-erb A-p gene gives rise to 2 distinct mRNA products, p, and p2, the
protein products of which bind T3. The expression of these 5 proteins varies widely
between species and tissues, though in general, the a, and p, are believed to bind T3 and
mediate the appropriate changes in gene expression. The T3-receptor complex is believed
to bind to a gene specific sequence of nucleotides, upstream from the transcription start
site. These nucleotides sequences are termed, thyroid response elements (TRE). The
TRE for the growth hormone (GH) gene is known to lie between nucleotide residues, -190
and -173. Interaction of the T3-receptor complex is believed to involve "zinc fingers", with
evidence in support of the T3-receptor complex acting in a heterodimeric form. The
interaction of the T3-receptor complex with the TRE is believed to increase transcription
of the gene, and hence increases mRNA formation for the appropriate specific protein.
1.06 : Metabolism of thyroid hormones
Thyroid hormones (iodothyronines) can undergo various reactions classified as either 5'-
monodeiodination, 5-monodeiodination, conjugation, decarboxylation, deamination or
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ether bond cleavage. The importance and occurrence of these various reactions are
described below and summarised for T4 in figure 1d.
a) Ether bond cleavage, decarboxylation and deamination
These three reactions are the least important in the metabolism of iodothyronines (Visser,
1990). Ether bond cleavage is an oxidative reaction which occurs when tissue peroxidase
activity is stimulated, and yields diiodotyrosine as one of its products. This reaction is
believed to occur in phagocytosing leucocytes, and may be more important in the rat than
in man.
Decarboxylation and deamination are side chain modification reactions both of
which can occur in man. Decarboxylation and deamination of T4 account for only 2% of
T4 metabolism forming 3,3',5,5'-tetraiodothyroacetic acid (TA4). In comparison,
decarboxylation and deamination of T3 accounts for about 14% of T3 metabolism, forming
3,3',5-triiodothyroacetic acid (TA3).
b) Conjugation reactions of iodothyronines
Conjugation of compounds is a major metabolic reaction for the disposal of a large variety
of synthetic and endogenous compounds (Visser, 1990). lodothyronines are no
exception, and can be deactivated by conjugation with glucuronic acid or sulphate. Both
of these processes occur predominantly in the liver and increase the water solubility of
the iodothyronines, hence favouring excretion in the urine or bile.
Glucuronation of iodothyronines, requires uridine diphosphate (UDP)-glucuronic
acid (UDPGA) which is formed from glucose-1 -phosphate and uridine triphosphate (UTP)
via an intermediate (UDP-glucose). The conjugation of UDPGA to the OH-group of the
iodothyronine outer ring requires the catalytic activity of UDP-glucuronyltransferases
(UDPGTs), a group of homologous, transmembrane enzymes found in the liver, kidney,
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Figure 1d : Pathways for the metabolism of T4.
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intestine and numerous other tissues. The products of this conjugation are UDP (which
is recycled), and iodothyronine-glucuronide conjugates. All glucuronide conjugates
excreted in the bile can undergo enterohepatic cycling, and iodothyronines are no
exception. The action of p-glucuronidase found in the intestine allows hydrolysis of
iodothyronine-glucuronide conjugates and hence the iodothyronines can once again enter
the circulation.
Sulphation of phenolic compounds including iodothyronines is catalysed by a
homologous group of enzymes known as phenol sulphotransferases (PSTs) which are
found in various tissues including the liver, kidney, intestine and brain. Sulphation of the
4'-OH group of iodothyronines is believed to be catalysed by the TS-type PST, using 3',-
phosphoadenosine-5'-phosphosulphate (PAPS) as the sulphate donor, to yield the
iodothyronine-sulphate conjugate. The metabolic pathways of iodothyronine-sulphate
conjugates are described in the next section.
c) Deiodination of iodothyronines
The deiodination of iodothyronines plays a central and very important role in the
production of active thyroid hormone and the subsequent catabolism of the
iodothyronines. In the rat, approximately 80% of plasma T3 is normally derived from 5'-
monodeiodination of T4, with the remaining 20% being secreted directly by the thyroid
(Visser, 1988). This 5'-deiodination of T4 occurs predominantly in peripheral tissues such
as liver and kidney, and is catalysed by type-l iodothyronine deiodinase (ID-I). In addition
within certain tissues, a second deiodinase (type-ll iodothyronine deiodinase, ID-II) is
found which can catalyse 5'-deiodination of T4. However unlike T3 produced by ID-I, T3
produced by ID-II is not thought to be available to the general circulation and is utilised
locally (Silva and Larsen, 1983). Both 5 and 5'-deiodination can also deactivate thyroid
hormones by deiodination to form thyromimetically inert metabolites. Thyroxine undergoes
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5-monodeiodination to produce the inactive form of thyroid hormone, rT3. This reaction
can be catalysed by ID-I or by a third deiodinase, type-Ill iodothyronine deiodinase (ID-Ill).
The rT3 produced by ID-I or ID-II can undergo 5'-deiodination to produce diiodothyronine
(T2), which can also be produced by 5-deiodination of T3. The T2 produced by both
pathways is then subjected to further deiodination to produce 3' or 3-monoiodothyronine.
The sulphate conjugates of T2, T3 and T4 have all been shown to have lower K„,
values than their unconjugated analogues for deiodination by the type-l iodothyronine
deiodinase (ID-I). The outer ring deiodination (5'-deiodination) of T2 has been shown to
increase as a result of sulphation. In contrast, only inner ring deiodination (5-deiodination)
of T3S and T4S by ID-I is increased, with no outer ring deiodination of T3S or T4S detected.
Sulphation of rT3 has no effect on either 5 or 5'-deiodination by ID-I. Hence in general,
sulphonation of iodothyronines results in more rapid deiodination of iodothyronines within
the liver to the thyromimetically inactive forms, 3' or 3-monoiodothyronine (Visser, 1990).
1.07 : Selenium and selenoproteins
The trace element, selenium is found in the 6lh group of the periodic table, one row below
sulphur, and has an atomic weight of 78.96. Selenium and sulphur share similar chemical
properties, such as covalent radii and the ability to make use of dn-pir multiple bonding.
As selenium and sulphur are similar, compounds that contain carbon-selenium-carbon
bonds can be metabolised by the enzyme which catalyses the reaction of the
corresponding sulphur compound (Sunde, 1990).
Selenium was first recognised as an essential nutritional element in 1957 when it
was shown to prevent liver necrosis in vitamin E-deficient rats (Schwarz and Foltz, 1957).
Subsequently, glutathione peroxidase (GPx) was identified as a "functional" selenoprotein
(Rotruck et al, 1973) and consequently the action of GPx was used to explain the
synergistic effects of selenium and vitamin E supplementation in the prevention of cardiac
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and skeletal muscle myopathies, and liver necrosis observed in farm and laboratory
animals (Combs and Combs, 1986b). Other selenium-binding proteins or protein subunits
have now been demonstrated in bacteria and in animals (Evenson and Sunde, 1988;
Behne et al, 1988). Selenium can be incorporated into proteins as a selenomethionine
(non-specifically instead of methionine) or as selenocysteine (specifically in response to
acodon UGAas described below) (McConnell and Hoffman, 1972; Voordouw et al, 1989;
Chambers ef al, 1986; Mullenbach etal, 1987). To date, only 6 mammalian selenoproteins
have been identified which have selenium specifically incorporated into the protein as a
selenocysteine residue
Cytosolic glutathione peroxidase (GPx) or "classical" GPx, which was first
described by Rotruck et al, consists of 4 identical subunits, each with a molecular weight
of 23 kDa and one selenocysteine residue (Rotruck et al, 1973).
Phospholipid hydroperoxide glutathione peroxidase (PLGPx) which is found in
porcine heart and liver has been shown to be a 20 - 23 kDa monomeric selenoenzyme,
distinct from "classical" GPx (Ursini et al, 1982; Schuckelt et al, 1991). Unlike "classical"
GPx, PLGPx can metabolise phospholipid hydroperoxides, lipid peroxides and low density
lipoprotein, and is believed to prevent peroxidative damage to membranes (Thomas et al,
1990; Maiorino et al, 1991).
Plasma glutathione peroxidase (PGPx) is also distinct from the "classical" GPx and
is tetrameric with a molecular weight of 21.5 - 23 kDa per subunit (Takahashi and Cohen,
1986; Takahashi et al, 1990). PGPx is a glycoprotein, and is believed to be synthesised
almost exclusively in the kidney (Yoshimura etal, 1991). The function of PGPx may lie in
the metabolism of GSH in the kidney, and hence the protection of the membranes which
filter the blood to produce urine.
Selenoprotein P is a plasma selenoprotein with a molecular weight of 55 kDa (Burk
and Gregory, 1982) and has been shown to be a glycoprotein containing 7.5
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selenocysteinyl, 17 cysteinyl and 23 histidyl residues per mole (Read ef al, 1990). Cloning
of the protein has shown 10 inframe TGA codons which could specify selenocysteine (Hill
et al, 1991)}. The role of selenoprotein P is yet to be established though selenium
transport and antioxidant roles have been proposed.
Type-I iodothyronine 5'-deiodinase (ID-I) has been demonstrated to be a
selenoenzyme, with a UGA codon present in the mRNA for the enzyme (Berry et al,
1991 b). A full description of ID-I and its role in thyroid hormone metabolism can be found
later in this introduction.
Selenoprotein W is the most recent selenoprotein to be identified in skeletal
muscle (Vendeland et al, 1993), though its existence has previously been suggested by
studies into white muscle disease found in selenium deficient animals (Muth etal, 1959).
Four proteins were found by Vendeland et al with molecular weights of 9550, 9596, 9858
and 9898 daltons, with one selenium atom per mole of protein. At present there is no
information as to the exact structure of the native protein or its role.
The carbon for selenocysteine synthesis is known to come from serine (Sunde and
Evenson, 1987), with the synthesis of specific-selenoproteins shown in bacteria to be
dependent on the products of 4 genes (SelA, SelB, SeIC and SelD) (Bock et al, 1991b;
Burk, 1991). The SeIC gene product is a unique form of tRNA, which acts as a
serine/phosphoserine carrier and recognises the UGA stop codon. The SelA gene codes
for a pyridoxal phosphate-containing, selenocysteine synthetase enzyme which converts
the serine on the tRNA, specified by the SeIC product to selenocysteine in the presence
of the product form by the SelD protein, which is chemically equivalent to selenide. The
SelD product requires ATP and magnesium for its activity, and is thought to produce
phosphoselenoate (Ehrenreich et al, 1992). The serine is first phosphorylated to
phosphoserine before the phosphate group is substituted with selenite, as
phosphoselenoate to produce selenocysteinyl tRNA. The SelB product is required for
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cotranslation and insertion of selenocysteine into proteins and is similar to the elongation
factor Tu which transports amino acid tRNAs to the ribosome, however SelB is believed
to be selenocysteinyl tRNA specific. The gene products for selenocysteine incorporation
in eukaryotes and prokaryotes are believed to be very similar (Mizutani et al, 1992).
In addition to a UGA codon, a specific 3'-untranslated (3'ut) segment needs to be
present for human and rat ID-I expression (Berry etal, 1991a). A different 3'-ut sequence
is required for incorporation of selenocysteine into "classical" GPx, however the 3'ut
sequences of ID-I and GPx can be interchanged, without loss of expression. These 3'ut
sequences are believed to form a 3-dimensional "stem loop" structure, which allows
recognition of the UGA codon as selenocysteine instead of a termination codon. Rat
mRNA for selenoprotein P has also been shown recently to possess "stem loop" structures
in the 3'ut sequence which are required for translation (Berry etal, 1993). In contrast, the
"stem loop" structure which confers selenocysteine incorporation in bacterial formate
dehydrogenase is not in the 3'ut sequence, but in the coding region (Bock et al, 1991a;
Heiderefa/, 1992).
1.08 : Location and properties of iodothyronine deiodinases
There are 3 known isoenzymes of iodothyronine deiodinase, and these have been given
the names type-l, II and III. Although these isoenzymes have not been purified the
enzymes have been characterised on the basis of a number of physicochemical properties
and are summarised below, in table 1a and also in a number of reviews. (Kaplan, 1986;
Leonard and Visser, 1986; Silva and Larsen, 1986; Visser, 1989; Kohrle et al, 1993;









































































Table 1a : Properties of the iodothyronine deiodinases.
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a) Type-I iodothyronine deiodinase (ID-I)
ID-I has been shown to catalyse both 5 and 5'-monodeiodination and exhibits a clear
order of substrate preference, with rT3 deiodinated in preference to T4 and T3 (rT3>T4>T3).
This enzyme is localised in the microsomal membrane where it represents 0.01 - 0.025%
of membrane-associated protein. ID-I is believed to consist of two subunits with a total
molecular weight of 50 - 60 kDa, although it is unclear if the enzyme is homo- or
heterodimeric. The substrate binding subunit of ID-I has been shown using 125l-
bromoacetyl derivatives of rT3, T4 and T3 to have a molecular weight of 27 - 28 kDa. ID-I
catalyses both 5 and 5'-deiodination with the pH and level of substrate sulphation
determining which reaction predominates. The optimum pH for 5-deiodination is 8.0 - 8.5,
with optimum 5'-deiodination occurring at pH 6.5 - 7.0. Sulphation of the 4'-OH of T3 and
T4 has been shown to enhance 5-deiodination, while decreasing 5'-deiodination.
Therefore a combination of pH change and sulphation may be responsible for determining
whether ID-I primarily catalyses 5 or 5'-deiodination. At present it is unclear if 5 and 5'-
deiodination by ID-I is catalysed by the same active site. However, the reaction kinetics
and inhibitors of 5-deiodination are identical to those for 5'-deiodination, and hence this
is consistent with the use of the same site by both reactions, with some slight change or
"wobble" in the active site.
It has been proposed that the rate of deiodination by ID-I is controlled by either an
NADPH-glutathione-redox system or an NADPH-thioredoxin-dependent redox system. The
activity of ID-I has been shown to be dependent on the presence of reduced glutathione
(GSH). The ratio of reduced GSH to oxidised GSH (GSH : GSSG) appears to affect the
rate of deiodination, with the absolute concentration of GSH having no significant effect.
Data from in vivo experiments suggests that the redox state of the cell, presumably via the
ratio of GSH : GSSG, controls ID-I activity. Hence, NADPH-linked reduction of GSSG by
GSH reductase may well be the important physiological control system. However, there
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is also in vitro evidence for a GSH-independent supply of reducing equivalents to ID-I by
a NADPH-thioredoxin coupled system. Whether a similar system is present in vivo is
unclear. It is of interest that in vitro assays of ID-I activity usually make use of dithiothreitol
(DTT), which is a more potent activator of ID-I than GSH.
The reactions of ID-I have been shown to follow "ping-pong-type" kinetics. Steady-
state reaction kinetics for ID-I have shown that the reaction consists of two steps, with
reactivation of the native enzyme requiring reduced thiols (RSH) (figure 1e). The active,
reduced form of the enzyme (E-Se ) reduces the iodine-carbon bond of the iodothyronine
by the transfer of 2 electrons, with the Se of the enzyme forming a selenoyl iodide with
the newly released iodide. This partially oxidised group is then reduced by reduced thiols
to regenerate the activated enzyme. One of the important characteristics of ID-I is its
inhibition by 6-n-propyl-2-thiouracil (PTU) at micromolar concentrations; with the reaction
scheme described for ID-I elucidated with the use of this compound (figure 1e). PTU is
believed to reversibly form a stable compound with the oxidised form of the enzyme. The
activity of ID-I can also be inhibited by propranolol, gold thioglucose and by iodinated
radiocontrast agents (ipodate and iopanoic acid). The mechanism of action for
propranolol remains to be elucidated, while the competitive inhibition by radiocontrast
agents may rest in the iodine content of this group of compounds. A mechanism of action
for gold thioglucose has been suggested (Berry etal, 1991c), and involves the formation
of a stable complex when gold reversibly binds to the reduced form of the enzyme (figure
1 e).
The first evidence that selenium was required for the function of ID-I came from a
series of comprehensive studies using selenium deficient rats. These experiments have
been comprehensively reviewed recently (Beckett and Arthur, 1993). The first suggestion
that ID-I was a selenoenzyme came when selenium status was observed to affect plasma
T4 and T3 concentrations. Selenium deficiency caused significant increases in plasma
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Figure 1e : Proposed mechanism of Type-I iodothyronine deiodinase and its inhibition
by PTU and gold thioglucose.
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total and free T4 concentrations, and was accompanied by a reduction in plasma total T3.
ID-I activity in the liver and kidney homogenates was markedly impaired in selenium
deficiency, and could not be restored by adding thiols or pyridine nucleotides. The
described changes occurred within four weeks, and ID-I activity could be restored within
3 days by a single, 200pg intraperitoneal injection of selenite. The decreased ID-I activity
was shown not to be due to reduced food intake, increased oxidative damage, lack of
essential co-factors or the presence of an ID-I inhibitor. This evidence lead to the
suggestion that ID-I was a selenoenzyme.
To confirm this hypothesis, 75Se-selenite was administered to rats, and this resulted
in the substrate binding subunit of ID-I being labelled with 75Se (Arthur et al, 1990b).
Other workers independently produced similar 75Se labelling of ID-I using the rat as a
model and subsequently showed that astoiochiometricamount of selenium is associated
with the ID-I substrate binding subunit (Behne et al, 1990). In addition, affinity labelling
experiments using [125l]-bromoacetyl derivatives of rT3, T3 and T4 confirmed that the fall in
ID-I activity observed in selenium deficiency was due to decreased expression of ID-I and
not a modification of enzymic activity (Arthur et al, 1991b; Beckett et al, 1992).
Whilst the above experiments were being reported, Berry and Larsen were using
expression cloning in Xenopus oocytes to characterise rat ID-I. The full details of these
experiments and subsequent work can be found in a recent review (Berry and Larsen,
1992). In summary, rats were made hyperthyroid by administration of 5 daily injections
of T3. Subsequently, Poly A + mRNA was prepared from hepatic tissue using standard
methods and reverse transcribed using an Xba 1 oligo dT primer. The cDNA was size-
selected for sequences between 1.8 and 2.6 kb, ligated to EcoR1 adaptors and then
inserted in the phage vector k Zap II. The resulting library was subdivided, amplified and
converted to a blueprint plasmid by in vivo excision. Plasmid DNA was linearised and
transcribed in vitro by using T7 RNA polymerase. Xenopus oocytes were then injected
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with 0.5 - 20 ng mRNA and subsequently assayed for deiodinase activity. Once a positive
pool of clones was identified, a matrix approach was used to isolate a single clone
encoding deiodinase activity. Using the outlined methods, these workers identified a 2.1
kilobase section of complementary DNA which coded for ID-I. The sequence of mRNA
obtained from this cDNA sequence was shown to contain an in-frame uracil-guanine-
adenine (UGA) codon at the 382-384 position. As describe above, the UGA codon is
normally read as a stop codon, but can also serve as the codon for selenocysteine. Site
directed mutagenesis of the UGA codon to UUA (code for leucine) or UAA (another stop
codon) resulted in an inactive ID-I mutant protein being formed. Changing the UGA codon
to UGU, which codes for cysteine resulted in a mutant ID-I with only 20% of the activity
exhibited by the wild type enzyme (Berry et al, 1991b). As described previously a 3'ut
sequence which allows the formation of a "stem loop" structure was found to be required
for full translation of ID-I mRNA. Berry and coworkers also showed that two of the
histidine residues (positions 158 & 174) in rat ID-I were important for maximum ID-I activity,
with the histidine residue at position 174 found to be required for hormone binding (Berry,
1992). Subsequent cloning of the human ID-I has revealed that it also has a UGA codon
at position 382, and the predicted amino acid sequence has 88% homology with the rat
ID-I (Mandel et al, 1992).
ID-I was originally thought to occur only in the liver and kidney. However, ID-I
activity has now also been found in a wide range of other tissues including skeletal
muscle, heart, spleen, lung, intestine, lactating mammary glands, salivary glands, pituitary,
brain and white adipose tissue. However, ID-I activity in these tissues is quite low,
ranging between 0.1 and 5% of the activity found in liver and kidney. The thyroid also has
an ID-I which appears to have even higher levels of activity than hepatic ID-I (Green, 1978;
Erickson et al, 1981). Thyroidal ID-I has been shown to have similar reaction kinetics,
sensitivity to PTU, substrate specificity, and mRNA identity to that of hepatic ID-I.
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However, unlike hepatic ID-I whose expression can be induced by thyroid hormones,
thyroidal ID-I expression is induced by TSH and thyroid stimulating immunoglobulins
(TSIs) (Erickson et al, 1982; Wu, 1983; Ishii et al, 1981).
b) Type-ll iodothyronine deiodinase (ID-II)
Unlike ID-I, ID-II can only catalyse 5'-deiodination, and hence lacks 5-deiodinase activity
(table 1a). ID-II has been shown to be membrane bound, with a substrate binding subunit
which exhibits a molecular weight of approximately 27 - 29 kDa. Gel filtration studies have
suggested that native ID-II may have a molecular weight of approximately 200 kDa (Safran
etal, 1991; Safran and Leonard, 1991). Studies into the substrate specificity of ID-II have
revealed that T4 is the preferred substrate, with rT3 the other main substrate deiodinated
by ID-II. As with ID-I, ID-II has an absolute requirement for reduced thiols (RSH).
However, ID-II requires much higher concentrations of RSH, and as yet the physiological
form of RSH has not been elucidated. The 5'-deiodination catalysed by ID-II is believed
to follow "sequential type" reaction kinetics, although the exact mechanism is unknown.
Sequential reaction kinetics imply that both the cofactor and substrate interact with ID-II
prior to the formation of the product. ID-II has been shown to be insensitive to PTU
inhibition at micromolar concentrations, and this confirms that ID-II does not utilise a
hyperreactive Se' group. However, radiocontrast agents do competitively inhibit ID-II as
well as ID-I, although the mechanism of action is once again unclear.
The level of ID-II activity found in the brain, pituitary and brown adipose tissue
(BAT) has been shown to decrease in selenium deficiency, and this observation originally
led workers to believe that ID-II was a selenoenzyme (Beckett etal, 1989). It is noteworthy
that when selenium and iodine deficiency occur together, brain ID-II activity increases,
while pituitary and BAT ID-II activity decreases (Arthur etal, 1991a). The exact mechanism
underlying this divergence of expression is as yet unknown, however levels of brain ID-II
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have been shown to rise in thyroidectomized rats, and hence a change in thyroid hormone
status is implicated (Chanoine et al, 1992). In contrast to Beckett and Arthur's
observations, other workers using cultured glial cells have shown that ID-II activity is
unaffected by the concentration of selenium in the growth medium (Safran et al, 1991).
In addition, these workers could not demonstrate incorporation of 7SSe into ID-II when glial
cells were grown in the presence of [75Se]-selenite. Furthermore, ID-II has been shown
to be 100-fold less sensitive to inhibition by gold thioglucose than ID (i.e. similar in
sensitivity to the cysteine mutant of ID-I) (Berry and Larsen, 1992). Although ID-II has not
been cloned as yet, the above evidence strongly suggests that ID-II is not a
selenoenzyme. It is thought that the enzyme has a cysteine residue instead of
selenocysteine at its active site. The decrease in ID-II observed by Beckett and Arthur in
selenium deficient rats can be explained by elevation of plasma T4 (Beckett et al, 1989).
Selenium deficiency results in reduced ID-I activity and hence elevated plasma T4. High
plasma T4 is believed to cause increased degradation of ID-II, resulting from increased
inactivation and internalisation of the enzyme. T4 promotes a rapid interaction of ID-II with
F-actin stress fibres, and this results in the removal of ID-II and its transport to endosomes.
In the absence of T4, the internalisation of the enzyme is much slower and is directed to
dense lysosomes by an F-actin independent pathway (Farwell and Leonard, 1989; Farwell
etal, 1993).
The tissue distribution of ID-II is much more limited than ID-I, with only the brain,
central nervous system (CNS), pituitary and BAT shown to express ID-II. The role of ID-II
is though to be restricted to local production of T3, though the T3 status of these tissues
has widespread effects on metabolism.
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c) Type-Ill iodothyronine deiodinase (ID-Ill)
Little is known about ID-Ill. The enzyme is known to catalyse 5-deiodination in a reduced
thiol-dependent manner utilising sequential reaction kinetics. Unlike the other IDs, ID-Ill
appears to prefer T3 to T4 as the substrate for deiodination, and thus ID-Ill can be
considered as an enzyme of thyroid hormones deactivation. ID-Ill is believed to be
membrane bound, but its molecular weight has not been determined. The enzyme has
been shown to be insensitive to PTU, but like the other IDs it is competitively inhibited by
radiocontrast agents. Furthermore, like ID-II it is not thought to be a selenoenzyme. ID-Ill
is found in the brain, CNS, placenta and skin, though its role is uncertain. In the placenta,
ID-Ill may act to supply iodine to the foetus. Under normal conditions, ID-Ill is the main
source of plasma rT3 (Hennemann, 1986).
1.09 : Thyroidal ID-I and its role in thyroidal T3 production
Under normal conditions the thyroid provides approximately 20% of plasma T3, with the
bulk of T3 being derived from peripheral 5'-deiodination of plasma T4 (Visser, 1988). The
production of T3 by the thyroid is generally thought to result from de novo synthesis
(Adams and Larsen, 1973). However Green suggested that a system, independent of the
thyroperoxidase (TPO) was responsible, at least in part for thyroidal T3 production (Green,
1978). This system has been suggested to be ID-I, and the importance of ID-I in thyroidal
T3 production has now been reaffirmed (Laurberg, 1980; Laurberg, 1984). Laurberg using
perfused dog thyroids showed that preferential accumulation of T3 and rT3 was inhibited
to some degree by PTU, but not by methimazole. PTU and methimazole both inhibit
thyroid hormone synthesis, but PTU in addition can inhibit ID-I. Hence, Laurberg argued
that a significant proportion of T3 was produced from 5'-deiodination of T4.
In conditions which give rise to elevated plasma TSH such as iodine deficiency,
there is a switch to thyroidal T3 as the main source of plasma T3 (Adams and Larsen,
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1973). This switch is believed to be the main adaptive mechanism for limiting the serious
effects of iodine deficiency (Silva, 1985). Iodine deficiency thus leads to a decrease in
plasma T4, while plasma T3 is maintained. Presumably this decrease in plasma T4
diminishes the negative feed back control of TSH secretion, exerted by T4 at both the
hypothalamus and the pituitary. Hence an increase in TSH secretion occurs, with a
subsequent rise in plasma TSH. In addition to the observed increase in thyroidal T3
production, the amount of T4 produced is reduced. The mechanism by which plasma TSH
causes these changes in thyroidal T3 and T4 production is under debate. The ratio of T3
to T4 on thyroglobulin has been shown to rise in iodine deficiency, and hence one
proposed mechanism is that TSH mediates its changes via increased de novo synthesis
of T3 (Adams and Larsen, 1973). Presumably, as a result of lower thyroidal iodine
concentration, the prevailing conditions favourthe production ofmonoiodotyrosyl residues
on thyroglobulin. Hence the probability of two diiodotyrosyl residues coupling to form T4
is lowered, while the probability of a mono and a diiodotyrosyl residue coupling to form
T3 is increased.
Another hypothesis is that T3 is increased through enhanced intrathyroidal 5'-
deiodination of T4 to T3. The thyroid is known to contain ID-I, and TSH has been shown
to stimulate the expression of ID-I via the cyclic-AMP second messenger cascade
(Erickson et al, 1982; Wu, 1983; Ishii et al, 1983). Pazos-Moura and coworkers
demonstrated in the rat that iodine deficiency can cause elevation of thyroidal ID-I activity
(Pazos-Moura et al, 1991). As a result of their findings, these workers postulated that
intrathyroidal 5'-deiodination of T4 is an important mechanism in the preferential production
of T3 by the thyroid in iodine deficiency, a hypothesis also supported by other workers
(Green, 1978; Laurberg, 1980; Laurberg, 1984; Chanoine et al, 1993).
In addition to 5'-deiodination, Laurberg also presented evidence for preferential
secretion of T3 (Laurberg, 1980). This effect was postulated to be due to more rapid
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liberation of T3 from thyroglobulin than T4, however the effect was short lived and is
therefore unlikely to contribute significantly in conditions which give rise to long term
elevation of plasma TSH. A combination of increased de novo synthesis and thyroidal 5'-
deiodination are therefore the most likely mechanisms which could give rise to the
increased production of T3 by the thyroid under TSH stimulation.
Various groups have studied the source of thyroidal T3 using isolated human
thyrocytes grown in monolayer or suspension culture. Ollis and coworkers demonstrated
that T3 could be secreted by thyrocytes in primary culture in response to stimulation by
TSH (Ollis et al, 1985). However, this secretion of T3 was found to result from the release
of preformed T3, with no evidence that human thyrocytes in culture could synthesis T3.
Other workers have proposed that T3 secreted by thyrocytes can arise from de novo
synthesis (Kraiem etal, 1988). Kraeim's findings were supported by Sato and coworkers
who demonstrated iodine trapping, organification and release of thyroid hormones from
follicular thyrocytes in suspension culture (Sato et al, 1988). Enhancement of these
markers of thyroid function where observed in the presence of DMSO (1.7%) and low FCS
(1%). These workers concluded that human thyrocytes can synthesis T3 and T4 de novo
so long as they are not allowed to dedifferentiate. Hence they proposed that 1.7% DMSO
and lower FCS (1%) prevented the dedifferentiation of the thyrocytes and thus allowed
maintenance of normal function.
1.10 : Iodine, selenium and thyroid hormone status
In addition to selenium, iodine is also considered to be a trace element, found in group
7, row 5 of the periodic table. Iodine is required for thyroid hormone synthesis, and thus
iodine deficiency has a profound effects on thyroid hormone status. The effects of iodine
deficiency have been known for a long time, with iodine deficiency believed to cause two
distinct forms of cretinism. Neurological cretinism is believed to be caused by maternal
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iodine deficiency during the development of the fetus, and as its name suggests, involves
severe impairment of mental development, though stunted growth is not usually observed.
In contrast, myxoedematous cretinism is caused when iodine deficiency occurs during
childhood. This form of cretinism results in stunted growth and some mental deficiency.
Thus, both forms of cretinism result from hypothyroidism, but at different developmental
stages, either as a fetus or as a child. Iodine deficiency causes plasma TSH to increase,
plasma T4 to decrease, while plasma T3 tends to remain essentially unchanged. These
changes are mediated by a series of events which are initiated by transient decreases in
both plasma T3 and T4 resulting in decreased negative feed back of TSH secretion in the
pituitary and elevated plasma TSH. Elevated plasma TSH causes an increase in thyroidal
T3 production, at the expense ofT4. Hence plasma T3 levels are restored to near normal,
while plasma T4 decreases. The exact mechanisms which give rise to this switch to
thyroidal T3 production are not fully known, and are discussed above. Reduced plasma
T4 also has profound effects on the synthesis of growth hormone in the pituitary. Lower
plasma T4 in a child will result in a decreases in growth hormone synthesis, and hence
the stunted growth observed in myxoedematous cretinism. Hypothyroidism during
pregnancy can presumably t decrease maternal plasma T4 and so give rise to insufficient
T3 levels in the brain of the fetus, thus resulting in neurological cretinism (Delange, 1974;
Hetzel et at, 1988).
In various regions of the world including Northwest China and Central Africa, both
selenium and iodine deficiencies occur together and have been shown to have more
profound effects on growth and development than iodine deficiency alone (Vanderpas et
at, 1990; Goyens et at, 1987). Therefore selenium deficiency may prove to have an
important role in the pathogenesis of myxoedematous endemic cretinism, by exacerbating
some aspects of hypothyroidism associated with iodine deficiency (Arthur et at, 1990c).
Indeed markers of hypothyroidism such as increased plasma TSH and decreased plasma
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T4 are exacerbated by concurrent selenium deficiency; changes which are most probably
due to modification of the pituitary and hepatic deiodination pathways.
1.11: Aims of the thesis
The aims of the thesis were to :
1) Optimise the conditions for the growth of human and sheep thyrocytes in
primary culture, and subsequently determine the source of thyroid
hormones secreted from these cultures.
2) Investigate species differences in thyroidal ID-I activity and expression.
3) Study the control of ID-I activity and expression by TSH and the activation
of various second messenger systems using cultured human thyrocytes
in primary culture.
4) Investigate the selenium-dependence of ID-I expression and activity in
human thyrocytes grown in primary culture.
5) Determine the effects of selenium, iodine and combined selenium and
iodine deficiencies on thyroidal ID-I expression in vivo.
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Section 2 : MATERIALS AND GENERAL METHODS
2.01 : Equipment and Chemical Suppliers
Commercially available equipment and chemicals were obtained from the following
sources:-
Amersham International pic, Northern Europe Region, Lincoln Place, Green End,
Aylesbury, Buckinghamshire, U.K.
Na125l (specific activity, 44.4 MBq/pg); Na2(75Se03) (specific activity, 74MBq/mg); L-3,3',5'-
Tri-[125l]-iodothyronine ([12Sl]-rT3) (specific activity, 44 MBq/^g).
Merck Ltd, Hunter Boulevard, Magna Park, Lutterworth, Leicestershire, U.K.
Acetic acid; acrylamide; ammonium solution; bromophenol blue; chloroform; dimethyl
sulphoxide; dipotassium hydrogen orthophosphate; ethanol; glycerol; glycine;
hydrochloric acid; hydrogen peroxide; 2-mercaptoethanol; methanol; N,N'-
methylenebisacrylamide; microcrystalline cellulose; orthophosphoric acid; potassium
iodide; potassium dihydrogen orthophosphate; sodium acetate trihydride; sodium borate;
sodium chloride; sodium dodecyl sulphate; sulphuric acid; thin layer chromotography
plates (cellulose-F, 5565); tris(hydroxymethyl) methylamine.
Bio-Rad Laboratories, Bio-Rad House, Maylands Avenue, Hemel Hempstead,
Hertfordshire, U.K.
Low range molecular weight markers; N,N,N',N'-tetramethyl ethylenediamine (TEMED).
Boehringer Mannheim U.K., Lewes, Sussex, U.K.
Dispase (type II); ethylenediaminetetraacetic acid (EDTA).
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ICN Flow, Unit 18, Thame Park Business Centre, Wenham Road, Thame, Oxfordshire,
U.K.
Amphotericin B; bovine serum albumin (reagent grade, fraction V); Ca2+/Mg2+ free Earle's
balanced salt solution; Costar cell culture flasks (75 cm3); Dulbeco's modified Eagle's
medium (DMEM, w/o phenol red); Earle's balanced salt solution (EBS, w/o phenol red);
0.22 /vm filters (sterile); L-glutamine; penicillin; streptomycin; 12 well plates.
Kodak Diagnostics Ltd, Mandeviile House, 62 The Broadway, Amersham,
Buckinghamshire, U.K.
L-[125l]Thyroxine ([125I]-T4) (specific activity >44 MBq/pg); L-3,3',5-Tri-[125l]-iodothyronine
([125|]-T3) (specific activity > 44 MBq/pg).
Lockertex, Locker Wire Weavers Ltd, P.O. Box 161, Church Street, Warrington,
Cheshire, U.K.
Nylon gauze (100 and 30 pm).
Lome Diagnostics, P.O. Box 6, Twyford, Reading, Berkshire, U.K.
Worthington Collagenase (type I)
National Institute for Biological Standards and Control, P.O Box 1193, Potters Bar,
Hertfordshire, U.K.
Thyroid Stimulating Hormone (TSH) (NIBSC Code: 53/011).
Scottish Antibody Production Unit, Carluke, Lanarkshire, U.K.
Normal sheep serum; donkey anti-sheep serum; sheep anti-T3 serum; sheep anti-T4
serum.
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Sigma Chemical Company Ltd, Fancy Road, Poole, Dorset, U.K.
Adenosine 5'-triphosphate; ammonium persulphate; S-anilino-1 -naphthalene sulphonic
acid (ANS); 8-bromoadenosine 3'5'-cyclic monophosphate; bromoacetic acid n-hydroxy-
succinimide ester; controlled process serum replacement-5 (CPSR-5); Coomassie brilliant
blue (R-250 and G-250); cyanogen bromide; 5,5'-diethyl-barbituric acid (barbitone);
dipotassium hydrogen orthophosphate; dithiothreitol; gelatin; goldthioglucose; glutathione
(reduced form); glutathione reductase; iopanoic acid; methimazole; N,N-
dimethylformamide; nicotinamide adenine dinucleotide phosphate (type X); phosphate
buffered saline (PBS) powder; propylthiouracil; Sephadex G25; Sephadex LH20; sodium
selenite; tert-butanol; trichloroacetic acid; triethylamine; trypsin (type III); x-ray film (Kodak
X-OMAT XAR-5 film).
2.02 : Materials obtained from non-commercial sources
Normal human serum used to quench the ID-I assay was kindly supplied by Mr A. Jordan
(Scottish Blood Transfusion Service). Human thyroid tissue was obtained with the help
of Dr A. Toft, Dr K. MacLaren, Mr D. Lee, Sister R. Macmillan, the staff of Theatre 4 at the
Royal Infirmary of Edinburgh and the staff of Edinburgh University Department of
Pathology.
2.03 : Isolation and culture of thyrocytes
Human thyrocytes were isolated from human thyroid tissue (surplus to routine examination
by a pathologist) from patients undergoing thyroid surgery, whilst ovine thyrocytes were
isolated from sheep thyroids obtained from the local abattoir. Cells were isolated using
a modified version of a dog thyroid cell culture method (Rapoport, 1975) as previously
described (Beech et at, 1993). The tissue was finely minced with scissors and the
resulting fragments were then washed four times with EBS before digestion for 2 h in 50
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ml of an enzyme cocktail containing dispase (0.5% w/v), trypsin (0.25% w/v), coliagenase
(0.1% w/v) and BSA (2% w/v) in EBS. Following digestion, an equal volume of EBS was
added and the mixture filtered through a 100 yum mesh gauze to remove undigested
tissue. The resulting filtrate, containing released thyroid cells, was centrifuged at 125 g
for 15 min to pellet the thyrocytes and leave the majority of erthyrocytes in suspension.
The pellet was resuspended in EBS and re-centrifuged twice, and the cells finally
resuspended in 50 ml of DMEM containing 10% (v/v) CPSR-5 (fetal calf serum treated to
remove immunoglobulins and endotoxins), penicillin (100 U/ml), streptomycin (100yug/ml),
amphotericin B (2.5 yug/ml) and added glutamine (2 mmol/L). The cell suspension was
then filtered through a 30 yum mesh gauze and the cell yield measured with a modified
Neubauer haemocytometer.
Finally the thyrocytes were plated out in DMEM/10% CPSR-5 into 12-well plates
(2.5 cm diameter) at a density of 5x105 cells/well in 1 ml of medium, or into 75 cm2 flasks
in 20 ml of medium at a density of 10x106 cells/flask. The cells were incubated at 37°C
in an atmosphere of 5% C02 for 24 h before the medium was changed and any additions
made.
2.04 : Radioimmunoassay of thyroid hormones
a) Preparation of radioimmunoassay buffer
The RIA buffer was prepared by dissolving 18.42g of barbitone in 2L of distilled water
using gentle heat and agitation to obtain a 45 mmoi/L barbitone buffer. To 100 ml of the
barbitone buffer, 0.2g of thiomersal and 2.0g of gelatine were added and allowed to
dissolve using gentle heat before being returned to the bulk of the buffer. On cooling to
room temperature the pH of the buffer was adjusted to pH 8.6 using 10M NaOH and the
buffer stored at 4°C.
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b) Preparation of pre-precipitated radioimmunoassay antibodies
Pre-precipitated anti-T3 and anti-T4 antibodies were prepared by adding 0.5 ml of the
appropriate sheep serum antibody to 0.5 ml of normal sheep serum and 15 ml of donkey
anti-sheep serum. The mixture was incubated for 1 hour at room temperature before
being gently centrifuged (180g) for 5 mins, to pellet the pre-precipitated antibody. The
pre-precipitate was washed twice with barbitone buffer and stored at 4°C for use.
To determine the titre of antibody required for a sensitive radioimmunoassay an
antibody dilution curve was performed. A series of 1:2 dilutions of the antibody were
performed and 200pl of each of the dilutions were added to 600/jl of tracer (see Section
2.04c). Following a 2 hour incubation at room temperature the samples were centrifuged
at 2400g for 30 mins. The supernatant was then tipped off and the tops of the tubes
blotted dry before the tubes were counted for 125l activity (one tube was left untipped as
a blank). The dilution factor was then plotted against the % of counts retained (compared
to the blank) and the dilution factor which would yield 60% binding was determined
(example, figure 2a).
Non-specific binding (NSB) reagent was prepared in a similar way as the anti¬
thyroid hormone pre-precipitated antibodies, but using 1 ml of normal sheep serum and
15 ml of donkey anti-sheep serum only. The NSB was then diluted 1:40 and used to
dilute the pre-precipitated antibodies to give a working stock solution, with binding of
approximately 60% in the absence of antigen.
c) Radioimmunoassay of thyroid hormones
The pre-precipitate RIA assays used to determine T3 and T4 are those previously described
(Beckett et al, 1987), and are summarised below: Thyroxine and triiodothyronine stock
solutions (1 mmol/L T4 and T3 respectively) were prepared in methanol and a range of
standards prepared (T4, 0 - 250 nmol/L; T3, 0 - 20 nmol/L) by dilution of the stock solutions
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Dilution Factor
Figure 2a : An example of an antibody dilution curve used to determine the dilution
factor required to give a sensitive RIA for T3 and T4.
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with EBS. These standards were used to construct a standard curve each time the assays
were performed.
Working radiolabeled tracer was prepared by adding 74 kBq of the appropriate
radiolabel to 100 ml of barbitone buffer containing 0.01% (w/v) ANS. Sample or standard
(50pl) was added to 600pl of working tracer, before pre-precipitated antibody (200pl) was
added and the tubes agitated. Following a 3h incubation the tubes were centrifuged for
30 min (4°C, 2400g), the supernatant decanted, and the pellet counted in a Nuclear
Enterprises, NE1600 gamma counter. Results were then interpolated by the SASPro
Immunoassay D.P. program of P.R. Edwards, Department of Molecular Endocrinology,
Middlesex Hospital, London, U.K.
d) Production of solid-phased Tantibodies
Sufficient water was added to 20g of microcrystalline cellulose to produce a slurry light
enough to be kept well mixed by a magnetic stirrer and "flea". The pH was adjusted to
between 10 and 11, and maintained within this range using 1M NaOH as 1 g of cyanogen
bromide was slowly added. After approximately 10 min, the slurry was poured onto a
glass sinter and washed 3 times with 500 ml of a 0.1 M NaHC03 solution. The slurry was
washed once with 500 ml of borate buffer (4.763g of sodium borate with 135 ml of 0.1 M
HCI, made up to 1 litre, pH 8.6), before being made into a slurry once again in borate
buffer. Reconstituted antibody in borate buffer was added to the slurry at a ratio of 1 ml
of antibody, to 2g of the original dry cellulose and the mixture incubated overnight with
gentle agitation. The antibody/cellulose slurry was centrifuged (300g, 10 min) and the
pellet washed with 50 ml of acetate buffer (4.9g sodium acetate trihydrate with 9.4 ml
glacial acetic acid in 1 litre of water, pH 4). Following centrifugation, the pellet was
washed with 50 ml glycine buffer (0.1 M, with 2 g/L gelatine, 100 mg/L thiomersal, pH'd to
10.5 with NaOH) and centrifuged once again. This protocol of alternate washing with
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acetate and glycine buffers was repeated twice more, with the slurry remaining in glycine
buffer at the end of the wash protocol. The slurry was then diluted 1:100 with glycine
buffer on the basis of the volume of antibody used (e.g. 5 ml antibody, 500 ml final
volume). An antibody dilution curve was then constructed for each solid-phased antibody
as described in Section 2.04b to determine the dilution factor required for a % binding of
60%.
2.05 : Assay of ID-I activity in homogenates
a) [125l]-rT3 method
Tracer was purified before use to reduce contamination by free [125l]-iodide. This reduced
the background to the assay and produced a more sensitive assay. Purification of the
tracer was performed by passing the [125l]-rT3 tracer through a small (approx 2 ml)
Sephadex G25 column equilibrated with 100 mmol/L potassium phosphate buffer (pH 7.4)
containing 1 mmol/L EDTA. [12Sl]-iodide was eluted by approximately 10 ml of the assay
buffer. The [125l]-rT3 was then eluted using a 1% (w/v) BSA solution in assay buffer, with
the recovery of [125l]-rT3 between 50% and 85% depending on the age of the tracer. The
purified tracer was stored at 4°C for upto a week before use.
ID-I activity was determined by measuring the rate of 125l released from [125l]-rT3
(Sawada et al, 1986). The activity of ID-I in tissue samples was determined as follows:
The tissue was homogenized in assay buffer to obtain a 20% (w/v) homogenate. After
centrifugation in a Beckman GS-6R benchtop centrifuge for 15 min at 300g, the
supernatant was removed and the ID-I activity assayed by incubating 200/l/I of supernatant
sample with 100^1 of purified tracer (3.7kBq [125l]-rT3 with non-isotopic rT3 added to a final
rT3 concentration of 2 nmol/L) in the presence of 5 mmol/L DTT. Following a 15 min
incubation the reaction was stopped using 0.5 ml of human serum (which binds the rT3
and T2) and the protein in the sample precipitated by adding 0.5 ml 10% (w/v)
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trichloroacetic acid (TCA). The precipitated protein, together with the bound tracer, were
then pelleted by centrifugation (1500g, 10 min) and 0.5 ml of the supernatant (s) along
with the remaining supernatant and pellet (p) were counted for 125l activity using an
Nuclear Enterprises, NE1600 gamma counter. The % of 125l released from [125l]-rT3 was
determined using the following formulae (s-(s+p)x100) and corrected for the blank (buffer
and tracer only). If the % release of 125l exceeded 20% which is the effect range of the
assay, the sample was diluted so that the % change stayed between 0.2 and 20. The
amount of 125l released was calculated using the following correction factor; 1% released
= 4.6 fmols rT3 deiodinated.
b) Non-isotopic T4 method
The tissue was homogenised in assay buffer as described in Section 2.05a to produce
a 20% homogenate. To 450/l/I of homogenate, 50/4 of T4 (0.5 mg/ml) was added to start
the assay. The reaction was stopped at time zero, and 10 min using 1 ml of ethanol.
Subsequently, the precipitated proteins were pelleted by centrifugation at 2400g for 15
min. The supernatant was then removed and diluted 1:10 with barbitone buffer and
assayed for T3 using the RIA described in Section 2.04c. The amount of T3 in the time
zero sample was then subtracted from the 10 min sample to yield the amount of T3
produced in 10 min. Subsequently the activity of ID-I in the sonicated sample was
calculated.
2.06 : Assay of ID-I activities in cell sonicates
At the end of the incubation time, the medium bathing the thyrocytes was removed and
the cells washed twice with 1 ml of EBS. The cells were then removed from the plate in
1 ml of ID-I assay buffer using a rubber policeman. Each of the cell suspensions were
sonicated for approximately 5 seconds before the ID-I activity was determined by the [125l]-
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rT3 method using 200/71 of cell sonicate under the same conditions as described in Section
2.05a. The incubation time was altered where necessary to allow a significant level of 125|
production.
2.07 : Protein determination
All protein determinations were carried out using the Bradford dye-binding method
(Bradford, 1976), adapted for use on a Cobas Fara (Roche Diagnostics, Welwyn Garden
City, U.K.) centrifugal analyzer. Coomassie brilliant blue (G250) was prepared as
described by Bradford except that the reagent was filtered before use through a Whatman
grade 1 filter paper. Reagent (256/jI) was added to each cuvette and incubated at 37°C
for 100 s, with an initial absorbance reading (595 nm) taken at 95 s. After the addition of
the sample (25/71) and water diluent (50/71), the cuvettes were incubated at 37°C for a
further 180 s, prior to a final absorbance reading taken at 595 nm.
A standard curve was also constructed using bovine serum albumin at
concentrations from 0 to 100 mg/L. The change in absorbance due to the standard was
calculated and then used to plot a standard curve. The protein concentration of unknown
samples were then interpolated from this curve. Samples which had protein
concentrations above 100 mg/L were diluted with distilled water to allow the absorbance
change to lie within the range of the standard curve.
2.08 : Preparation and use of N-Bromoacetyl-[125l]-rT3 affinity label
The N-Bromoacetyl-[125l]-rT3 affinity label was synthesized using a modified version (Arthur
ef al, 1990a) of the Nikodem method (Nikodem et al, 1980). 200/71 of [125l]-rT3 (specific
activity > 44 MBq///g rT3) was added to an Ependorf tube and evaporated to dryness
under a stream of dry nitrogen. To this, 20/71 of a 1.5 mg/ml solution of bromoacetic acid
n-hydroxy-succinimide ester in dimethylformamide was added, followed by 5//I of 10%
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triethylamine in dimethylformamide. Following a 50 min incubation the mixture was
purified by applying it to a small (approximately 2 ml) Sephadex LH20 column previously
equilibrated with 0.1 mol/L HCI. Unreacted [125l]-rT3 was eluted first using 0.1 mol/L HCI
and finally the affinity label was eluted using 95% ethanol. The affinity label wasstoredat -
20°C in a sealed vial prior to use for upto 2 months. (N.B. The affinity label and all the
materials used for its synthesis must be kept free of moisture, to avoid corruption of the
synthesis).
Samples were diluted with 50 mmol/L Tris/HCI, 3 mmoi/L EDTA, 3 mmol/L DTT
buffer before 50pg of protein in a volume of 50pl was added to a tube containing 7.4kBq
of dried label (dried under dry N2). The label was allowed to react for 15 min before being
diluted 1:3 with "boiling mix" consisting of SDS (35 mmol/L), glycerol (1.4 mmol/L), 2-
mercaptoethanol (0.3 mmol/L) and bromophenol blue (15 mmol/L) and the samples
heated to 90°C for 10 min. The samples were then loaded on an sodium dodecyl
sulphate/polyacrylamide-gel electrophoresis (SDS/PAGE) gel and the proteins separated
and then visualised using autoradiography.
2.09 : SDS/Polyacrylamide-gel electrophoresis
SDS/PAGE was carried out in gels (0.1 cm x 16.5 cm x 18 cm) at room temperature using
a Protean II electrophoresis system (Bio-Rad Laboratories Ltd, Watford, Hert, U.K.) in the
presence of 1% SDS (w/v), using the buffer system described previously (Laemmli, 1970).
The "resolving gel" was 14 cm long and consisted of 12% (w/v) polyacrylamide and 2.6%
(w/v) NN'-methylenebisacrylamide in 375 mmol/L Tris/HCI buffer (pH 8.8). The "stacking
gel" was 2.5 cm long and comprised of 3% (w/v) polyacrylamide in a 125 mmol/L Tris/HCI
buffer pH 6.8 and was formed on top of the "resolving gel" with a 15 well "comb".
Protein samples were prepared for electrophoresis by heating at 90°C for 10 min
in "boiling mix". The desired volume of the "boiling mix" was applied to each well in the
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"stacking gel" and electrophoresis carried out at 50 mA, through the "stacking gel" and
then at 25 mA, through the "resolving gel". The current was stopped when the
bromophenol blue marker was within 0.5 cm of the end of the gel. The gel was stained
with a 0.2% (w/v) Coomassie Brilliant Blue R in a water/methanol/acetic acid (50:50:7, by
vol.) solution and destained in several changes of a water/methanol/acetic acid (88:5:7
by vol.) solution for 2 days.
The stained gel was then "sandwiched" between 2 sheets of gel drying film and
dried using a Genevac CVP50 vacuum pump (Genevac, England, U.K.) in conjunction
with a Rapidry, programable, heated gel drier (Atto, U.K.). The molecular weights of the
standard proteins were plotted against the distance travelled and a standard curve drawn
(e.g. figure 2b); from this curve, the molecular weights of the unknown proteins were
determined (ID-I shown as an example).
2.10 : Autoradiography of SDS/PAGE gels
Autoradiography of SDS/PAGE gels was performed using Kodak X-OMATXAR-5 X-ray film,
and consisted of placing the dried gels in close contact with the film in an exposure
cassette. Exposure of the film to the gels at -70°C was varied so that a sharp image was
produced (15h - 4 days). All work with the undeveloped film was performed under an
llford 914 filtered safety light (7.5 watt). Exposed x-ray films were kindly processed by the
staff of the Department of Radiology in the Royal Infirmary of Edinburgh.
2.11 : Statistical analysis of data
Unless stated otherwise, all data in this thesis was subjected to a unpaired Student t-test,
using the Instat statistical computer software package manufactured by Graph Pad
Software, San Diego, CA, USA. Where a statistically significant difference occurred, the
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Figure 2b : An example of a molecular weight vs distance travelled plot used to
determine the molecular weight of unknown bands on a 12% SDS-PAGE
gel.
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Section 3 : PRODUCTION OF THYROID HORMONES BY SHEEP
AND HUMAN THYROCYTES IN PRIMARY CULTURE
Under normal circumstances, approximately 80% of plasma T3 is produced from plasma
T4 as a result of 5'-deiodination in peripheral tissues (e.g. liver and kidney). These tissues
have been shown to contain type-l 5'-iodothyronine deiodinase (ID-I) which is responsible
for this 5'-deiodination and is known to be a selenoenzyme, containing stoichiometric
amounts of selenium (Beckett et al, 1987; Behne et al, 1990; Berry ef at, 1991 b; Safran et
at, 1990). The remaining 20% of plasma T3 arises directly from the thyroid. However, in
conditions where plasma thyrotropin (TSH) is elevated, such as in iodine deficiency, the
thyroid becomes the major source of plasma T3 (Adams and Larsen, 1973). It is unclear
wether this increase in thyroidal T3 production arises from the release of T3 from
thyroglobulin, synthesized in a de novo fashion (Visser, 1988) or from the action of
thyroidal ID-I on thyroidal T4 (Laurberg, 1984).
In primary culture, human thyrocytes produce T3, and it has been suggested that
the T3 secreted by cultured human thyrocytes arises from de novo synthesis (Kraiem et
al, 1988), particularly if a follicular preparation is used and dimethylsulphoxide (DMSO)
and lower than usual concentrations of fetal calf serum are present in the culture medium
(Sato et al, 1988). Other workers have suggested that the T3 arises from release of
preformed intracellular T3 (Ollis et al, 1985). In contrast to human cultured thyrocytes,
sheep thyrocytes appear to produce both T3 and T4 (Becks et al, 1.987).
In this section I have studied the effects of TSH, Kl and various inhibitors of ID-I
and de novo synthesis on T3 production by human and sheep thyrocytes grown in primary
culture in order to investigate the significance of thyroidal deiodination of T4 as a possible
source of T3 production in this system. De novo synthesis of T3 and T4 was also
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investigated by studying the incorporation of 125l into T3 and T4 using thin layer
chromatography (TLC) and autoradiography.
3.01 : Methods
a) Time-course of T3 and T4 production by sheep thyrocytes
Sheep thyrocytes were prepared as described in Section 2.03. After 24 h, the medium
was removed from the thyrocytes in monolayer culture and the cells washed twice with
1 ml of EBS before 1 ml of fresh DMEM/10% CPSR-5 growth medium was added. Various
combinations of potassium iodide (Kl, 1 /jM) and TSH (1 U/L) were added to the
thyrocytes, so that 4 groups were created, a) Control (Kl TSH -); b) Kl +, TSH c) Kl -
,TSH +; and d) Kl + TSH + (+/- denotes presence/absence of TSH or Kl). The
thyrocytes were then incubated at 37°C in a 5% C02 incubator, and the growth medium
from triplicate wells removed after 2, 4, 6 and 8 days of incubation. The concentration of
T3 and T4 in the culture medium for each time point was determined by specific in-house
radioimmunoassays (Section 2.04c).
b) Effect of TSH and Kl on T3 and T4 production by human and sheep thyrocytes
Human and sheep thyrocytes were prepared as described in Section 2.03. After 24 h, the
medium was removed from the thyrocytes in monolayer culture and the cells washed twice
with 1 ml of EBS to remove unattached/non-viable thyrocytes and cytoplasmic
contaminants from damaged thyrocytes. Fresh DMEM/10% CPSR-5 growth medium (1
ml/well) was then added to the thyrocytes. To wells in triplicate a range of TSH doses (0 -
10 U/L) were added in the presence of a fixed concentration of Kl (10 /jM).
In other experiments, thyrocytes were incubated in the presence of a range of Kl
doses (0-100 pM) with a fixed concentration of TSH (1 U/L) present. Following an
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incubation period of 5 days the concentrations of T3 and T4 secreted into the culture
medium were determined by the respective in-house radioimmunoassays (Section 2.04c).
c) Effect of IPA, PTU and methimazole on T3 and T4 production by human and sheep
thyrocytes
Human and sheep thyrocytes were washed and provided with fresh growth medium as
described in Section 3.01b, but with the addition of both TSH (1 U/L) and Kl (10/rmol/l)
to the medium (optimum concentrations for TSH and Kl were determined from the above
experiments). Increasing doses of a range of different inhibitors were then added to wells
in triplicate. The inhibitors used were iopanoic acid (IPA, an ID-I inhibitor), methimazole
(an inhibitor of T3 and T4 de novo synthesis) or 6-n-propyl-2-thiouracil (PTU, an inhibitor
of ID-I activity as well as de novo synthesis). The thyroid hormone concentration in the
overlying medium after a further 5 days was determined using specific radioimmunoassays
for both T3 and T4 as previously described (Section 2.04c), and the results expressed as
the amount of T3 or T4 produced per well per 5 days. To confirm that there were no
significant changes in protein resulting from the various additions, the previously
described additions were also made to other human and sheep thyrocytes. After a further
5 days in culture, the thyrocytes were washed twice and the removed from the wells in 1
ml of ID-I assay buffer using a rubber policeman. Subsequently, the thyrocytes were
sonicated and the protein content of the sonicates determined as described in Section
2.07.
d) Effect of dimethylsuiphoxide and fetal calf serum on T3 and T4 production from
human thyrocytes in primary culture.
Human and sheep thyrocytes were prepared, cultured for 24 h and washed as described
in Section 3.01a. Fresh medium was added back to the washed thyrocytes, with various
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additions, made such that 4 groups were created : i) 10% CPSR-5, DMSO ii) 10%
CPSR-5, DMSO +; iii) 1% CPSR-5, DMSO and iv) 1% CPSR-5, DMSO + (all thyrocytes
were grown in the presence of 1 U/L TSH and 10/iM Kl, DMSO +/- denotes the
presence/absence of 1.7% DMSO). Following an incubation period of 5 days, the
concentrations of T3 and T4 secreted in the culture medium were determined by the
respective in-house radioimmunoassays (Section 2.04c).
e) Incorporation of 125l into thyroid hormones by human and sheep thyrocytes
Human and sheep thyrocytes were isolated as described in Section 2.03 and plated out
in 75cm2 flasks in 20 ml DMEM/10% CPSR-5 at a density of 10 million cells per flask.
After 24 h the medium was removed, the cells washed twice with 20 ml EBS before fresh
medium (DMEM/10% CPSR-5) was added containing 1.85 MBq of Na125l (specific activity
^ 44.4 MBq//;g) with or without TSH (1 U/L). After a further incubation for 5 days, the
medium was removed and the T3 and T4 was immunoprecipitated from the medium by
incubation with excess solid-phased anti-T/r4 immunoglobulins for 15 h at 25°C (solid-
phased immunoglobulins produced as described in Section 2.04d). The samples were
then centrifuged at 180 g for 15 min, and the antibody pellet washed with 20 ml Kl (1M)
and re-centrifuged. The pellet was then resuspended in 5 ml of methanol and the
suspension left for 15 h at 25°C to extract the bound hormones. After a further
centrifugation at 180 g for 15 min, the methanolic supernatant was evaporated to dryness
and the residue, containing immunoextracted T3 and T4 taken up in 100/vl methanol, with
40/jI used per sample.
The 40/jI samples were then loaded onto a 20 cm square cellulose TLC plate and
run for approximately 20 h using chloroform : tertiary butanol: ammonia (2M), (60:376:70
by vol.) as the developing solvent. Appropriate 125l standards of T3 and T4 were also run
on the same plate. No detectable Na125l was carried over onto the TLC plates, as
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determined by autoradiography. Once the TLC plate had dried, autoradiography was
employed to demonstrate the presence of iodinated T3 and T4 as described for dried
SDS/PAGE gels (Section 2.10).
3.02 : Results
a) Time-course of T3 and T4 production by sheep thyrocytes
In the absence of TSH and Kl, the amount of T3 and T4 produced by the sheep thyrocytes
was low, and slowly increased with the length of the incubation (figure 3a). Addition of
Kl alone had little effect, though a very slight increase was seen in both thyroid hormones
above that observed in the control. The addition of TSH alone caused increases in both
T3 and T4, with maximum T3 and T4 seen after 8 days of incubation. A similar pattern was
seen when Kl and TSH were added together, though the amount of T3 and T4 produced
increased by more than 10-fold compared to the TSH + Kl - triplicate after 8 days
incubation.
b) Effect of TSH and Kl concentration on T3 and T4 production by human and sheep
thyrocytes
T3 and T4 production by sheep thyrocytes showed a clear dose-dependence on TSH, with
the observed maximum production seen at a TSH concentration of 1 U/L (figure 3b).
Human thyrocytes also produced T3 in a dose dependent manner with respect to TSH,
with maximum T3 production observed at 1 U/L TSH (figure 3c). However, T4 production
by human thyrocytes was low and failed to be stimulated by TSH. In fact the T4
concentration in the medium decreased when TSH was present at 1 U/L (figure 3c).
The production by sheep thyrocytes of both thyroid hormones increased with the
concentration of Kl, with the maximum production of both hormones observed at 10 /l/M
(figure 3d). Concentrations of Kl > 20 fjM caused significant decreases in T3 and T4
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production when compared to that observed at 10 pM (figure 3d). The production of T3
and T4 by human thyrocytes was unaffected by Kl, with no significant change in the
concentration of either thyroid hormone found (figure 3e).
c) Effect of IPA, PTU and methimazole on T3 and T4 production from human and sheep
thyrocytes
In sheep thyrocytes, methimazole and PTU produced a dose-dependent inhibition of both
T3 and T4 accumulation, with a maximal effect seen for both compounds at 1 mM (figure
3f & 3g). At this dose, methimazole caused a 35% decreases in T3 and T4, while PTU
caused a 50% decreases in both T3 and T4. IPA had no significant effect on T3 and T4
accumulation in the growth medium bathing the thyrocytes (figure 3h).
In human thyrocytes, methimazole caused on significant change to the accumulation of T3 in the
medium, while the amount of T4 decreased slightly. In contrast to the sheep thyrocytes,
PTU and IPA caused a significant increase in T4 and a corresponding decrease in the
accumulation of T3 (figure 3j & 3k). Maximal effects occurred at 10 mmol/L PTU which
caused a 50% increase in T4 and an 80% decrease in T3 (figure 3j). In the case of IPA,
maximal effects occurred at 100 pmol/L IPA and consisted of an 80% increase in T4 and
a 70% decrease in T3 (figure 3k).
No significant change in the protein content of the wells could be seen when
sheep and human thyrocytes were exposed to the various additions (human thyrocytes
shown, figure 31).
d) Effect of dimethylsulphoxide and fetal calf serum on T3 and T4 production by
human thyrocytes in primary culture.
The addition of DMSO to the human thyrocytes produced no significant change in the
amounts of both T3 and T4 secreted into the overlying medium, regardless of the
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concentration of CPSR-5 (figure 3m). In comparison, the thyrocytes grown in the presence
of 10% CPSR-5 exhibited higher levels of T3 and T4 into the overlying medium than those
grown in the presence of 1% CPSR-5.
e) Incorporation of 125l into T3 and T4 by human and sheep thyrocytes
In the presence of TSH, incorporation of 125l into T3 and T4 occurred in TSH stimulated
sheep thyrocytes, with no detectable incorporation occurring when TSH was absent (figure
3n). With human thyrocytes, no 125l incorporation into T3 and T4 could be detected
irrespective of the presence or absence of TSH.
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Figure 3a : Time-dependent thyroid hormone production by sheep thyrocytes in
primary culture with/without Kl (1 OfjM) and/or TSH (1 U/L) present, (a: TSH
Kl b: TSH Kl +; c: TSH +, Kl d: TSH +, Kl +). The accumulated
medium content of T3 (o) and T4 (A) was measured and the data
expressed as mean ± SEM of triplicate wells for 2, 4, 6 and 8 days in
culture (representive experiment, performed twice). Significant differences
were observed across the time course and between the various additions




Figure 3b : Effect of increasing doses of TSH on thyroid hormone production from
sheep thyrocytes in primary culture for 5 days in the presence of 10pM
Kl. The accumulated medium content of T3 and T4 was measured and the
data expressed as mean ± SEM of triplicate wells in a representative
experiment carried out on at least three occasions. The accumulation of
T3 and T4 with TSH concentrations above 500 mU/L was significant
compared to the control (- TSH). A significant decrease was also seen























































Figure 3c : Effect of increasing doses of TSH on thyroid hormone production from
human thyrocytes in primary culture for 5 days in the presence of 10^M
Kl. The accumulated medium content of T3 and T4 was measured and the
data expressed as mean ± SEM of triplicate wells in a representative
experiment carried out on at least three occasions. The changes in
accumulated T3 and T4 as TSH concentrations exceeded 500 mU/L were
significant when compared to the control (- TSH). Significant changes





Figure 3d : Effect of increasing doses of Kl on thyroid hormone production from
sheep thyrocytes grown in primary culture for 5 days in the presence of
1 U/L TSH. The accumulated medium content of T3 and T4 was measured
and the data expressed as mean ± SEM of triplicate wells in a
representative experiment carried out on at least three occasions. Kl
concentrations in excess of 1 pM gave significant increases in T3 and T4
accumulation compared to the control (- Kl). At a concentrations of
100pM, Kl caused a significant decrease in both T3 and T4 accumulation,
when compared to 10^M (p < 0.01).
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Figure 3e : Effect of increasing doses of Kl on thyroid hormone production from
human thyrocytes grown in primary culture for 5 days in the presence of
1 U/L TSH. The accumulated medium content of T3 and T4 was measured
and the data expressed as mean ± SEM of triplicate wells in a
representative experiment carried out on at least three occasions. No

























Figure 3f: Effect of 5 days exposure to methimazole on thyroid hormone production
from sheep thyrocytes grown in primary culture. The accumulated
medium content of T3 (□) and T4 (A) was measured and the data
expressed as mean ± SEM of triplicate wells in a representative
experiment carried out on at least three occasions. Methimazole at
concentrations above 10"7M caused significant decreases in T3 and T4
accumulation when compared to the control (i.e. - methimazole).
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Figure 3g : Effect of 5 days exposure to PTU on thyroid hormone production from
sheep thyrocytes grown in primary culture. The accumulated medium
content of T3 (□) and T4 (A) was measured and the data expressed as
mean ± SEM of triplicate wells in a representative experiment carried out
on at least three occasions. PTU in excess of 10'9M caused significant































Figure 3h : Effect of 5 days exposure to IPA on thyroid hormone production from
sheep thyrocytes grown in primary culture. The accumulated medium
content of T3 (□) and T4 (A) was measured and the data expressed as
mean ± SEM of triplicate wells in a representative experiment carried out
on at least three occasions. IPA at a concentration of 10"4M caused a
significant increase in T4 accumulation compared to the control (i.e. - IPA).
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Figure 3i : Effect of 5 days exposure to methimazole on thyroid hormone production
from human thyrocytes grown in primary culture. The accumulated
medium content of T3 (o) and T4 (A) was measured and the data
expressed as mean ± SEM of triplicate wells in a representative
experiment carried out on at least three occasions. Methimazole at
concentrations in excess of 10"4M gave a significant decrease in T4






































Figure 3j : Effect of 5 days exposure to PTU on thyroid hormone production from
human thyrocytes grown in primary culture. The accumulated medium
content of T3 (□) and T4 (A) was measured and the data expressed as
mean ± SEM of triplicate wells in a representative experiment carried out
on at least three occasions. Significant decreases in T3 accumulation
occurred at PTU concentrations above 10"3M, while a significant increase





Figure 3k : Effect of 5 days exposure to IPA on thyroid hormone production from
human thyrocytes grown in primary culture. The accumulated medium
content of T3 (□) and T4 (A) was measured and the data expressed as
mean ± SEM of triplicate wells in a representative experiment carried out
on at least three occasions. Significant decreases in T3 accumulation
occurred at IPA concentrations above 10"SM, while significant changes in
T4 accumulation occurred above 10'8M when compared to the control (i.e.
- IPA).
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Figure 31 : Effect of 5 days exposure to TSH (1 U/L), methimazole (10"3M), PTU (103)
or IPA (10"4M) on the protein content of human thyrocytes grown in
primary culture. The total protein content of each well was measured and
the data expressed as mean ± SEM of triplicate wells in a representative
experiment carried out on at least three occasions. No significant
changes in the protein content of the wells occurred.
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Figure 3m : Effect of 5 days exposure to DMSO (1.7%) on thyroid hormone production
from human thyrocytes grown in primary culture with either 1% or 10%
CPSR-5 (fetal calf serum) present. The accumulated medium content of
T3 (□) and T4 (A) was measured and the data expressed as mean ± SEM
of triplicate wells in a representative experiment carried out on at least
three occasions. The presence of DMSO caused no significant change
in T3 and T4 accumulation, though the lower concentration of CPSR-5 did






















































Sheep Sheep Human Human Sheep
-TSH +TSH -TSH +TSH +TSH
♦ T3+T4
Figure 3n : A thin-layer chromatography of radiolabeled tri-iodothyronine and
thyroxine, immunoprecipitated from culture medium following a 5 day
incubation of sheep and human thyrocytes with Na125l in the presence and
absence of TSH (1 U/L). The TLC shows incorporation of 125l into T3 and
Td in sheep, but not human thyrocytes in response to TSH stimulation.
Lane 5 contains similar amounts of the material run in Lane 2 with the
addition of [125I]-T3 and [1Z5I]-T4 to act as internal standards.
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3.03 : Discussion
In the absence of TSH, the production of both thyroid hormones by sheep thyrocytes was
very low (figure 3a). Addition of TSH alone caused a significant increase in the amount
of both thyroid hormones, though maximum production required both TSH and Kl. In my
experiments maximum concentrations of T3 and T4 were observed after 8 days, however
the levels of T3 and T4 could well have continued to rise. Obviously, some of this effect
might be due to growth and proliferation of the thyrocytes, however it is unlikely that a 10-
fold increase could be the result of just cell proliferation. In subsequent experiments, a
5 day incubation was chosen as this length of time allows significant levels of both thyroid
hormones to be produced and convenient timing of the experiments.
The production of T3 and T4 by sheep thyrocytes was clearly dependent on both
the TSH and Kl concentration, with maximum production of both thyroid hormones at 1
U/L and 10 /jM respectively (figures 3b & 3d). At concentrations of TSH and Kl above the
optimum values (> 1 U/L TSH and > 10^M Kl), significant decreases in the production
of both thyroid hormones were observed. Other workers have shown using human thyroid
slices and human thyrocytes in primary culture that high TSH concentrations bring about
the stimulation of the Ca2+-phosphatidylinositol (Ca2+-PI) cascade and inhibition of the
cAMP cascade (Laurent ef al, 1987; Laurent et al, 1989; Raspeetal, 1991b; Maenhautef
al, 1990; Raspe and Dumont, 1992). The Ca2+-PI cascade is believed to control the
synthesis of T3 and T4 via control of the rate limiting steps of thyroid hormone synthesis
(iodine and hydrogen peroxide supply to thyroperoxidase), while the cAMP cascade
mediates release of T3 and T4 from thyroglobulin (Raspe and Dumont, 1992).
Consequently, it is possible that excess TSH might be able to increase synthesis of both
thyroid hormones in sheep thyrocytes, but reduce the amount of T3 and T4 secreted into
the overlying medium.
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The observed decreases in the T3 and T4 content of the medium at Kl
concentrations in excess of 10 pM are supported by Becks et al, who demonstrated that
"excessive" concentrations of iodide (z 10 pM) reduce the amount of T3 and T4 secreted
by sheep thyrocytes (Becks etal, 1987). Several other workers have also shown inhibition
of thyroid hormone secretion by iodide (Mashita et al, 1982; Laurberg, 1982), as well as
inhibition of iodine transport, organification and thyroid hormone synthesis (Wolff and
Chaikoff, 1948; Grollman etal, 1986; Shimodaetal, 1966; Bagchiefa/, 1977; Braverman
and Ingbar, 1963). This inhibition of thyroid hormone secretion by high levels of iodide
has been postulated to occur by an organified iodine intermediate (X~l), based on the
observations that relief from the effects of excess iodide are found on administration of
drugs which inhibit iodine organification (Van Sande and Dumont, 1973). This X~l
species is believed to inhibit adenylate cyclase, possibly via stimulating an inhibitory GTP-
binding transduction protein (GJ (Van Sande and Dumont, 1973; Cochaux et al, 1987;
Corvilain etal, 1988; Raspe and Dumont, 1992). In addition to thyroid hormone secretion,
the X~l intermediate has also been shown to inhibit glucose transport, uridine
incorporation and hydrogen peroxide generation (Corvilain et al, 1988).
The accumulation of T3 and T4 in the medium bathing the sheep thyrocytes was
inhibited by methimazole and PTU (figures 3f & 3g). Methimazole and PTU both inhibit
a number of steps in the de novo synthesis of T3 and T4 including oxidation of iodide,
iodination of tyrosyl residues to produce mono/di-iodotyrosines and the coupling of these
iodotyrosyl residues on thyroglobulin to make the thyroid hormones. In addition, when
125l was added to the growth medium, incorporation of 125l into both T3 and T4 occurred,
but only in the presence of TSH (figure 3n).
These data clearly establish that sheep thyrocytes are able to produce both T3 and
T4 by de novo synthesis under these culture conditions. However, in the sheep, ID-I can
have no significant role in thyroidal T3 production since the thyroid of this species lacks
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notable levels of ID-I expression (Section 4.02a,b). In support of this, the addition of
iopanoic acid (a specific ID-I inhibitor) had no effect on T3 production by sheep thyrocytes
(figure 3h).
Accumulation of T3 in the medium bathing the human thyrocytes occurred in a
dose-dependent manner with respect to TSH, with maximum concentrations of T3
measured at 1 U/L TSH (figure 3c). In contrast, the T4 content of the medium was reduced
as the concentration of TSH exceeded 0.5 U/L, with the largest reduction measured at 1
U/L TSH. However unlike sheep thyrocytes, the T3 and T4 accumulating in the medium
bathing the human thyrocytes appeared to be independent of the Kl concentration (figure
3e). Moveover, the human thyrocytes also failed to incorporate 125l into T3 or T4, even
under TSH stimulation (figure 3n). Finally, T3 production by the human thyrocytes was
clearly inhibited in a dose-dependent manner by IPA and PTU, but not by methimazole.
These observations are consistent with T3 production by human thyrocytes arising
from deiodination of endogenous T4 present within the thyrocytes, with little or no de novo
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synthesis of T4 or T3. These data support the findings of other workers, who showed that
human thyrocytes grown in culture are unable to concentrate and organify free iodide
even after several days in culture (Bidey et al, 1977; Ollis et al, 1985). These workers
showed that T3 continued to accumulate in the overlying medium, and Ollis et al proposed
that human thyrocytes in primary culture release T3 from intracellular stores when
stimulated with TSH, rather than by synthesizing new T3. A significant component of this
secreted T3 may well arise from 5'-deiodination of T4 as human thyrocytes express
significant levels of ID-I, in contrast to sheep thyrocytes (Section 4.02a,b). The TSH-
dependent production of T3 by human thyrocytes can be explained on the basis of the
TSH-responsiveness of ID-I, most probably mediated by cyclic AMP (Erickson etal, 1982;
Ishii et al, 1983).
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Other workers have proposed that T3 production from isolated human thyrocytes
in primary culture arises from de novo synthesis (Kraiem et al, 1988). These workers
based their conclusions on the observation that PTU inhibited T3 production, an
observation confirmed here (figure 3j), However, since PTU inhibits de novo synthesis of
thyroid hormones and the deiodination of T4, the inhibition of T3 accumulation in the
medium by PTU clearly can not distinguish between these two sources of T3. Kraeim et
al also reported that methimazole inhibited T3 production, though no data in support of this
statement was published. Furthermore, the effects of IPA were not examined in their
study. We found no inhibitory effects of methimazole on T3 production, even at
concentrations as high as 10 mM.
Sato etal using a culture system of isolated human follicles demonstrated that the
presence of DMSO (1.7%) enhanced the effects of TSH on a number of thyroid functions
(iodine trapping, organification and release of T3 and T4) (Sato et al, 1988). In their
experiments, lowering the concentrations of fetal calf serum from 10% to 1% resulted in
further enhancement of these markers of thyroid function. They postulated that this
enhancement was possibly because DMSO prevented dedifferentiation of the thyrocytes,
and as a consequence allowed de novo synthesis of thyroid hormones. In addition, they
stated that high concentrations of fetal calf serum (10%) caused deterioration of thyroid
function, but could not explain this observation. I have tried on numerous occasions to
repeat the findings of Sato et al with respect to de novo synthesis of T3 and T4 by human
thyrocytes, but have not observed any effect of DMSO in the human thyrocyte system
(figure 3m). Furthermore, I found that a reduced concentration of fetal calf serum (CPSR-
5) results in a reduction in the amount of T3 and T4 which accumulates in the overlying
medium. The reason behind these observed differences may lie in differences between
the thyrocyte preparations and other experimental methods used. Sato etal used follicular
preparations plated out in 24 well plates, previously treated with 0.5% agarose. The
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presence of agarose prevented cell attachment and hence the thyrocytes remained in
"suspension" culture. In contrast, I have used a preparation with few follicles present, and
allowed the thyrocytes to attach to the cell culture plates. In addition, I used human TSH
at 1 U/L as compared to Sato et al who used 0.1 U/L of bovine TSH. Although these
differences in method are not great, they remain the most likely cause of the differences
described. Indeed other workers has demonstrated that the thyrocytes have to be
arranged in follicles for the secretion of iodinated thyroglobulin (Lissitzky et al, 1971;
Winand et al, 1976; Wadeleux et al, 1978). However, why the human thyrocytes in this
study can notsynthesisethyroid hormones even when organised into TSH-induced follicles
remains to be explained.
In summary under the culture conditions used, sheep thyrocytes produce both T3
and T4 as a result of de novo synthesis. The formation of T3 by sheep thyrocytes cannot
be explained by deiodination of T4 as this tissue lacks significant amounts of ID-I (see
Section 4). In contrast, human thyrocytes produce T3 as a result of deiodination of
endogenous T4, with no significant de novo synthesis. Consequently in man, ID-I may well
contribute significantly to T3 secretion, particularly under conditions which giving rise to
stimulation of the TSH receptor such as iodine deficiency or Graves' disease. As the
sheep lacks thyroidal ID-I, this mechanism to maintain plasma T3 levels is unavailable.
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Section 4 : THYROIDAL ID-I EXPRESSION IN MAN AND ANIMALS
Data presented in Section 3 and the findings of numerous other workers (Green, 1978;
Laurberg, 1980; Laurberg, 1984; Pazos-Moura et al, 1991) suggest that significant
amounts of T3 can be produced as a result of 5'-deiodination of T4 in the thyroid,
particularly under conditions which give rise to high levels of TSH receptor stimulation,
such as iodine deficiency and Graves' disease. The possible importance of ID-I in
producing T3 is further supported by the finding of a number of other workers who have
shown that the thyroids of humans, dogs and rats contain an ID-I which is responsive to
TSH, via stimulation of the cyclic AMP pathway (Erickson et al, 1982; Wu, 1983; Ishii et
al, 1983; Silva ef al, 1984).
In this section I study the levels of ID-I expression in the liver and thyroid of a
range of animal species. I then proceed to investigate the effects of TSH and second
messengers on ID-I activity and expression in human thyrocytes grown in primary culture.
In addition, I compare the levels of activity and expression of ID-I found in thyroid tissue
from patients with multinodular goitre and Graves' disease.
4.01 : Methods
a) Species differences in hepatic and thyroidal ID-I activity
The livers and thyroids of the 11 species studied (sheep, llama, man, cattle, deer, pig,
goat, rat, guinea-pig, mouse and rabbit) were removed into liquid nitrogen within an hour
of death. Subsequently the tissues were thawed, homogenised in ID-I assay buffer to
obtain a 20% (w/v) homogenate and centrifuged for 15 min at 300g before being assayed
for ID-I activity as described in Section 2.05a.
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b) Species differences in the affinity labelling of thyroidal homogenates
The thyroids and livers from 8 species (sheep, llama, man, cattle, deer, pig, goat and rat)
were thawed and homogenised in labelling buffer (50 mmol/L Tris/HCI buffer containing
3 mmoi/L EDTA and 3 mmol/L DTT, pH 7.4) to obtain a 20% (w/v) homogenate. The
homogenates were then centrifuged at 300g for 15 min and diluted to a protein
concentration of 1 g/L. The homogenates were labelled with n-bromoacetyl-[125l]-rT3 as
described in Section 2.08. The proteins were separated by SDS-PAGE and the gels
autoradiographed as described in Sections 2.09 and 2.10. The hepatic homogenates
were labelled in the presence of PTU (500 pM) and rT3 (10pM). PTU and rT3 selectively
inhibit the binding to, and affinity labelling of ID-I by n-bromoacetyl-[1Z5l]-rT3. This work
was performed by Dr. J.R. Arthur and F. Nicol as part of a collaborative study.
c) Effect of TSH on thyroidal ID-I activity in human thyrocytes
Human thyrocytes were prepared as described in Section 2.03. After 24 h in monolayer
culture the medium was removed from the thyrocytes and the cells washed twice with 1
ml of EBS before 1 ml of fresh growth medium (DMEM/10% CPSR-5) was added. To wells
in triplicate a range of TSH doses was added in the presence of 100 nmol/L selenium (Se,
added as sodium selenite). After 5 days the thyrocytes were washed again and the
contents of each well removed in 1 ml of ID-I assay buffer after using a rubber policeman
to detach the thyrocytes from the well. The ID-I activity and protein content of the
thyrocyte sonicates were then determined as described in Sections 2.06 and 2.07.
d) Effect on thyroidal ID-I activity of activating the different second messenger
systems found in human thyrocytes
Human thyrocytes were prepared and washed as described above. To wells in triplicate,
various compounds were added in the presence and absence of TSH (1 U/L). These
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included i) 8-bromoadenosine 3':5'-cyclic monophosphate (8-bromo-cAMP, 10"4M), ii) the
phorbol ester, phorbol 12-myristate 13-acetate (PMA, 10"6M), iii) the calcium ionophore,
A23187 (10"6M), iv) PMA and A23187 together or v) 1%dimethylsulphoxide (DMSO, added
as a control for PMA and A23187 which were added in 1% DMSO). After 5 days the
thyrocytes were washed and removed from the wells as described in Section 4.01c and
assayed for ID-I activity and protein (Section 2.06 and 2.07).
e) Changes in the affinity labelling of human thyrocytes after activation of the different
second messenger systems
Human thyrocytes were prepared as described in Section 2.03 and plated out in 75cm2
flasks at a density of 10 million cells per flask in 20 ml of growth medium (DMEM/10%
CPSR-5). After 24 h the medium was removed and the cells washed twice with 20 ml of
EBS before 20 ml of fresh growth medium was added. To half of the cells, PMA and
A23187 were added, both at a concentration of 1 fjM in the presence or absence of TSH
(1 U/L). The remaining cells were grown in the absence of PMA/A23187 but with the
presence or absence of 1 U/L TSH.
After 5 days incubation the medium was removed and the cells washed twice as
before with EBS. The cells were then washed with 20 ml of 0.02% (w/v) EDTA in
Ca2+/Mg2+-free EBS, before being incubated with gentle agitation for 5-10 min with 20 ml
of 0.25% (w/v) Trypsin, 0.02% (w/v) EDTA in Ca2+/Mg2+-free EBS to remove the cells from
the flask. The released cells were then diluted 2-fold with DMEM/10% CPSR-5 before
being pelleted by centrifugation at 125 g for 15 min and washed with 20 ml of EBS.
Following re-centrifugation another wash and centrifugation was performed before the cell
pellet was frozen at -70°C. Subsequently the cell pellets were sonicated in 1 ml of
labelling buffer, diluted to a protein concentration of 1 g/L and affinity labelled as
described in Section 2.08.
89
In light of the results obtained using the affinity label (i.e changes in intensity of
the 44.5 and 45 kDa affinity labelled bands), creatine kinase (CK) activity was measured
in the cell sonicates on a Kodak Ektachem 700 analyzer (assay kindly performed by Dr.
A.F. Howie). The activity of creatine kinase wasmeasuredjsing the method recommended
by the Scandinavian Committee on Enzymes (Scand.J.Clin.Lab.Invest, 1976:36,711). The
method consisted of a creatine kinase - glycerol kinase - L-a-glycerophosphate oxidase -
peroxidase linked enzyme assay system to produce a coloured dye, the concentration
of which was assayed by absorbance spectrophotometry. The reaction sequence is as
follows, with the enzymes and co-factors for each reaction listed in brackets
a) creatine phosphate + ADP -* creatine + ATP (CK, N-acetylcysteine, Mg2+)
b) ATP + glycerol -* a-glycerophoshate + ATP (glycerol kinase)
c) a-glycerophosphate + 02 dihydroxyacetone phosphate + H202 (L-a-
glycerophosphate oxidase)
d) H202 + leuco dye precursor -* coloured dye + H20 (peroxidase)
A11 pi sample of each sonicate was used, and the reactions allowed to proceed for 5 min
at 37°C prior to an absorbance measurement at 670 nm. The absorbance reading was
read off on a standard curve, and the activity of CK determined by the analyzer.
f) Effect of activating the second messenger systems on thyrocyte morphology
Human thyrocytes were prepared and washed as described above. To wells in triplicate
various additions were made such that 3 groups were created :-1) TSH -, PMA/A23187 -
; 2) TSH +, PMA/A23187 -; and 3) TSH +, PMA/A23187 + (+/- denotes the presence or
absence of TSH (1 U/L) or PMA/A23187 (both at 10'6M). After an incubation period of 4
days the medium was removed, the thyrocytes were washed twice with 1 ml EBS and then
fixed. Subsequently the fixed thyrocytes were photographed using a phase-contrast light
microscope (x 20 magnification). The fixing and photography of the thyrocytes was kindly
performed by Dr. D. Harrison of the Department of Pathology, University of Edinburgh.
g) Comparison of thyroidal ID-I activity in thyroid tissue from various thyroid disease
states
Threetypesof human thyroid tissue (normal from around a carcinoma, multinodular goitre
& Graves') were obtained from patients undergoing thyroid surgery and stored at -70°C.
The different tissues were then homogenised in ID-I assay buffer to produce a 20% (w/v)
homogenate, subjected to centrifugation (300g, 15 min) and then assayed for ID-I activity
as described in Section 2.05a.
h) Differences in the affinity labelling of thyroid tissue homogenates from various
thyroid disease states
Human thyroids were also homogenised in labelling buffer, diluted to a protein
concentration of 1 g/L in labelling buffer, and affinity labelled as described in Section 2.08
in the presence or absence of PTU (500 pM) and rT3 (10 ^M).
4.02 : Results
a) Species differences in hepatic and thyroidal ID-I activity
There was a large variation in the activity of ID-I measured in the liver from the different
species, but all showed substantial levels of activity ranging from 119 to 1045 fmol/min
per mg protein (table 4a). However, only in the thyroid tissue from rat, man, mouse and
guinea-pig could significant thyroidal ID-I activity be measured (1295, 283, 79 & 56 fmol
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iodine released/min per mg protein respectively). All other species had very low thyroidal
ID-I specific activities (0.3 - 3.6 fmol/min per mg, i.e. less than 0.3% of that of the rat).
b) Species differences in the affinity labelling of thyroidal homogenates
The liver homogenates from all species showed an ID-I band in the region of 27.3 to 29.0
kDa, though there were small but clear differences in the molecular weight of this band
between species (table 4b). The identity of ID-I in the livers of all species was confirmed
by the inhibition of affinity labelling by PTU/rT3. A second band was also apparent in the
liver of all species studied, which had a consistent molecular weight of 53.2 kDa. When
thyroid homogenates were run on SDS/PAGE and autoradiographed, only rat and man
exhibited a band corresponding in molecular weight to that of ID-I in the liver of the
corresponding species (figure 4a; table 4b). The thyroids of the other species studied
(sheep, llama, cattle, deer, pig and goat), exhibited bands within the molecular weight
region of 30.5 - 33 kDa, though no band was found with the lower molecular weight
corresponding to that of ID-I in the liver of the same species. The nature and identity of
these other bands is unknown.
The presence or absence of the ID-I band in the thyroid of the various species
correlated well with ID-I activity, thus indicating that the very low enzyme activities were
due to a lack of expression of the enzyme, rather than an inhibition of activity. All the
thyroid glands from these species had significant levels of glutathione peroxidase activity,
often used as a marker of selenium status, thereby confirming that the lack of ID-I activity
was not due to selenium deficiency (personal communication from Dr. J.R. Arthur).
c) Effect of TSH on thyroidal ID-I activity in human thyrocytes
Addition of TSH at concentrations of 10, 50, 100 and 200 mU/L to the thyrocytes had no
significant effect on the level of ID-I activity measured in the thyrocyte sonicates after
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culture (figure 4b). At TSH doses of 500 mll/L and above, a significant stimulation of ID-I
activity was produced, with an apparent maximum stimulation of approximately 9-fold
observed at 1 U/L. At higher doses of TSH the level of ID-I activity decreased significantly
when compared to the optimum dose of 1 U/L TSH.
d) Effect on thyroidal ID-I activity of activating the different second messenger
systems found in human thyrocytes
Once again TSH caused a significant stimulation of ID-I activity, (a 3-fold stimulation in the
experiment illustrated, figures 4c). In the absence of TSH, the addition of PMA, A23187
or DMSO caused no significant change in the level of ID-I activity measured in the human
thyrocytes. In contrast the addition of 8-bromo-cAMP resulted in a 3-fold increase in ID-I
activity, similar in magnitude to that found with TSH at 1 U/L. When PMA and A23187
were added together in the absence of TSH a small decrease (= 33%) in ID-I activity was
observed (figure 4c).
In the presence of TSH, a slight but not significant decrease in the level of ID-I
activity was observed when PMA or DMSO were added (figure 4c). The addition of
A23187 caused a 30% decrease, while 8-bromo-cAMP caused no further increase in ID-I
above that observed with TSH alone. When added together, PMA and A23187 caused
approximately a 4-fold decrease in ID-I activity when compared to the TSH control.
e) Changes in the affinity labelling of human thyrocytes after activation of the different
second messenger systems
In the absence of TSH and PMA/A23187 the affinity label bound to a band with a
molecular weight of 28.1 kDa, the same molecular weight as ID-I (figure 4d). When TSH
only was present the intensity of the 28.1 kDa band was enhanced, signifying induction
of the protein (ID-I) by TSH. In the presence of PMA and A23187 the intensity of the ID-I
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affinity labelled band (M.W. 28.1 kDa) decreased significantly, wether TSH was present
or not. Track 7 shows the labelling of human liver microsomes and once again the
presence of ID-I, as well as 5 other bands (approximate M.W. of 32.0, 42.0, 43.0, 58.0 &
59.2).
PMA and A23187 in addition to reducing ID-I expression, also changed the
expression of several other affinity labelled proteins. The intensities of five bands (M.W.
= 42.0, 44.5, 45.0, 58.0 & = 59.0 kDa) were decreased with PMA/A23187, while the
intensities of two other bands (~ 24.0 and = 25.8 kDa) were increased. The identity and
function of most of these proteins is unknown, though the two 45 kDa proteins are of the
same molecular weight as two mitochondrial isoenzymes of creatine kinase. In support
of this the activity of creatine kinase in the cell sonicates was also found to decrease with
the addition of PMA/A23187 (table 4c), while in the presence of TSH the activity of
creatine kinase rose, and was accompanied by an increase in the intensity of the 45 kDa
affinity labelled bands. The two proteins whose labelling was increased by PMA/A23187
(= 24.0 & 25.8 kDa) have approximately the same molecular weight as glutathione S-
transferases (GSTs), a group of proteins known to be involved in drug metabolism. One
could therefore speculate as to the identity of these labelled bands, though further
investigation would be required to confirm their identity.
In addition to the changes in protein expression seen with the affinity label, other
changes were observed on visual inspection of the gel when stained with Coomassie blue
(figure 4e). The intensity of six bands decreased with PMA/A23187 (tracks 2,4 & 6) in the
presence (tracks 3 - 6) or absence (tracks 1 & 2) of TSH, M.W. = 27.5, 35.0, 36.0, 37.5,
44.5 and 45.0 kDa. Four other proteins with M.W. = 26.5, 26.75, 33.5 & 34.0 kDa were
apparently induced by PMA/A23187. The identity of these proteins is unknown at present.
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f) Effect of activating the second messenger systems on thyrocyte morphology
Figure 4f shows the thyrocytes from all 3 groups grown in monolayer culture. In the
absence of TSH no follicles were observed, while the addition of TSH (1 U/L) caused the
formation of follicles. When PMA and A23187 were present in addition to TSH, no follicles
were observed.
g) Comparison of thyroidal ID-I activity in thyroid tissue from various thyroid disease
states
The level of ID-I activity measured in normal and multinodular thyroid tissues were
statistically indistinguishable and ranged between 8-46 fmol/min per mg protein (figure
4g). In contrast, the ID-I level in tissues from patients with Graves' disease were
significantly higher, with a range of activities from 116 - 246 fmol/min per mg protein.
h) Differences in the affinity labelling of thyroid tissue homogenates from various
thyroid disease states
Affinity labelling of multinodular goitre, Graves' disease and normal tissue resulted in the
appearance of approximately 8 predominant radiolabeled bands, including ID-I at a
molecular weight of 28.1 kDa (figure 4h). The presence of PTU and rT3 during labelling
resulted in the disappearance of the 28.1 kDa band, once again providing strong
evidence that the 28.1 kDa band is ID-I. Normal and multinodular tissues generally
showed low to moderate ID-I band intensity, with higher ID-I band intensity generally seen
in the Graves' disease tissues.
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Table 4a : Activity of ID-I in the thyroids and livers of the various species listed,
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Figure 4a : Autoradiography of an SDS-PAGE gel of thyroid homogenates from
various species labelled with bromoacetyl-[125l]-rT3. Tracks 1-8 show
sheep, llama, human, cattle, deer, pig, goat and rat respectively. The
mobilities of molecular mass markers are also indicated.
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Table 4b : Molecular weight of hepatic ID-I from various species as determined by
autoradiography of an SDS-PAGE gel of homogenates labelled with
bromoacetyl-[125l]-rT3 affinity label in the presence and absence of PTU and
rT3 (inhibitors of ID-I labelling). Affinity labelled bands observed within the
molecular mass region of hepatic ID-I in the corresponding thyroid
homogenates are also shown. Only human and rat thyroid tissue
expressed a protein band with the corresponding molecular weight of
hepatic ID-I in the same species (denoted by *). This data was produced
by Dr. J.R.Arthur and F. Nicol of the Rowett Research Institute, Aberdeen,
U.K as part of a collaborative study.












Figure 4b : Thyrocytes were cultured in the presence of 100 nmol/L sodium seienite
and concentrations of TSH from 0 to 10 U/L. Values shown are mean ±
SEM of triplicate incubations in a representative experiment carried out on
at least three occasions. Significant differences in ID-I activity from the
control (- TSH) were observed at TSH concentrations above 500 mU/L.
Concentrations of TSH in excess of 5 U/L caused a significant decrease
in ID-I activitycompared to TSH at 1 U/L (p < 0.05).
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Figure 4c : Thyrocytes were cultured in the presence of 100 nmol/L sodium selenite,
in the presence or absence of TSH, with further additions to wells in
triplicate of 8-Bromo-cAMP (104M), PMA (106M), A23187 (10"6M), PMA
with A23187 (10'6M) and DMSO (1 % v/v). Values shown are mean ± SEM
in a representative experiment carried out on at least 3 occasions.
Significant differences in ID-I activity from the control values were
observed with 8-Bromo-cAMP and PMA/A23187 when in the absence of
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Figure 4d : Autoradiography of an SDS-PAGE gel of thyrocyte sonicates labelled with
bromoacetyl-[125l]-rT3 affinity label after growth in the presence or absence
of various compounds. Tracks 1 & 2 show affinity labelling of thyrocytes
in the presence of TSH, with (track 1) and without (track 2) PMA/A23187
present. Tracks 3 - 6 show affinity labelling of thyrocytes grown in the
presence (tracks 3 & 4) or absence (tracks 5 & 6) of TSH, with (track 3 &
5) and without (track 4 & 6) PMA/A23187 present. Track 7 shows human
liver microsomes labelled with the affinity label as a control. The









Table 4c : Creatine kinase activity measured in human thyrocytes grown in the
presence or absence of TSH and in the presence or absence of PMA and








- TSH, - PMA/A23187
-TSH, + PMA/A23187
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Figure 4e : Photograph of a Coomassie-blue stained SDS-PAGE gel of thyrocyte
sonicates after growth in the presence or absence of various compounds.
Tracks 1 - 4 show thyrocytes grown in the presence (tracks 3 & 4) or
absence (tracks 1 & 2) of TSH, with (tracks 2 & 4) and without (track 1 &
3) PMA/A23187 present. Tracks 5 and 6 show thyrocytes from a different
preparation grown in the presence of TSH, with (track 6) and without
(track 5) PMA/A23187. Tracks A and B show human liver microsomes.
The mobilities of the molecular mass markers are also indicated.
A B 1 2 3 4 5 6
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Figure 4f: Photographs of human thyrocytes grown in the presence of various
compounds (Photograph A (no additions); Photograph B (TSH +,
PMA/A23187 -); and Photograph C (TSH +, PMA/A23187 +). The follicle








Figure 4g : Comparison of the level of ID-I activity found in normal, multinodular and
Graves' tissue as determined by the release of 125l from [125l]-rT3. No
significant difference in ID-I activity was demonstrated between normal
and nodular tissue, while ID-I activity in Graves' tissue was significantly
higher than either normal or nodular hyperthyroid tissue (5 patients per
group, p < 0.05 using a Mann-Whitney unpaired t-test).
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Figures 4h : Autoradiography of SDS-PAGE gels of thyroid homomgenates from three
types of thyroid tissue labelled with bromoacetyl-[1z5l]-rT3 in the absence
(a) or presence (b) of ffyPTU. Tracks 2, 4 & 8 show normal tissue, tracks
3, 7, 11, 14 & 15 show Graves', with the remaining tracks (1, 5, 6, 9, 10,
12,13) showing multinodular tissue. The mobilities of the molecular mass















All of the species studied showed significant hepatic ID-I expression (table 4a), but with
slight variations in the molecular weight of this enzyme (table 4b). These findings confirm
those of other workers (Schoenmakers et al, 1992) who have shown that, in general all
species have hepatic ID-I with similar turnover rate and specific activity, but with variation
in molecular weight between 25.7 and 29.1 kDa. However, Schoenmarkers et al also
found that the dog, for reasons not explained, exhibited much lower rates of ID-I turnover
than the other species studied (man, mouse, rabbit, cow, pig, sheep, goat, chicken or
duck), and like the rat, the dog had much higher levels of hepatic ID-I. In contrast, the
expression of thyroidal ID-I shows a much higher degree of species variation (table 4a).
As previously reported the human thyroid expresses ID-I (Ishii et al, 1981; Toyoda et al,
1992) and in addition, the thyroids of rat, guinea-pig and mouse also contained significant
levels of ID-I activity. The thyroids of the other species studied (sheep, llama, cattle, deer,
pig, goat and rabbit) showed barely detectable ID-I activity (< 0.3% of the activity of that
found in the rat) (table 4a).
Affinity labelling of the thyroid homogenates demonstrated variation in the intensity
of the ID-I band, as determined by autoradiography (figure 4a), which paralleled the
activity measurements. Thus, the variation in thyroidal ID-I activity between the species
is as a result of differences in the level of ID-I expression, and not differences in the
specific activity of the enzyme. To generalise, it would also appear that herbivores and
the pig lack thyroidal ID-I, while omnivores (rat, mouse, guinea-pig and man) express
significant levels of thyroidal ID-I. Why demarcation exists is unclear, though it may be
relevant that herbivores lack a potential source of plasma T3, which may become important
in conditions where TSH is elevated, such as in iodine deficiency.
In agreement with other workers I have found human thyroidal ID-I to be
responsive to TSH (figure 4b), and that the stimulation of ID-I expression is mediated via
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the cAMP second messenger pathway (figure 4c) (Ishii et al, 1983). The level of ID-I
activity was increased in a dose-dependent manner when TSH was added, with a
maximum response seen at 1 U/L TSH. Above this dose a significant decrease in activity
occurred. Previous workers have shown that high TSH concentrations stimulate the Ca2+-
phosphatidylinositol (Caz+-PI) cascade in human thyroid slices and human thyrocytes in
primary culture (Laurent et al, 1987; Laurent ef al, 1989; Raspe et al, 1991; Maenhaut et
al, 1990). These workers demonstrated increases in the concentrations of inositol-1,4,5
phosphate (IP3) and intracellular calcium (Ca2*) when 10 U/L TSH was added. They
concluded that TSH, at concentrations 10-fold higher than those required for maximal
stimulation of the cAMP cascade, activates phospholipase C, which catalyses the
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to yield IP3 and diacylglycerol
(DAG). The ability of TSH to stimulate both the cAMP and Ca2+-PI cascades has been
reported to occur through two distinct types of TSH receptor (Lefort et al, 1984; Laurent
et al, 1987). In this regard, several other hormones and neurotransmitters (e.g.
vasopressin and glucagon) have been shown to stimulate both pathways through different
receptors (Jard, 1983; Wakelam and Murphy, 1986). However, more recent work using
Chinese hamster ovary (CHO) cells transfected with the cDNA for the human TSH receptor
has shown that both pathways can be stimulated by TSH via one type of TSH receptor,
possibly by activation of Gs and Gq transducing GTP binding proteins (Van Sande et al,
1990).
The decrease in ID-I activity I found on addition of high concentrations of TSH
(figure 4b, TSH > 5 U/L) could be explained by activation of the Ca2+-PI pathway. This
hypothesis is supported by the data in figure 4c, where the phorbol ester, PMA and the
calcium ionophore, A23187 were added together in the presence of TSH (1 U/L). As a
result, a marked decrease in ID-I activity to basal levels was observed. Addition of PMA
and A23187 together is known to simulate the combined effects of DAG and Ins 1,4,5 P3
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respectively. It is logical therefore that stimulation of the Ca2+-PI pathway by other agents
might also result in a reduction in ID-I activity. Accordingly, ATP, bradykinnin and
thyrotropin-releasing hormone (TRH) might also modify ID-I activity as these agents have
been shown to stimulate the Ca2+-PI pathway in primary cultured human thyrocytes (Raspe
etal, 1991). Stimulation of the Ca2+-PI pathway by ATP has also been shown to occur in
the rat thyroid cell line FRTL-5, possibly through a P2 purinergic receptor (Okajima et al,
1988). In conjunction with this stimulation of the Ca2+-PI cascade, ATP can inhibit cAMP
accumulation, probably by inhibition of adenylate cyclase rather than activation of
phosphodiesterase, the enzyme responsible for hydrolysis of cAMP (Okajima etal, 1989).
These workers proposed that the inhibition of adenylate cyclase by ATP was mediated by
activation of the P2i or the A, purinergic receptor subtype, with these receptors making use
of a Gj or G-like transducer protein. It is noteworthy that ATP is often co-released from
cholinergic and adrenergic nerves (Gordon, 1986; Burnstock and Kennedy, 1986), and
that the thyroid has been shown to have extensive cholinergic and adrenergic innervation
(Melander, 1986). In addition, TRH and bradykinnin have also been shown to act as
neurotransmitters (Emerson, 1986; Steranka et al, 1988). It is interesting therefore to
speculate that release of ATP, TRH or brabykinnin could occur in the thyroid, thereby
giving rise to decreased ID-I expression via activation of the Ca2+-PI cascade (Raspe and
Dumont, 1992). In fact ATP could reduce ID-I expression both by the stimulation of the
Ca2+-PI cascade and by the inhibition of the cAMP cascade.
The level of ID-I expression in the thyrocytes was determined in the presence and
absence of various compounds (TSH, PMA/A23187) by comparing the intensity of the
affinity labelled proteins visualized by autoradiography (figure 4d). The level of ID-I activity
was found to correlate closely with the level of ID-I expression, as determined from the
intensity of the affinity labelled ID-I band. TSH (1 U/L) caused an increase in the level of
ID-I expression, while PMA/A23187 (both at 10"6M) caused a clear decrease in expression
116
of the ID-I band (M.W = 28.1 kDa). This data confirms that activation of the Ca2+-PI
pathway does cause reduced ID-I expression.
In addition to labelling ID-I, the affinity label also bound to several other proteins,
both in the human liver microsomes and in the human thyrocyte sonicates (figure 4d).
Five major bands were seen in the human liver microsomes (M.W. = 32.0, 42.0, 43.0, 58.0
& 59.2 kDa). The identity of these proteins remains to be investigated. Human thyrocytes
exhibited several proteins whose expression changed on addition of PMA/A23187. The
expression of three unidentified proteins was inhibited by PMA/A23187 (M.W. =42.0, 58.0
& 59.2), as was the expression of two proteins with molecular weights of 44.5 and 45.0
kDa. Kohrle etal identified two isoenzymes of mitochondrial creatine kinase (Mi-CK) with
molecular weight of approximately 45 kDa, using the affinity label bromoacetyl-[125l]-T3
(Wyss et al, 1993). In conjunction with the observed decrease in intensity of the two 45
kDa affinity labelled bands, I have also shown a decrease in the creatine kinase (CK)
activity when PMA/A23187 was present. TSH appeared to stimulate CK activity and the
expression of the two = 45 kDa proteins when PMA/A23187 was absent (table 4c, figure
4e). It is possible therefore that the two 45 kDa proteins are mitochondrial isoenzymes of
CK, although further investigation is required to confirm the identity of these proteins,
possibly via the use of Western blotting or mRNA identification techniques.
The affinity labelled band intensities of two proteins (M.W. = 24.0 & 25.8 kDa) were
increased by PMA/A23187. These proteins are approximately the same molecular weight
as the subunits of the glutathione S-transferases (GST) iosenzyme family. GSTs are a
family of multigene, cytosolic, phase 2 detoxification enzymes of which there are at least
seven in man. This group of isoenzymes catalyses the conjugation of reduced glutathione
to numerous electrophilic, hydrophobic compounds in the first step of mercapturic acid
formation. Certain GST isoenzymes have been demonstrated to have peroxidase activity
and are able to reduce organic hydroperoxides to their respective alcohols. Potential
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substrates for GSTs include fatty acids and DNA, and hence GST peroxidase activity may
represent part of a repair mechanism for both DNA and lipids. Non-catalytic properties
of GSTs include ligand-binding of various organic compounds such as bilirubin, steroids
and bile salts (Beckett and Hayes, 1993). Once again further investigation is required to
confirm the identity of these proteins.
Further to the changes seen in protein expression using the affinity label,
PMA/A23187 caused the expression of several other proteins to change, as assessed
when the gels were stained with Coomassie blue and visually inspected (figure 4e). Six
proteins decreased with PMA/A23187 (M.W. = 27.5, 35.0, 36.0, 37.5, 44.5 & 45.0 kDa),
while four proteins were induced (M.W. = 56.7, 26.75, 33.5 & 34.0). As described above
the - 45.0 kDa protein bands could be mitochondrial isoenzymes of creatine kinase. The
other proteins are yet to be identified. It is clear therefore that PMA and A23187 have
profound effects on the expression of a wide range of proteins, most probably refecting
the ability of this combination to simulate the Ca2+-PI cascade. In addition to the changes
in protein expression observed with PMA/A23187, these compounds when added together
caused inhibition of TSH-induced follicle formation (figure 4f). The observed changes in
protein expression may also reflect changes in cell growth and the degree of thyrocyte
differentiation.
When thyroidal ID-I activity was measured in the thyroid tissue from different
thyroid disease states, a large degree of variation was observed. The level of ID-I activity
measured in normal and multinodular hyperthyroid tissues was similar and ranged
between 8 - 46 fmol/min/mg (figure 4g). It is not known if the normal regulatory
mechanisms controlling ID-I expression operate in nodules where there is automonous
synthesis of thyroid hormones. Certainly if the expression of ID-I is still under the control
of TSH, one might expect that the ID-I activity should be similar in normal tissue and
nodular tissue since preoperatively both types of patients would have been rendered
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euthyroid (normal TSH levels) by pharmacological manipulation. The thyroid tissues taken
from patients with Graves' disease had significantly higher levels of ID-I activity ranging
from 116 - 246 fmol/min/mg (Mann-Whitney t-test, p < 0.014). Other workers also noted
increased ID-I activity in the thyroid tissue from patients suffering from Graves' disease
(Ishii etal, 1981). This increase is likely to be due to the presence and activity of thyroid
stimulating immunoglobulins (TSIs). It has been shown that TSIs can stimulate the
adenylate cyclase of human thyrocytes by binding to the TSH receptor (McKenzie and
Zakarija, 1976; Van Sande etal, 1980; Field etal, 1980). Stimulation of adenylate cyclase
via the TSH receptor is therefore most probably responsible for this increase in ID-I
activity. However unlike TSH, excessive concentrations of TSIs for reasons unknown, are
unable to stimulate the Ca2+-PI cascade in human thyroid slices (Laurent et at, 1991).
These workers therefore concluded that the pathogenesis of Graves' disease can be fully
accounted for by the ability of TSIs to stimulate adenylate cyclase.
The thyroid tissues which exhibited elevated ID-I activity also exhibited higher ID-I
band intensity when affinity-labelled with bromoacetyl-[125l]-rT3 (figure 4h). Labelling the
thyroid homogenates in the presence of rT3 (10pM) and PTU (500/jM), compounds which
bind to ID-I and interfere with the binding of the affinity label, resulted in the
disappearance of the 28.1 kDa band, thereby confirming the identity of this band as ID-I.
Therefore, those tissues with high ID-I activity demonstrate increased ID-I expression as
recently described (Toyoda et at, 1992), rather than an increase in the specific activity of
the enzyme. The ability of TSIs to stimulate ID-I expression, with no obvious mechanism
to guard against excessive over expression, may therefore be an important factor in the
pathogenesis of Graves' disease (Ishii et at, 1981; Toyoda et at, 1992), Indeed, during
Graves' disease there is an increase in the proportion of T3 produced directly by the
thyroid (Larsen, 1975), and ID-I could well produce a significant amount of this thyroidal
formed T3.
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Section 5 : THE SELENIUM-DEPENDENCE OF ID-i IN HUMAN
THYROCYTES GROWN IN PRIMARY CULTURE
In addition to ID-I, various other selenoproteins have also been reported in the thyroid
gland of rats (Behne et al, 1988). Behne et al showed that when [75Se]-selenite was
administered to rats, 11 proteins were labelled with 75Se in the thyroid. These proteins
had molecular weights of 12.1, 15.6, 18.0, 19.7, 23.7, 27.8, 55.5, 59.9, 64.9, 70.1 and 75.4
kDa. The protein with a molecular weight of 23.7 kDa is most probably a subunit of
glutathione peroxidase (GPx) (Rotruck et al, 1973), the enzyme responsible for the
protection of tissue from peroxidative damage. The protein with a molecular weight of
27.8 Kda was shown to be ID-I (Beckett etal, 1987; Behne et al, 1988; Behne et al, 1990;
Kohrle etal, 1990a; Kohrle etal, 1990b). The function and role of the remaining proteins
remains to be elucidated, however some of these proteins may well have important
biological roles, since in selenium deficiency they appear to be supplied with selenium in
preference to glutathione peroxidase (Behne et al, 1988). In selenium deficiency ID-I is
also supplied with selenium in preference to GPx, since rat hepatic ID-I activity was
decreased to 10% of the activity found in selenium-supplemented rats, while GPx
decreased to less than 1% of the supplemented animals (Beckett et al, 1987; Beckett et
al, 1989; Arthur et al, 1990d).
In addition to its roles in GPx and ID-I activity, selenium has also been shown to
have various other important functions. In vitro experiments have shown selenium is
required for cell growth, but inhibits the growth of cells in a reversible manner at high, but
sub-toxic levels (Medina and Oborn, 1981; Medina and Oborn, 1984; Medina et al, 1985).
Similar levels of selenium were alsoshown/'n vivo to act in an anti-carcinogenic manner in
various animal models (Medina, 1986; Ip, 1986; Combs and Combs, 1986a). Clearly
selenium has far reaching and widespread roles in biological systems.
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In this section I have studied the effects of selenium supply on thyroidal ID-I using
primary cultured human thyrocytes. I have thenproceededo investigate the effects of
adding gold thioglucose (a compound that bind to selenocysteine) to human and sheep
thyrocytes in primary culture. In addition I have investigated selenium trapping by human
thyrocytes, and also studied the expression of various selenoproteins found in human
thyrocytes.
5.01 : Methods
a) Effect of selenium on ID-I activity in human thyrocytes
Human thyrocytes were prepared as described in Section 2.03 from normal, multinodular
or Graves' thyroid tissue. The thyrocytes were plated out in 12 well plates at a cell density
of 5x10s cells/well in 1 ml of medium (DMEM/10% CPSR-5) and incubated for 24 hours in
a 37°C, 5% C02 incubator. After 24 h, the culture medium was removed and the
thyrocytes washed twice with 1 ml EBS before fresh DMEM was added (containing no
CPSR-5). Selenium, as sodium selenite, was added at concentrations ranging from 10 to
1000 nM to wells in triplicate, in the presence or absence of TSH (1 U/L). After a further
24 h, the medium was removed, the thyrocytes washed again and fresh medium added
containing the same concentrations of TSH and selenium as in the initial incubation. The
thyrocytes were then cultured for a further 4 days before being washed twice with EBS
and removed from the plate as described in Section 4.01c. ID-I activity in the thyrocyte
sonicates was measured as previously described in Section 2.06. The protein content of
each sonicates sample was also determined and used to correct the ID-I activity for
protein (Section 2.07).
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b) Effect of different cell culture protocols on selenium status
To investigatewhether or not the adopted cell culture protocol could significantly alter
selenium status, human thyrocytes were prepared as described in Section 2.03 and grown
in 75cm2 flasks at a density of 10 million cells per flask in 20 ml of growth medium
(DMEM/10% CPSR-5). After 24 h the medium was removed from the flasks, and the
thyrocytes washed twice with 20 ml of EBS. To half of the flasks, 20 ml of fresh growth
media with TSH (DMEM/10% CPSR-5/1 U/L TSH) was added, and the thyrocytes cultured
for a further 5 days. The remaining thyrocytes were cultured in 20 ml of serum free growth
medium with TSH (DMEM/1 U/L TSH) for 24 h prior to an extra wash protocol consisting
of two washes (20 ml per wash). Subsequently, 20 ml of fresh DMEM/1 U/L TSH was
added and the thyrocytes cultured for a further 4 days (N.B. total time in culture was equal
to those thyrocytes grown with 10% CPSR-5 present). At the end of the incubation period
the thyrocytes were harvested as previously described (Section 4.01 e) and the cell pellets
frozen at -70°C. The GPx and selenium levels were kindly measured by Dr. J.R. Arthur
and F. Nicol of the Rowett Research Institute by methods previously described (Beckett
etal, 1990; Arthur, 1988).
c) Effect of gold thioglucose on T3 and T4 production by human and sheep thyrocytes
in primary culture
Human and sheep thyrocytes were prepared and grown as described in Section 2.03.
After 24 h the medium was removed from the thyrocytes in monolayer culture and the cells
washed twice with 1 ml of EBS before 1 ml of fresh growth medium (DMEM/10% CPSR-5)
containing Kl (10 pM) and TSH (1 U/L) was added. To wells in triplicate, gold thioglucose
was added to give a concentration of range from 10'9M to 10"4M. After 5 days incubation
the concentration of T3 and T4 secreted into the culture medium was determined as
described in Section 2.04c.
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d) Effect of gold thioglucose on ID-I activity in human thyrocytes
Human thyrocytes were prepared as described in Section 2.03. After 24 h, the culture
medium was removed and the thyrocytes washed twice with 1 ml of EBS before fresh
growth medium (DMEM/10% CPSR-5) containing TSH (1 U/L) was added. To wells in
triplicate gold thioglucose was added over a concentration range of 10'9 to 10"3 molar.
The thyrocytes were then cultured for a further 5 days before being washed three times
with EBS and removed from the plate as described in Section 4.01c. ID-I activity in the
thyrocyte sonicates was measured as previously described (Section 2.06). The protein
content of each well was also measured and used to correct the ID-I activity for protein
(Section 2.07).
e) Labelling of selenoproteins in human thyrocytes using [75Se]-selenite
Human thyrocytes were prepared as described in Section 2.03, plated out in four 75cm2
flasks at a density of 10 million cells per flask in 20 ml of growth medium (DMEM/10%
CPSR-5) and subsequently incubated at 37°C with a 5% COz atmosphere. After 24 h, the
medium was removed and the cells washed twice with 20 ml of EBS before 0.74 MBq of
[75Se]-selenite (specific activity 74 MBq/mg) was added to each flask in 20 ml of fresh
growth medium. To half of the cells, PMA and A23187 were added, both at a
concentration of 1 pM in the presence or absence of TSH (1 U/L). The remaining cells
were grown in the absence of PMA/A23187 and in the presence or absence of 1 U/L TSH.
After a further 5 days the growth medium was removed, the thyrocytes washed
twice with EBS and then removed from the flasks as described in Section 4.01 e. The
resulting pellets were then sonicated in 1 ml EBS prior to determination of the protein
concentration. Samples were then diluted to a protein concentration of 1 g/L using
labelling buffer before being heat treated (90°C, 10 min) with "boiling mix" at a ratio of 2:1
(sample : boiling mix). The samples were loaded (20pg/track) and run on an SDS/PAGE
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gel as described in Section 2.09. The resulting gel was dried and autoradiographed as
described in Sections 2.09 and 2.10.
f) Investigation of selenium trapping by human thyrocytes
Human thyrocytes were prepared as described in Section 2.03 and maintained in
suspension culture at a cell density of 1 x106 thyrocytes/ml of growth medium (DMEM/10%
CPSR-5) in 50 ml pots. TSH at 1 U/L was added to half the thyrocytes, and all the
thyrocytes were pre-incubated for 16 h. Four pots were set up; two were incubated at
37°C for the duration of the experiment, and the other two at 4°C for 18 h (N.B. switched
to 4°C 2 h prior to the start of the experiment), with a further 9 h incubation at 37°C.
Hence 4 groups were created; a) TSH -, 4°C; b) TSH 37°C; c) TSH +, 4°C and d) TSH
+ , 37°C (+/- TSH denotes presence/absence of 1 U/L TSH). After the pre-incubation, the
experiment was started by the addition of [75Se]-selenite (specific activity 74 MBq/mg
Se) to each pot to give a final concentration of tracer equal to 74 kBq per ml of growth
medium. After thorough mixing, 400/71 samples in triplicate were removed from each pot
into Eppendorf tubes at specified times (0 - 27 h) after the addition of the 75Se-selenite,
and centrifuged at 3500 g for 5 minutes to pellet the thyrocytes. Subsequently, the pellets
were washed 3 times with 1 ml of isotonic saline (0.9%, w/v), before being counted for the
radioactivity resulting from gamma decay of 75Se.
5.02 : Results
a) Effect of selenium on ID-I activity in human thyrocytes
A large degree of variability was observed in the level of ID-I activity in the thyrocytes
when exposed to TSH (1 U/L) and the various concentrations of selenium, when
comparing thyrocytes from different preparations (figure 5a - 5e). Addition of TSH to the
thyrocytes in the absence of selenium resulted in a significant increase in some
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experiments (figure 5a - 5c), while in others a small, but not significant increase occurred
(figure 5d & 5e). Addition of a range of selenium concentrations (0 - 1000 nM) to the
thyrocytes in the absence of TSH failed to cause any significant change in the level of ID-I
activity in all 5 experiments (figure 5a - 5e). In contrast, ID-I activity increased in the
presence of TSH, as the selenium concentration rose to an optimum concentration of 500
nM in 3 of the experiments (figure 5a - 5c); the other 2 experiments exhibiting a similar
pattern though the changes were not significant (figures 5d & 5e). A higher concentration
of selenium (1000 nM) resulted in a significant decrease in activity when compared to the
optimum concentration of 500 nM, though the level of ID-I activity still remained above the
level observed without added selenium, but in the presence of TSH. Overall similar
patterns of change were observed in normal (figure 5a), multinodular (figure 5b) and
Graves' (figure 5c) derived thyrocytes.
b) Effect of different cell culture protocols on selenium status
The thyrocytes grown in the absence of CPSR-5 (i.e serum free), had a tendency to
exhibited lower levels of GPx and selenium than those grown in the presence of CPSR-5
(table 5a), though the differences were not significant (i.e. p > 0.05 using an unpaired t-
test and a Welch test, respectively).
c) Effect of gold thioglucose on T3 and T4 production by human and sheep thyrocytes
in primary culture
Gold thioglucose failed to cause any significant change in the amount of T3 produced by
the human thyrocytes in primary culture (figure 5f). In contrast to this, the amount of T4
produced was slightly decreased by the addition of gold thioglucose, with very small
amounts of both thyroid hormones produced (figure 5f). The production of both T3 and
T4 by sheep thyrocytes was much higher and increased significantly with the addition of
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gold thioglucose at concentrations above 10"7M for Ta and 10"5 for T4 (figure 5g). The
maximum observed increases in both thyroid hormones occurred at 10"4M, and consisted
of a 65% rise, though even higher increases in T3 and T4 concentration might occur at
gold thioglucose concentrations in excess of 10"4M.
d) Effect of gold thioglucose on ID-I activity in human thyrocytes
Gold thioglucose at a concentrations at and below 10"7M caused no significant change
in the ID-I activity measured in the human thyrocyte sonicates (figure 5h). In contrast, the
addition of gold thioglucose at concentrations in excess of 10® showed significant
inhibition of ID-I activity. Maximum inhibition was observed at 10"3M and consisted of a
7-fold decrease in the measured level of ID-I activity when compared to the control (no
gold thioglucose).
e) Labelling of selenoproteins in human thyrocytes using [7SSe]-selenite
Approximately 17 major bands were labelled with 75Se when the human thyrocytes were
grown in the presence of [75Se]-selenite (figure 5i). Eight bands appeared to be labelled
with equal intensity in all of the samples, regardless of the additions made. These
proteins had approximate molecular weights of 15.0,18.0, 20.0, 21.5, 22.5, 25.0, 26.5 and
56.0 kDa. In addition to these, the labelling of other proteins varied according to the
additions made. TSH had no noticeable effect on the expression of most of the proteins,
the exception being ID-I (M.W = 28.1). The expression of ID-I increased with TSH, but
was decreased significantly in the presence of PMA and A23187. The expression of 3
other bands also decreased on addition of PMA and A23187 (M.Ws = 24.0, 66.2 & 72.5
kDa). PMA and A23187 did however induce the expression of other proteins with
approximate molecular weights of 31.7, 51.5, 58.5, 63.0 and 97.4 kDa. The 58.5 kDa
protein was also present in thyrocytes grown without PMA and A23187, regardless of the
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presence or absence of TSH. The intensity of this band however, was much higher when
PMA and A23187 were present.
f) Investigation of selenium trapping by human thyrocytes
A significant amount of [75Se]-selenite was trapped by thyrocytes after 27 h of incubation,
regardless of the manipulations made (figure 5j). TSH had no significant effect on the rate
of 75Se trapping or total amount of 75Se trapped by the human thyrocytes after 27h. There
was a clear, significant difference in the rate of 75Se trapping between the groups
incubated at 37°C or 4°C. Those thyrocytes incubated at 37°C trapped approximately
60,000 cpm of 75Se, and reached a plateau after 12 h. In contrast, those maintained at
4°C trapped only 8,000 cpm in the same period of time, but on further incubation at 37°C
they increased the rate of trapping such that both groups had trapped the same amount
of 75Se 60,000 cpm) after 27 h (figure 5j).
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Figure 5a : Effect on ID-I activity of adding selenium to the medium of human
thyrocytes isolated from normal tissue, grown in the presence (□) or
absence (A) of TSH (1 U/L) for 5 days. Values shown are the mean ±
SEM of wells in triplicate. TSH caused a significant increase in ID-I
activity (p < 0.05), with a further significant rise at selenium
concentrations of 100 nM or greater. Selenium at a concentration of 1000





Figure 5b : Effect on ID-I activity of adding selenium to the medium of human
thyrocytes isolated from multinodular hyperthyroid tissue, grown in the
presence (□) or absence (A) of TSH (1 U/L) for 5 days. Values shown are
the mean ± SEM of wells in triplicate, with a significant increase observed
in the presence of TSH at selenium concentrations of 50 nM or greater.
TSH also caused a significant increase in ID-I activity in the absence of
selenium (p < 0.001).
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Figure 5c : Effect on ID-I activity of adding selenium to the medium of human
thyrocytes isolated from Graves' hyperthyroid tissue, grown in the
presence (□) or absence (A) of TSH (1 U/L) for 5 days. Values shown are
the mean ± SEM of wells in triplicate. Significant increases in ID-I activity
occurred at 100 and 500 nM selenium, in the presence of TSH. A
significant decrease in ID-I occurred between 500 and 1000 nM selenium
(p < 0.01). TSH caused a significant increase in ID-I activity in the
absence of selenium (p < 0.01).
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Selenium Added (nmol/L)
Effect on ID-I activity of adding selenium to the medium of human
thyrocytes isolated from Graves' hyperthyroid tissue, grown in the
presence (□) or absence (A) of TSH (1 U/L) for 5 days. Values shown are
the mean ± SEM of wells in triplicate. No significant changes were
observed.
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Selenium Added (nmol/L)
Effect on ID-I activity of adding selenium to the medium of human
thyrocytes isolated from Graves' hyperthyroid tissue, grown in the
presence (□) or absence (A) of TSH (1 U/L) for 5 days. Values shown are
the mean ± SEM of wells in triplicate. No significant changes were
observed.
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Table 5a : Level of selenium and GPx activity in human thyrocytes grown in the
presence or absence of 10% CPSR-5 (fetal calf serum). Thyrocytes grown
in the absence of CPSR-5 were also subjected to an extra washed in an
attempt to deplete the thyrocytes of selenium. No significant changes
occurred. These measurements were kindly performed by Dr. J.R. Arthur
and F. Nicol of the Rowett Research Institute, Aberdeen, U.K.
Culture Protocol GPx Activity Selenium Level
(U/mg, n = 6) (ng/mg, n = 3)
DMEM only 0.035 ± 0.005 1.55 ± 0.52
DMEM/10% CPSR-5 0.045 ± 0.002 1.83 ± 0.11
133
Figure 5f : Effect of 5 days exposure to gold thioglucose on thyroid hormone
production from human thyrocytes grown in primary culture in the
presence of TSH (1 U/L). The accumulated medium content of Ta (□) and
T4 (A) was measured and the data expressed as mean ± SEM of triplicate
wells in a representative experiment performed on at least three
occasions. Significant decreases in T4 accumulation occurred with gold




























Figure 5g : Effect of 5 days exposure to gold thioglucose on thyroid hormone
production from sheep thyrocytes grown in primary culture in the
presence of TSH (1 U/L). The accumulated medium content of T3 (□) and
T4 (A) was measured and the data expressed as mean ± SEM of triplicate
wells. Significant increases in T3 and T4 accumulation occurred at gold
thioglucose concentrations of 10"7 or greater when compared to the







































Figure 5h : Effect on ID-I activity of adding gold thioglucose to human thyrocytes
grown in primary culture in the presence of TSH (1 U/L) for 5 days.
Values shown are the mean ± SEM of triplicate wells in a representative
experiment carried out on three occasions. Concentrations of gold
thioglucose in excess of 10"6M caused significant decreases in ID-I activity.
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Figure 5i : Autoradiography of an SDS-PAGE gel of thyrocyte sonicates labelled with
75Se during growth in the presence or absence of various compounds.
Thyrocytes were grown in the presence (tracks 3 & 4) and absence (track
1 & 2) of TSH (1 U/L), and also in the presence (tracks 2 & 4) and
absence (tracks 1 & 3) of PMA/A23187 (10"6M). Track 5 shows affinity
labelled human liver microsomes used as an aid in determining the
identity of the ID-I band. The mobilities of the molecular mass markers









Figure 5j : Effect of temperature and TSH on 75Se trapping in human thyrocytes
pelleted by centrifugation after incubated in suspension culture in the
presence of 74kBq/ml of 75Se. Thyrocytes incubated at 4°C were switched
to 37°C after 18 h (denote by I). Thyrocytes were grown either in the
presence (□) or absence (A) of TSH (1 U/L). Values shown are mean ±
SEM for samples taken in triplicate for a representative experiment carried
out on three occasions. At 37°C, time points above 1 hr showed
significant trapping of 75Se in the presence and absence of TSH. Until the
thyrocytes were switched to 37°C, the thyrocytes incubated at 4°C showed
no significant trapping of 75Se, but had statistically trapped the same

































TSH added at a concentration of 1 U/L induced an increase in ID-I activity, even in the
absence of added selenium (figures 5a - 5e). In the absence of TSH, the addition of
increasing amounts of selenium had no significant effect on ID-I activity (figures 5a - 5e).
In contrast, in most thyrocyte preparations a small, dose-dependent increase (2 or 3-fold)
in ID-I activity could be seen as selenium was added to the thyrocytes grown in the
presence of TSH. These data suggest that thyrocytes retained sufficient selenium to allow
a limited increase in ID-I expression. Indeed, the data produced subsequently (table 5a)
demonstrates that the thyrocytes retained significant levels of selenium and GPx activity
under the culture conditions used, though the levels of both selenium and GPx had a
tendency to be slightly lower in the absence of CPSR-5, than in the presence of 10%
CPSR-5. This data, in conjunction with the observed increases in ID-I activity implies that
selenium supply may be slightly inadequate under these conditions for normal levels of
selenoprotein expression.
Other workers have also shown a dependence of ID-I on selenium concentration
using cells in culture (Oertel et al, 1993). Using the porcine-kidney cell line (LLC-PK1)
these workers demonstrated a clear dependence of ID-I activity on selenium, with a
plateau observed at 10 nmol selenite/L. Clearly there is a significant difference between
the LLC-PK1 and primary cultured human thyrocyte systems with respect to the
concentration of selenite required for maximum ID-I activity (10 nM and 500 nM
respectively). The cause of this difference is unclear, however this difference may be an
artefact of using cell lines. Cell lines often behave differently than primary cultured cells;
for example the human thyroid cell lines HTori-3 and FTC-133 lack ID-I expression, while
primary cultures of multinodular, normal and Graves' human thyroid tissues all express
significant levels of this enzyme (Beech, 1992; Ishii et al, 1981; Oertel etal, 1991). I also
observed with the human thyrocytes that selenite at a concentration of 10 /vM or greater
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was cytotoxic to human thyrocytes, while Oertel and coworkers show similar, cytotoxic
effect of selenite at the slightly lower concentration of 5 /uM. Oertel et al, also found that
the full expression of glutathione peroxidase (GPx) required 10 - 20-fold higher
concentrations of selenite than for the full expression of ID-I. My data and that of Oertel
et al clearly demonstrates that ID-I levels are maintained or can even be increased in
selenium-deficient conditions, while the level of GPx expression decreases. These
findings support the hypothesis of Behne etal, who proposed the existence of a molecular
hierarchy for selenium supply, with selenoproteins other than glutathione peroxidase
receiving a preferential supply of selenium (Behne et al, 1988).
Addition of gold thioglucose to human thyrocytes grown in the presence of TSH
and Kl caused no significant change in the level of T3 produced by the thyrocytes, but a
small, significant decrease in T4 production was noted (figure 5f). Since gold thioglucose
has been shown to inhibit selenoenzymes by binding to the selenocysteine residue found
at the active site (Chaudiere and Tappel, 1984), it might be expected that the addition of
gold thioglucose would cause an increase in T4 production and a decrease in T3
production by inhibiting ID-I activity. Indeed, gold thioglucose does inhibit ID-I as
described below, and hence the reason for the lack of a gold effect on thyroid hormone
production is unclear at present. In contrast to the human thyrocytes, addition of gold
thioglucose to sheep thyrocytes produced large changes in the amount of thyroid
hormones found in the culture medium (figure 5g). Production of T3 and T4 were both
significantly increased when gold thioglucose was added at concentrations above 10"6M.
This increase in thyroid hormone production may be mediated by an inhibition of
glutathione peroxidase, the selenoenzyme responsible for protecting the thyrocytes
against peroxide damage by hydrogen peroxide. Inhibition of GPx could result in a
significant increase in the intracellular concentration of hydrogen peroxide. The availability
of hydrogen peroxide has been shown to be the rate limiting step in the organification of
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iodine by thyroperoxidase (TPO) and hence thyroid hormone synthesis (Ahn and
y
Rosenberg, 1970; Bjorkman and Ekholm, 1988). Thus elevated levels of intracellular
hydrogen peroxide could increase organification of iodine and hence increase synthesis
of both thyroid hormones.
The addition of gold thioglucose to human thyrocytes grown in the presence of
TSH (1 U/L) resulted in a significant decrease in the level of ID-I activity measured in the
thyrocyte sonicates (figure 5h). At concentrations below 10'7M, gold thioglucose caused
no significant change in ID-I activity, while concentrations in excess of 10"6M resulted in
large decreases in ID-I activity. Maximum inhibition of ID-I occurred at 10"3M and
consisted of a 88% decrease. Berry et al have also shown inhibition of ID-I by gold
thioglucose, with a 40% inhibition observed at 10 nM in vitro (Berry et al, 1991b).
Furthermore, these workers have shown that gold thioglucose at 100-fold higher
concentrations can inhibit a mutant form of ID-I, consisting of cysteine substituted for
selenocysteine, and thereby confirm that gold thioglucose acts by binding to the reactive
selenium of the selenocysteine found at the active site.
When human thyrocytes were grown in the presence of [75Se]-selenite,
approximately 17 major [75Se]-labelled bands were visible on an autoradiograph (figure
5i). These proteins had approximate molecular weights of 15.0, 18.0, 20.0, 21.5, 22.5,
24.0, 25.0, 26.5, 28.3, 31.7, 51.5, 56.0, 58.5, 63.0, 66.2, 72.5 and 97.4 kDa. Eight proteins
were equally expressed by all of the thyrocytes, regardless of the various additions made
to the growth medium (M.Ws = 15.0, 18.0, 20.0, 21.5, 22.5, 25.0, 26.5 and 56.0 kDa). The
identity of most of these proteins is unknown, however some of these proteins have been
previously shown to be expressed in various rat tissues (Behne et al, 1988) and hence
they are not specific to the human thyroid. The expression of the remaining 9 proteins
was modified by the addition of PMA/A23187 (both at 1 fjM) and/or TSH (1 U/L) to the
culture medium. TSH had no noticeable effect on the expression of most of the labelled
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proteins with the exception of ID-I (M.W. = 28.1). In the presence of PMA and A23187 the
ID-I band disappeared, as did 3 other bands with approximate molecular weights of 24.0,
66.2 & 72.5 kDa. PMA and A23187 also induced the expression of several other proteins
with molecular weights of 31.7, 51.5, 58.5, 63.0 and 97.4 kDa. Induction of the 58.5 kDa
protein band was marked, however unlike the other proteins induced by PMA/A23187 this
58.5 kDa protein was also present in thyrocytes grown in the absence of PMA/A23187.
The existence of selenoproteins with molecular weights of 58, 56 and 14 kDa has
been reported by various members of Medina's group (Morrison etal, 1988b; Morrison et
al, 1988a; Bansal etal, 1989b; Bansal etal, 1990b; Bansal etal, 1990a). These workers
showed that the 58 kDa selenoprotein could mediate the growth inhibitory effects of high
selenium in murine mammary epithelial cells, or at least that its expression correlated well
with the selenium sensitive mechanisms which could control growth. In addition these
workers have showed that higher levels of this selenoprotein were present in cells which
were not dividing, when compared to cells undergoing rapid cell division, with evidence
for inhibition of DNA synthesis by this protein (Morrison et al, 1988b; Morrison et al,
1988a).
The 56 kDa and 14 kDa selenoproteins (now termed SP56 & SP14) were also
investigated by Medina's group (Bansal et al, 1989b), and are distinct from the 58 kDa
protein (Lanfear etal, 1993). Expression of the SP56 and SP14 proteins in various rodent
tissues was shown by Medina and coworkers to be independent of dietary selenium, with
the DNA for the SP56 and SP14 proteins also shown to lack an in-frame TGA codon which
could code for a selenocysteine residue (Bansal et al, 1990b; Bansal et al, 1990a).
Hence, these proteins are not like the selenoproteins characterised in recent years (e.g.
GPx, selenoprotein P, ID-I etc.) which contain a selenocysteine residue. It has been
suggested that selenium mediates it's effects by modifying the function of pre-existing
proteins, two of which may be SP56 and SP14 (Bansal et al, 1990b). Wether the function
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of the 58 kDa selenoprotein is mediated in a similar manner is not known at present.
However, the addition of methionine and serine together has been shown to increase the
expression of the 58 kDa protein, with this increase postulated to occur in response to
enhanced provision of selenocysteine (Morrison et al, 1988a). This observation implies
that the 58 kDa protein contains a selenocysteine specifically incorporated in response
to a UGA codon. The way in which selenium is associated with the SP56 and SP14
selenoproteins is unclear at present, however several proteins retained 75Se during and
after electrophoresis on an SDS-PAGE gel and hence the selenium must be tightly bound
to these proteins.
The selenoprotein, SP14 is now thought to be the fatty acid binding protein
(FABP), found in liver (Bansal et al, 1989a). Furthermore, due to the homology between
FABP and two growth inhibition proteins found in bovine mammary glands and in
fibroblasts, FABP has now be postulated to be involved in the control of cell growth. The
role of SP56 is still not fully elucidated. Initially, SP56 was thought to have a role as a
selenium transport protein or as growth regulation protein (Bansal etal, 1989b). However,
it has been demonstrated recently that the SP56 protein has a high degree of sequence
homology with the 56 kDa, acetaminophen-binding protein (AP56) (Lanfear ef al, 1993).
The AP56 protein has been shown to protect against acetaminophen-induced hepatoxicity,
possibly by scavenging toxic electrophiles or acetaminophen metabolites. Due to
structural similarities, SP56 and AP56 are believed to have the same role. Indeed, there
is evidence to suggest that the detoxification of acetaminophen is dependent on selenium
status, though there is no direct evidence as yet for selenium-dependent acetaminophen-
binding to SP56 or AP56 (Lanfear et al, 1993).
The regulation of thyrocyte growth is believed to be under the control of all 3 main
second messenger cascades (Raspe and Dumont, 1992). As a generalisation, in the
thyrocyte the cAMP cascade is believed to cause proliferation and differentiation. The
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tyrosine kinases which are usually associated with receptors also bring about thyrocyte
growth, but cause dedifferentiation. Finally, the Ca2+-PI cascade appears to have limited
effects on growth and differentiation, but also causes an increase in protein synthesis,
with a pattern similar to that of tyrosine kinase. Overall, the 3 second messenger
cascades are believed to cause changes in the activity and/or expression of various,
unknown growth regulatory proteins (Dumont etal, 1992). The 58 kDa protein described
by Medina's group may well be one of these proteins, with its function dependent on
selenium supply. I have shown that PMA and A23187, which simulate the effects of
activating the Ca2+-PI cascade caused an increase in the band intensity of a 58.5 kDa
selenoprotein in human thyrocytes (figure 5g). This increase may be a result of increased
expression, though increased binding of 75Se to the pre-existing protein can not be ruled
out unless the mRNA from the protein is isolated and sequenced. Which of these
mechanisms is in operation is unclear, though it is intriguing to speculate that the 58.5
kDa protein may be the 58 kDa protein reported by Medina's group to modify cell growth.
Changes in this 58.5 kDa protein might also explain the morphological changes observed
on addition of PMA and A23187 to human thyrocytes in primary culture. These changes
consisted of the disappearance of TSH induced follicles (figure 4f).
I have also demonstrated temperature-dependent accumulation/trapping of [75Se]-
selenite in human thyrocytes in primary culture (figures 5j) which was not significantly
influenced by the presence of TSH in the growth medium. As the accumulation of selenite
was temperature-dependent, the mechanism responsible is most probably energy-
dependent. However, the experimental method does not distinguish between an active
transportmechanism or trapping/incorporation of selenite in selenoproteins. Other studies
offer support for an active transport mechanism, and these including the observation that
selenite can been be transported across the brush border membrane of small intestine
mucosal cells (Wurmli etal, 1989). Wurmli etal demonstrated that selenium (as selenite)
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can be transported across the brush border membrane as either selenotrisulphides or
selenopersulphides by Na+-dependent amino acid carriers after the reaction of selenite
with thiols such as cysteine or glutathione. As there would be an insufficient
concentration of thiol compounds within the growth medium, this mechanism is unlikely
to be involved in seienite uptake by human thyrocytes. Other workers have shown that
erthyrocytes can take up selenium, using selenite in preference to selenate or
selenomethionine (Lee et al, 1969; Jenkins and Hidiroglou, 1972; Sandholm, 1973a;
Sandholm, 1973b). However, this "active" uptake of selenite was found to result from the
modification of selenite and subsequent secretion of the product from the erthyrocyte,
which thereby maintained a concentration gradient of selenite into the erthyrocyte (Lee et
al, 1969). Whether selenite can be actively taken up or not, selenite is not normally found
to any extent in the body and hence it is not the physiological form of selenium which
could possibly be taken up by the thyroid in vivo. However, it is of interest that selenium
supplementation is usually performed with selenite, and hence selenite trapping may be
of importance under these conditions. Most naturally occurring dietary selenium is found
as selenomethionine or selenocysteine, with L-selenomethionine shown to be actively
transported in the intestine of hamsters by the methionine transport carrier (McConnell and
Cho, 1966).
The thyroid gland may also possess a methionine transport system, as TSH has
been shown to modify the intrathyroidal cytosolic pools of methionine (Cooper et al, 1986).
One could speculate that thyroidal uptake of selenomethionine could occur via a
methionine transport pathway, with this system stimulated by TSH. The ability of TSH to
maintain a supply of selenium to the thyrocyte in selenium deficiency is desirable since
TSH would be expected to increase intrafollicular H202 concentrations. The increase in
selenium supply would allow expression of GPx to be maintained and thus protect against
peroxidative damage.
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A selenomethionine or selenite uptake mechanism could possibly explain the
ability of human thyrocytes in primary culture to increase ID-I activity, even in the absence
of exogenous selenium by recovering selenium lost to the medium. The presence of a
selenium uptake system would also explain the reported ability of the thyroid to retain
selenium far longer than liver and kidney (Behne et al, 1988).
In summary, the data presented in this Section demonstrates that ID-I is indeed as
selenoenzyme, dependent on selenium supply for its expression and activity. However,
ID-I is only one of several selenoproteins present in human thyrocytes. One of these
selenoproteins with a molecular weight of » 58.5 kDa may have a role in the selenium-
mediated regulation of cell growth and division. Finally, thyrocytes could possess an
active uptake mechanism for selenium which would allow the thyroid to retain selenium
in preference to liver and kidney.
150
Section 6 : EFFECTS OF SELENIUM AND IODINE DEFICIENCY
ON THYROID HORMONE METABOLISM IN RATS
Iodine is an essential trace element for the production of thyroid hormones. Deficiency
of this element has been shown to have wide ranging effects on the mental and physical
development of the child and fetus, with severe iodine deficiency resulting in cretinism
(Hetzel, 1983). Iodine deficiency in adults also has profound effects, but these are
restricted to irregularities in the control of metabolism. There are a number of mechanisms
which can protect people from the harmful effects of iodine deficiency which include
increased iodine trapping by the thyrocytes, and an increase in the proportion of thyroid
hormone secreted from the thyroid as triiodothyronine (T3) (Adams and Larsen, 1973). As
a result the plasma T3 concentration is maintained at the expense of plasma thyroxine (T4)
(Silva, 1985).
Iodine deficiency can also increase the activity of thyroidal ID-I, and hence this
enzyme may contribute significantly to the amount of T3 secreted directly by the thyroid
(Green, 1978; Laurberg, 1980; Laurberg, 1984). As ID-I is selenium-dependent, it has
been suggested that selenium deficiency can exacerbate the effects of iodine deficiency
in rats (Arthur et al, 1990c). Dual deficiency of selenium and iodine has also been
suggested to be involved in the pathogenesis of endemic cretinism (Goyens et al, 1987;
Vanderpas et al, 1990).
In this section the effects of selenium, iodine and combine selenium/iodine
deficiency on ID-I, and plasma thyroid hormones are studied using the rat as a model.
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6.01 : Methods
a) Effect of selenium status on hepatic ID-I activity, plasma T3 and plasma T4
Male, Hooded Lister, weanling rats of the Rowett Institute strain were divided into six
groups and offered diets for 6 weeks, supplemented where appropriate with selenium as
follows : a) 0.005, b) 0.015, c) 0.025, d) 0.045, e) 0.1, and f) 0.4 mg selenium per kg of
diet mix (as sodium selenite). The rats were given free access to distilled water and food.
The food intake was recorded daily, with the body weight of animals recorded on a weekly
basis. At the end of the experiment, rats were anaesthetized with diethyl ether, and blood
taken into heparinized tubes by cardiac puncture. Livers were perfused with 0.15M KCI
at 4°C, removed and immediately frozen in liquid nitrogen.
Plasma T3 and T4 concentrations were assayed using the in-house
radioimmunoassay as described in Section 2.04c. The hepatic ID-I activities of the various
animals were determined in 20% homogenates as described in Section 2.05a.
b) Effect of selenium deficiency on thyroidal ID-I and GPx activities
Male, Hooded Lister, weanling rats of the Rowett Institute strain were divided into two
groups, one offered a selenium free diet (Se < 0.005 mg/kg of diet mix) and the other a
selenium supplemented diet (0.1 mg Se/kg of diet mix) for 6 weeks (selenium added as
sodium selenite). The rats were allowed free access to distilled water and food. At the
end of the experiment, the rats were anaesthetized with diethyl ether and the thyroids were
removed and immediately frozen in liquid nitrogen.
Glutathione peroxidase activities were measured at the Rowett Research Institute,
Aberdeen, by Dr. J.R. Arthur and F. Nicol as previously described (Beckett et al, 1990).
The thyroidal ID-I activities were assayed using the non-isotopic T4 method described in
Section 2.05b.
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c) Effect of selenium, iodine and combined selenium/iodine deficiency on ID-I
Male, Hooded Lister, weanling rats of the Rowett Institute strain were divided into four
groups and offered one of the following diets for 6 weeks : i) selenium and iodine
supplemented control (Se+ 1+), ii) selenium-deficient (Se-1+), iii) iodine-deficient (Se+
I-), and iv) selenium and iodine deficient (Se-1-). The basal diet (Se-1-) was prepared as
previously described, but with the omission of potassium iodate from the mineral mix
(Beckett et al, 1987). This basal diet mix contained less than 0.005 mg of selenium and
less than 0.1 mg of iodine per kg of diet. Where appropriate, the basal diet was
supplemented with 0.1 mg selenium/kg as selenite and/or 1.0 mg iodine/kg as potassium
iodate. The rats were given free access to distilled water and food. The food intake was
recorded daily, with the body weight of animals recorded on a weekly basis. At the end
of the experiment the rats were anaesthetized with diethyl ether, and the livers and
thyroids were removed and immediately frozen in liquid nitrogen. Subsequently the livers
and thyroids were defrosted, homogenised in ID-I assay buffer and assayed for ID-I
activity. The hepatic ID-I activity was assayed using the non-isotopic T4 method (Section
2.05b). Thyroidal ID-I activity was assayed using both the [125l]-rT3 and the non-isotopic
T4 method (Sections 2.05a, 2.05b) to avoid possible artefacts caused by any differences
in thyroid hormone concentration within the glands of the 4 groups.
6.02 : Results
a) Effect of selenium status on hepatic ID-I activity, and plasma T3 and plasma T4
Hepatic ID-I activity increased as the rats were supplemented with selenium (figure 6a).
A maximum increase in ID-I activity of approximately 12-fold was observed when selenium
supplementation reached values of 0.1 and 0.4 mg Se/kg. Selenium supplementation also
caused a small rise in the plasma T3 concentration, with a plateau observed between 0.1
and 0.4 mg Se/kg (figure 6b). In contrast, plasma T4 concentrations were reduced by
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selenium supplementation, with a decrease of approximately 60% observed at 0.1 and 0.4
mg Se/kg (figure 6b). No significant difference in food intake and body weight between
the groups was found.
b) Effect of selenium deficiency on thyroidal ID-I and GPx activities
No significant difference in thyroidal ID-I activity could be seen between the selenium
supplemented and selenium deficient groups (figure 6c). In contrast, GPx activity was
reduced by approximately 60% in the selenium deficient group (figure 6c).
c) Effect of selenium, iodine and combined selenium/iodine deficiency on ID-I
Hepatic ID-I activity decreased by approximately 8-fold in both the selenium deficient and
combined selenium/iodine deficient groups (figure 6d). Iodine deficiency alone had no
significant effect of hepatic ID-I activity when compared to the selenium/iodine
supplemented control group. Both the non-isotopic T4 and the [125l]-rT3 methods
essentially gave the same results with respect to the observed changes in thyroid ID-I
activity (figures 6e & 6f). The specific activities of thyroidal ID-I assayed using both
methods remained unchanged in the iodine deficient and combined selenium/iodine
deficiency groups (figure 6e & 6f). However, selenium deficiency caused a 50% decrease
in the specific activity when compared to the supplemented control (figure 6e & 6f).
Total ID-I activity within the thyroid remained unchanged in selenium deficiency,
when compared to the supplemented control. In contrast, both the iodine deficient and
combined deficient groups exhibited increases in total thyroidal ID-I activity (approximately
a 3-fold, and a 3.7-fold increase respectively) when compared to the supplemented





Figure 6a : Effect of dietary selenium on hepatic ID-I activity of rats maintained for 6
weeks on diets with the stated amounts of selenium supplementation.
The values shown are the mean ± SEM from the livers of the various
dietary groups (six rats per group). Significant increases in hepatic ID-I
activity were observed above 0.015 mg Se/kg.
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Figure 6b : Effect of dietary selenium on plasma Ta (□) and T4 (A) of rats maintained
for 6 weeks on diets with stated amounts of selenium supplementation.
The values shown are the mean ± SEM for the different dietary groups (6
animals per group). Significant increases in plasma T3 were observed at
selenium doses in excess of 0.025mg Se/kg, with significant decreases
in T4 observed at 0.015mg Se/Kg or above (compared to basal diet of





Figure 6c : Effect of selenium status on thyroidal ID-I and GPx activities measured in
rats maintained on selenium supplemented (Se-f) and selenium deficient
(Se-) diets for 6 weeks. The values shown are the mean ± SEM for each
group of rats (16 animals per group). No significant decrease in specific
ID-I activity could be seen with selenium deficiency, while a significant
























Figure 6d : Effect of selenium and iodine status on hepatic ID-I activity measured
using the non-isotopic T4 method in rats maintained for 6 weeks on one
of four diets : i) selenium and iodine supplemented (Se+ l+), ii) selenium
deficient (Se- l+), iii) iodine deficient (Se+ I-) or iv) combined
selenium/iodine deficient (Se-1-). The values shown are the mean ± SEM
of the various groups (5 animals per group). Significant decreases in
hepatic ID-I activity were observed with only the Se-1+ and Se-1- groups
compared to the Se+ 1+ control (p < 0.001).
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Figure 6e : Effect of selenium and iodine status on thyroidal ID-I activity measured
using the non-isotopic T4 assay method in rats maintained for 6 weeks on
one of four diets : i) selenium and iodine supplemented (Se+ l+), ii)
selenium deficient (Se-1+), iii) iodine deficient (Se+ I-) or iv) combined
selenium/iodine deficient (Se-1-). The values shown are the mean ± SEM
of the various groups (5 animals per group). A significant decrease in
specific thyroidal ID-I activity was observed in the Se- 1+ group.








Figure 6f: Effect of selenium and iodine status on thyroidal ID-I activity measured
using the [125l]-rT3 method in rats maintained for 6 weeks on one of four
diets : i) selenium and iodine supplemented (Se+ l+), ii) selenium
deficient (Se- l+), iii) iodine deficient (Se+ I-) or iv) combined
selenium/iodine deficient (Se-1-). The values shown are the mean ± SEM
of the various groups (5 animals per group). A significant decrease in
specific thyroidal ID-I activity was observed in the Se- l+ group.
Significant increases in total activity were observed in the Se-I- I- and Se-
I- groups.
163
TotalID-IAc ivity(fmol/m n) rou>i- j oooooooo
SpecificID-IActivity(fmol/m n/mg) -*-*■roouiui
6.03: Discussion
The data presented in this section confirms the importance of selenium in the metabolism
of thyroid hormones. Hepatic ID-I activity decreased by approximately 8-fold in selenium
deficiency as compared to selenium supplemented rats (figure 6d), confirming previous
work (Beckett etal, 1987; Beckett et al, 1993). Supplementation of the rats with selenite
restored hepatic ID-I activity, with a plateau observed between 0.1 and 0.4 mg Se/kg of
diet mix. Supplementation of selenium deficient rats with selenite also produced changes
in plasma T3 and T4 (figure 6b). Plasma T3 rose, while plasma T4 decreased as selenium
was fed at increasing doses to the rats. Once again a plateau was observed,
corresponding to the maximum hepatic ID-I activity observed. The effect of selenium on
hepatic ID-I has been reported before (Beckett etal, 1987) and was not unexpected as ID-I
is known to be a selenoenzyme (Berry etal, 1991b; Mandel etal, 1992). As peripheral 5'-
deiodination of T4 to T3 in tissues such as liver and kidney is known to provide
approximately 80% of plasma T3, modification of hepatic ID-I should affect plasma T3 and
T4 concentrations (Visser, 1988). However, the observed increase in plasma T3 as
selenium was added back to the rats was much lower than might have been expected
from the observed changes in hepatic ID-I activity. Reasons for this have been alluded
to previously, and include an adaptive response by the thyroid, mediated by elevated
plasma TSH (Beckett etal, 1987), and changes in the 5-deiodination of T3 to produce T2.
Selenium deficiency is known to increase plasma TSH, with inhibition of peripheral
ID-I believed to initiate the mechanism summarised in the schematic diagram (figure 6g).
Inhibition of peripheral ID-I (liver and kidney) results in a decrease in 5'-deiodination of T4
to T3, and hence there is an increase in plasma T4. High plasma T4 has been shown to
cause increased degradation of pituitary ID-II (Farwell and Leonard, 1989; Farwell et al,
\z"
1993), and therefore there is a reduction in the level of intrapituitary T3 production by ID-II.
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Figure 6g : Effect of selenium deficiency on ID-I, ID-II and thyroid hormone
metabolism.
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consequence of decreased ID-II activity is a decrease in pituitary T3. One consequence
of reduced levels of pituitary T3 is a reduction in the negative feedback control of TSH
secretion and hence increased plasma TSH levels (Arthur et at, 1990d). In addition,
reduced pituitary T3 also results in decreased synthesis of growth hormone. The rise in
plasma TSH is known to cause preferential production of T3 by the thyroid, though the
exact mechanisms are under debate (Section 3.03). This adaptive change induced by
selenium deficiency results in T4, T3 and I" depletion in the thyroid, and in conjunction with
a reduction in T3 metabolism (reduced peripheral ID-I) helps to stabilise plasma T3 (Beckett
etal, 1993).
Selenium deficiency had only limited effects on the thyroidal ID-I activity measured,
with no change or only a 50% decrease in the specific activity of thyroidal ID-I occurring
(figures 6c, 6e & 6f). These changes observed in the specific activity of thyroidal ID-I were
small compared to the changes observed in the level of hepatic ID-I activity which were
approximately 7-fold.
Iodine and combined iodine and selenium deficient animals showed no change
in the specific activity of thyroidal ID-I, but demonstrated significant increases (3 to 4-fold
respectively) in the total thyroidal ID-I activity measured using either the non-isotopic T4
or [125l]-rT3 assay method (figure 6e & 6f). These increases are most probably mediated
by elevated plasma TSH and an increase in the size of the thyroid gland. Indeed, both
TSH and thyroid size have been demonstrated to increase with iodine and combined
iodine and selenium deficiency, with the largest increases observed in the combined
deficient group (Beckett et al, 1993).
The expression of human thyroidal ID-I is known to be increased by TSH and
hence an increase in ID-I in response to elevated TSH is not surprising provided that the
supply of selenium is sufficient (Ishii etal, 1983). Furthermore, much larger decreases in
thyroidal T4 content were observed compared to the changes in thyroidal T3 content, with
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plasma T3 levels maintained at the expense of plasma T4 (Beckett et al, 1993; Chanoine
et al, 1993). These observations are consistent with the reported switch to thyroidal T3
production when plasma TSH is elevated in response to iodine deficiency (Adams and
Larsen, 1973).
Selenium deficiency has been reported to exacerbate the hypothyroid effects of
iodine deficiency (Beckett et al, 1993) and this has been implicated as a contributory
factor in the pathogenesis of myxoedematous endemic cretinism (Vanderpas etal, 1990;
Goyens etal, 1987). Long term selenium deficiency, in conjunction with iodine deficiency,
results in increased thyroid size, elevated plasma TSH, reduced thyroidal iodine, T3 and
T4, and a fall in plasma T4 when compared to iodine deficiency alone (Beckett ef al, 1993).
These changes may be mediated by an further reduction in the negative feed back control
of TSH secretion, when compared to iodine deficiency alone. This decrease in feed back
is most probably mediated by an additional reduction in pituitary 5'-deiodination. Hence,
as a result of selenium deficiency, the effects of hypothyroidism caused by iodine
deficiency are exacerbated, thereby causing further impairment of growth, development
and metabolism.
In addition, selenium deficiency has been postulated more recently to help protect
against neurological cretinism (Corvilain et al, 1993). These workers proposed that
decreases in peripheral ID-I (liver and kidney) and ID-II (pituitary and BAT) activity, caused
by concurrent selenium deficiency, could increase plasma T4 and hence help provide
sufficient T4 to the fetal brain to offset it's deficiency of T4 during iodine deficiency. In
addition, ID-II in rat brain has been shown to be further elevated in combined selenium
and iodine deficiency, compared to iodine deficiency alone (Silva et al, 1984; Beckett et
al, 1993). Hence elevated plasma T4 and brain ID-II could reduce the effects of
hypothyroidism on fetal brain development by maintaining brain T3 levels. Corvilain and
coworkers therefore put forward the hypothesis that selenium deficiency can protect
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against neurological cretinism, while increasing mxyoedematous cretinism, citing Central
Africa as an example. Indeed, the incidence of neurological cretinism is much lower in
iodine deficient areas with concurrent selenium deficiency, in comparison to areas
deficient in iodine alone, while the incidence of mxyoedematous cretinism is increased
(Corvilain et al, 1993).
In addition to its effects on thyroid hormone metabolism, selenium deficiency
caused a 60% reduction in the level of GPx found in the thyroid (figure 6c), where as a
100-fold reduction in hepatic GPx activity has been report by us to occur in rats fed the
same selenium deficient diet (Beckett etal, 1993). This data is consistent with previously
reported observations when [75Se]-selenite was administered to rats in vivo. The brain,
endocrine and reproductive tissues were found to retain 75Se for far longer than liver and
kidney (Behne et al, 1988). As a result of these findings, Behne et al postulated that a
tissue hierarchy for selenium supply might exist. In addition to a tissue hierarchy, these
workers also proposed a hierarchy at the molecular level, with a preferential supply of
selenium to selenoproteins other than GPx. Indeed, one of these selenoproteins appears
to be ID-I. Data present in this section clearly shows that the thyroid is supplied with
selenium in preference to liver, while ID-I is supplied with selenium in preference to GPx
in both the thyroid and liver.
The data presented here demonstrates that thyroidal ID-I expression can be
increased in vivo, even in selenium deficiency, as a result of increased plasma TSH. In
addition, thyroidal ID-I may have an important role in the provision of T3 by the thyroid
under hypothyroid conditions. Thyroidal GPx activity, although reduced by selenium
deficiency is not as severely affected as that of the liver, confirming the findings of Behne
and coworkers. In short, maintenance of thyroidal GPx activity should protect the thyroid
against excessive hydrogen peroxide (H2Q2) driven by elevated plasma TSH.
169
Section 7 : CONCLUDING REMARKS
In this thesis several aspects of thyroid hormone synthesis and metabolism have been
studied, with particular reference to the role of thyroidal ID-I. The main objectives of the
thesis were to determine the importance of thyroidal ID-I in the provision of T3 in man and
the rat, to study the dependence of this enzyme on selenium supply and to investigate the
hormonal and second messenger regulation of thyroidal ID-I.
Some debate has ensued over the past few years as to the source of T3 which
accumulates in the medium bathing human thyrocytes in primary culture. Some workers
have proposed that both T3 and T4 accumulate in the medium as a result of the secretion
of preformed T3 and T4, with no de novo synthesis (Ollis et al, 1985). In contrast, others
have published data which suggests that both T3 and T4 can be produced by human
thyrocytes in primary culture via de novo synthesis (Kraiem etal, 1988), particularly if the
thyrocytes remain differentiated (Sato et al, 1988). The data presented in this thesis
demonstrates that human thyrocytes grown in the primary culture described (Section 2.03)
do not produce T3 or T4 by de novo synthesis, even when the thyrocytes are grown in
conditions which should ensure that they are differentiated. Furthermore, the data clearly
shows that 5'-deiodination of endogenous T4 is responsible for a significant proportion of
T3 which accumulates in the medium under the conditions used. In contrast, ovine
thyrocytes when grown in identical conditions to the human thyrocytes produce T3 and T4
by de novo synthesis, with no evidence of T3 production via 5'-deiodination of T4. Indeed,
the data presented in Section 4 shows that sheep and many other species lack
expression of thyroidal ID-I. Why sheep, but not human thyrocytes produce T3 and T4 by
de novo synthesis is unclear, though the human thyrocytes may require one or more
paracrine factors in addition to those required by ovine thyrocytes.
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The importance of de novo synthesis and 5'-deiodination in the production of T3
by human and rat thyrocytes in vivo has also been open to debate, particularly in
conditions which lead to increased thyroidal T3 production. Adams and Larsen proposed
that preferential de novo synthesis of T3 occurred in iodine deficiency, driven by elevated
plasma TSH (Adams and Larsen, 1973). Others have proposed that thyroidal 5'-
deiodination of T4 in normal and hypothyroid conditions (e.g. iodine deficient) may be
important (Green, 1978; Laurberg, 1980; Laurberg, 1984; Pazos-Moura ef at, 1991). The
in vitro and in vivo data presented here supports the view that thyroidal ID-I can contribute
significantly to the T3 produced by the thyroid of man and the rat. Certain other species
including sheep, lack thyroidal ID-I expression and consequently thyroidal 5'-deiodination
of T4 cannot contribute to thyroidal T3 production in these species. A greater reliance
upon thyroidal de novo synthesis of T3 and peripheral production of T3 must occur in
species lacking thyroidal ID-I.
Stimulation of the TSH receptor by TSH or TSIs has been previously reported to
stimulate ID-I expression (Erickson et al, 1982; Wu, 1983; Ishii et al, 1981; Ishii ef al, 1983),
with this stimulation believed to be mediated by activation of the cAMP second messenger
cascade (Ishii et al, 1983). My work confirms that thyroidal ID-I expression can be
stimulated by TSH and TSIs, most probably mediated via activation of the cAMP cascade.
Furthermore, I have shown using human thyrocytes in culture that activation of the Ca2+-PI
second messenger cascade results in decreased ID-I expression. Activation of the Ca2+-PI
cascade occurs at high concentrations of TSH (Laurent et al, 1987; Laurent ef al, 1989;
Raspe ef al, 1991b; Maenhaut ef al, 1990), and is consistent with the decrease in ID-I
activity observed with excess TSH (Section 4). The Ca2+-PI cascade can also be activated
in the thyroid by ATP, TRH and bradykinnin (Raspe ef al, 1991b), and it is intriguing to
speculate that thyroidal ID-I expression may be under the control of these other agents in
addition to TSH.
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Differences in tissue and protein retention of 75Se has recently been demonstrated
by Behne et al, who also postulated that a hierarchy of selenium supply to various tissues
and to proteins within these tissues might occur (Behne et al, 1988). My work supports
the existence of a tissue and molecular hierarchy for selenium supply by demonstrating
preferential selenium supply to the thyroid at the expense of the liver, and within tissues
to ID-I at the expense of GPx. The mechanism whereby selenium is preferentially supplied
to the thyroid is unclear, however data presented here suggests the possible existence
of an energy-dependent mechanism for the accumulation of selenium within the thyrocyte.
To conclude, the experiments presented in this thesis demonstrate that
1) In the primary culture system used here, human thyrocytes produce T3 via 5'-
deiodination of endogenous T4, with little or no de novo synthesis. In contrast
ovine thyrocytes lack ID-I and produce both T3 and T4 by de novo synthesis.
2) Thyroidal ID-I where present, can play a significant role in the production of T3 in
both in vitro and in vivo systems, particularly when the TSH concentration is
elevated.
3) There is a great deal of species variation in the expression of thyroidal ID-I, with
herbivores lacking significant levels of expression compared to omnivores.
4) Expression of thyroidal ID-I is not dependent on selenium supply per se, since
thyrocytes in vitro and in vivo are able to increase ID-I expression in response to
TSH, even in low selenium conditions. Indeed, selenium status in the absence of
TSH has no effect on thyroidal ID-I activity.
5) Retention of selenium by thyrocytes appears to occur and involving an energy-
dependent process.
6) Expression of thyroidal ID-I is under the control of the cAMP cascade which
increases the expression of ID-I, while the Ca2+-PI cascade appears to decrease
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the expression of ID-I. As the PI pathway is stimulated by a number of
neurochemicals, there may be a physiological role for the PI pathway in the
regulation of ID-I expression in vivo.
TSH and TSIs can increase expression of thyroidal ID-I, presumably via the cAMP
cascade. In addition, high levels of TSH can cause reduced thyroidal ID-I
expression, most probably via the Ca2+-PI cascade
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ABSTRACT
«
We have studied the origin of tri-iodothyronine (T3)
secreted by human and sheep thyrocytes in primary
culture and also the expression of type-I thyroidal
iodothyronine deiodinase (ID-I) in the thyroid and
liver of man and various other animals. Inhibitors of
ID-I reduced T3 secretion from human but not sheep
thyrocytes. In contrast, inhibitors of de-novo thyroid
hormone synthesis reduced both thyroxine (T4) and
T3 production in sheep thyrocytes, but had no effect
on the T3 secreted by human thyrocytes. Eluman thyro¬
cytes did not produce T4 under the culture condi¬
tions used, although some endogenous T4 was present
in the cells following their isolation. Although thyro-
trophin (TSH) stimulated T3 production in both
human and sheep thyrocytes, iodine in the form of
potassium iodide was only essential for T3 and T4
production by the sheep cells. Although 12:,I from
Nal25I was incorporated into T3 and T4 in TSH-
stimulated sheep thyrocytes, no l2ff incorporation
into T3 or T4 was detected in TSH-stimulated human
thyrocytes. Using activity measurements and affinity
labelling, ID-I was present in the livers of all species
studied, but ID-I could not be detected in thyroid
tissue from cattle, pigs, sheep, goats, rabbits, deer or
llamas. In contrast, thyroid tissue from man, mice,
guinea-pigs and rats had significant ID-I activity and
expressed an affinity-labelled protein with a molecular
mass of approximately 28-1 kDa on SDS-PAGE.
These data show that under the culture conditions
used, sheep thyrocytes produced T3 by de-novo syn¬
thesis, whilst human thyrocytes produced T3 by deiod-
ination of endogenous T4. We conclude that thyroidal
ID-I shows marked species difference in its expression
and that, in those species which express the enzyme
(man, mice, guinea-pigs and rats, in this study), it
appears that it may make an important contribution
to thyroidal T3 production.
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INTRODUCTION
The thyroid gland is the exclusive source of thyroxine
(T4), while the active thyroid hormone, 3,3',5-tri-
iodothyronine (T3), may arise from two sources.
Approximately 80% of the plasma T3 pool is produced
by 5'-monodeiodination of T4 in non-thyroidal tissue,
particularly the liver and kidneys (Visser, 1988).
These tissues contain a type-I iodothyronine deiodin¬
ase (ID-I) responsible for 5'-deiodination; this
enzyme has been shown to be a selenoenzyme (Arthur
et al. 1990) containing stoichiometric amounts of
selenium (Behne et al. 1990). Cloning of the enzyme
has confirmed the presence of selenium, in the form
of a selenocysteine residue at the active site, coded for
by a UGA triplet (Berry et al. 1991). ID-I activity can
be inhibited by a number of compounds including
propylthiouracil (PTU) and iopanoic acid (IPA), but
is unaffected by methimazole. an inhibitor of thyroid
hormone synthesis. All species studied to date appear
to express ID-I in the liver although the enzyme may
show species differences in molecular mass
(Schoenmakers et al. 1992).
Under normal circumstances, approximately 20%
of plasma T3 arises from the thyroid, but in conditions
where plasma thyrotrophin (TSH) is elevated, such
as in iodine deficiency, the thyroid becomes the
major source of plasma T3 (Adams & Larsen, 1973).
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figure 1. Effect of increasing doses of thyrotrophin (TSH) on thyroid hormone production from (a) sheep and
(b) human thyrocytes grown in primary culture for 5 days in the presence of 10 pmoi potassium iodide/1. The
accumulated medium content of tri-iodothyronine (T3) and thyroxine (T4) was measured and the data were
expressed as means ±s.e.m. of triplicate wells in a representative experiment carried out on three occasions.
*P<0-05, **P<001 and ***P<0-001 compared with control levels (no TSH) (Student's r-test).
Thyroidal T3 is thought to arise from de-novo synthe¬
sis of and subsequent release from thyroglobulin
(Visser, 1988). However, thyroids from man, dog
and rat contain an ID-I that is responsive to TSH
(Erickson et al. 1982; Wu, 1983; Pazos-Moura et al.
1991). When TSH is increased, the expression of ID-I
is increased and it is possible that intrathyroidal
deiodination of T4 by ID-I may be an important
source of thyroidal T3 under these conditions.
In primary culture, human thyrocytes appear to
produce T3, and it has been suggested that the T3
secreted by cultured human thyrocytes arises from de-
novo synthesis (Kraiem et al. 1988), particularly if a
follicular preparation is used and dimethyl sulphoxide
(DMSO) is present (Sato et al. 1988). Other workers
have suggested that the T3 arises from release of pre¬
formed intracellular T3 (Ollis et al. 1985). In contrast
to human cultured thyrocytes, sheep thyrocytes
appear to produce both T3 and T4 (Becks et al. 1987).
In this study, inhibitors of thyroid hormone syn¬
thesis (PTU and methimazole) and of ID-I (IPA and
Journal of Endocrinology (1993) 136, 361 370
PTU) have been used to investigate T3 production by
human and sheep thyrocytes grown in primary culture
and, in particular, to investigate the possibility that
thyroidal deiodination of T4 may be an important
source of T3 production. We have also studied l25I
incorporation into thyroid hormones and determined
ID expression in liver and thyroid of various species.
MATERIALS AND METHODS
Materials
Dulbecco's modified Eagle's media (DMEM) and
Earle's balanced salt solution (EBSS) were obtained
from ICN Flow (Costa Mesa, CA, U.S.A.). Collagen-
ase was purchased from Worthington Biochemicals
Corporation via Lome Laboratories (Twyford,
Berks, U.K.), and the dispase supplied by Boerhinger
Mannheim U.K. (Lewes, E. Sussex, U.K.). TSH
(NIBSC code: 53/011) was supplied by the National
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figure 2. Effect of increasing doses of potassium iodide (KI) on thyroid hormone production from (a) sheep and
(b) human thyrocytes grown in primary culture for 5 days in the presence of 1 mU thyrotrophin/ml. The
accumulated medium content of tri-iodothyronine (TO and thyroxine (T4) was measured and the data were
expressed as means±s.e.m. of triplicate wells in a representative experiment carried out on three occasions.
**P<0'01 and ***/><0-001 compared with control levels (no KI) (Student's /-test).
Institute for Biological Standards and Controls
(London, U.K.) and the cellulose-F thin-layer chroma¬
tography (TLC) (5565) plates were purchased from
Merck via BDH (Poole, Dorset, U.K.). Penicillin/
streptomycin, amphotericin and glutamine were
obtained from NBL (Cramlington, Northumberland,
U.K.). l25I-Labelled T?. T4, reverse tri-iodothyronine
(rT3) and Nal25I were obtained from Amersham
International pic, Amersham, Bucks, U.K. Anti-T3
and T4 were kindly supplied by the Scottish Antibody
Production Unit, Carluke, Lanarkshire, U.K. All
other reagents including control processed serum
replacement 5 (CPSR-5) were obtained from Sigma
Chemical Co. (Poole, Dorset, U.K.).
Isolation and culture of human and sheep thyrocytes
Human thyrocytes were isolated from normal and
colloid goitre tissue (surplus to routine pathological
requirements) from patients undergoing thyroid surg¬
ery. The cells were isolated using a modified version
of the dog thyroid cell culture method of Rapoport
(1976). The tissue was sliced using a Stadie Riggs
microtome and the slices were finely minced with scis¬
sors. The resulting fragments were then washed four
times with EBSS and digested for 2 h in 50 ml of an
enzyme cocktail containing dispase (5 mg/ml), tryp¬
sin (0-25%, w/v) and collagenase (1 mg/ml) in EBSS.
Following digestion, an equal volume of 2% (w/v)
bovine serum albumin (BSA) in EBSS was added and
the mixture filtered through a 100 pm mesh gauze to
remove undigested tissue. The resulting filtrate, con¬
taining released thyroid cells, was centrifuged at 125 g
for 15 min to pellet the thyrocytes and leave the
majority of erthyrocytes in suspension. The pellet was
then resuspended in EBSS, re-centrifuged twice and
the cells finally resuspended in 50 ml DMEM contain¬
ing 10% (v/v) CPSR-5 (fetal calf serum treated to
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figure 3. Effect of 5 days exposure to methimazole on thyroid hormone production from (a) sheep and (h)
human thyrocytes grown in primary culture. The accumulated medium content of tri-iodothyronine (T,) (O,
human; A, sheep) and thyroxine (T4) (•, human; ▲, sheep) was measured and data were expressed as
meansis.e.m. of triplicate wells in a representative experiment carried out on three occasions. *P<005
**/><0-01 compared with control levels (no methimazole) (Student's r-test).
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smove immunoglobulins and endotoxins), penicillin
100 U/ml), streptomycin (100 pg/ml), amphotericin
I (2-5 gg/ml) and added glutamine (2 mmol/1). The
ell suspension was then filtered through a 30 pm
tesh gauze and the cell yield measured with a modi-
ed Neubauer haemocytometer. Finally the thyro-
ytes were plated out in DMEM/10% CPSR-5 into
2-well plates (2-5 cm diameter) at a density of 5 x 105
ells/well in 1 ml medium. The cells were incubated
t 37 °C in an atmosphere of 5% C02 for 24 h before
ny additions were made.
Sheep thyrocytes were isolated, using the same
lethod, from sheep thyroid tissue obtained within
0 min of death from animals in the local abattoir.
fleet of TSH and KI concentration on T3 and T4
oduction by human and sheep thyrocytes
fter 24 h, the medium was removed from the human
id sheep thyrocytes in monolayer culture and the
cells were washed with 1 ml EBSS before fresh
medium containing a fixed dose of KI (10pmol/l)
was added. Wells (in triplicate) contained a range of
TSH doses. In other experiments, the TSH was main¬
tained at 1 mU/ml whilst the amount of KI added to
the medium was varied. The concentration of T3 and
T4 in the culture medium was then determined by in-
house radioimmunoassay after a further 5 days in
culture.
Effect of IPA, PTU and methimazole on T3 and T4
production from human and sheep thyrocytes
After 24 h of incubation, the medium from both the
human and sheep thyrocytes was removed and the
cells were washed with EBSS before fresh medium
was added containing TSH (1 mU/ml), KI
(10pmol/'l) and inhibitors, as appropriate. The
inhibitors used were increasing doses of IPA (an ID-I
•urnal of Endocrinology (1993) 136, 361 370
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figure 4. The effect of 5 days exposure to propylthiouracil (PTU) on thyroid hormone production from (a)
sheep and (h) human thvrocytes grown in primary culture. The accumulated medium content of tri-iodothyronine
(TO (O. human; sheep) and thyroxine (T4) (•. human; A. sheep) was measured and data were expressed as
meansis.e.m. of triplicate wells in a representative experiment carried out on three occasions. *P<0-05,
**P<0 01 and ***P<0 001 compared with control levels (no PTU) (Student's /-test).
inhibitor), methimazole (inhibitor of T:, and T4 de-
novo synthesis) or PTU (inhibitor of both ID-I and
de-novo synthesis). Thyroid hormone production after
a further 5 days was quantified by radioimmunoassay
of the T-, and T4 accumulated in the culture media.
Previous experiments had shown that, within an
experiment, the addition of TSH. Kl. IPA. PTU and
methimazole produced no significant changes in pro¬
tein content of the cells during the 5 days of culture.
Results of T, and T4 production have therefore been
expressed as the total amount of T? and T4 produced
in 5 days by each incubation and not corrected for
protein.
Incorporation of l27I into T3 and T4 by human and
sheep thyrocytes
Human and sheep thvrocvtes were plated out in
75 cnr flasks in 10 ml' DMEM 10% CPSR-5 at a
density of 10 million per flask. After 24 h, the medium
was removed, and the cells were washed with EBSS
before fresh medium was added containing 50 pCi
Na12"I (specific activity > 1200 pCi/pg) with or
without TSH (1 mU/ml). After a further 5 days of
incubation the medium was removed and T3 and T4
were immunoprecipitated by incubation for 15 h at
25 C with solid-phase anti-T3/T4 immunoglobulins
added at amounts sufficient to precipitate more than
95% ofT, and T4 produced by the cells. The samples
were then centrifuged at 180# for 15min, and the
antibody pellet was washed with 20 ml 1 mol KI/1
and re-centrifuged. The pellet was then resuspended in
5 ml methanol and the suspension left for 15 h at
25 C to extract the bound hormones. After further
centrifugation at 180# for 15min. the methanolic
supernatant was evaporated to dryness and the
residue, containing the immunoextracted T3 and T4,
taken up in 100 pi methanol. The samples were
Journal of Endocrinology (1993) 136, 361 370
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figure 5. The effect of 5 days exposure to iopanoic acid (IPA) on thyroid hormone production from (a) sheep
and (h) human thyrocytes grown in primary culture. The accumulated medium content of tri-iodothyronine (T3)
(O, human; A, sheep) and thyroxine (T4) (•. human; A, sheep) was measured and data were expressed as
meansis.e.m. of triplicate wells in a representative experiment carried out on three occasions. *P<0-05,
**/><0 01 and ***/>< 0 001 compared with control levels (no IPA) (Student's r-test).
then run on 20 cm2 cellulose/TLC plates using
chloroform: tertiary butanol: ammonia (2 mol/1),
(60:376:70; by vol.) as the developing solvent. Auto¬
radiography was used to demonstrate the presence of
iodinated T3 and T4 (48 h exposure). Appropriate 125I-
labelled standards of T3 and T4 were also run on the
same plate. No detectable Na125I was carried over on
to the TLC plates, as determined by autoradiography.
dithiothreitol (DTT)/1 (pH 7-4) to obtain a 20%
(w/v) homogenate. After centrifugation for 15 min at
300 g, the supernatant was removed and ID-I activity
assayed by measuring the release of I25I from ,25I-
labelled rT3, as described previously (Sawada et al.
1986) but using rT3 at a final concentration of
2 nmol/1. Under these conditions, reactions were lin¬
ear up to 60 min with 25- 180 pg of protein.
Determination of ID-I activity in thyroid liver
homogenates from various species
Thyroidal and hepatic tissue from cattle, pigs, sheep,
goats, rabbits, deer, llamas and rats were obtained
within 30 min of death, whilst the human tissue was
obtained as for culture. All tissue was stored at
— 70 °C before portions of these tissues were homo¬
genized in a potassium phosphate (100mmol/l)
buffer containing 5 mmol EDTA/1 and 20 mmol
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Affinity labelling of liver and thyroid homogenates
Liver and thyroid homogenates from the various
species were labelled with N-bromoacetyl[l25l]rT3
using a modified version of the method describee! by
Nikodem et al. (1980). This method is outlined in our
previous paper (Arthur et al. 1991), except that whole
homogenates were used in the present study instead
of microsomes. The labelled homogenates were then
subjected to sodium dodecyl sulphate-polyacrylamide
3*
Thyroidal ID-I in sheep and human thyrocytes s. g. beech and others 367
Sheep Sheep Human Human Sheep
-TSH +TSH - TSH +TSH +TSH
+ T, + T4
figure 6. A thin-layer chromatograph of radiolabeled tri-iodothyronine (TO
and thyroxine (T4) immunoprecipitated from cell medium following 5 days
incubation of sheep and human thyrocytes with Nal25I, showing the
incorporation of '~5I into T, and T4 in sheep but not human thyrocytes under
thyrotrophin (TSH) stimulation. Lane 5 contains similar amounts of the
material run in lane 2 with the addition of l25I-labelled T, and l25I-labelled T4 to
act as standards.
table 1. Activities of iodothyronine deiodinase type-I in
the thyroids and livers of various species, expressed
as the amount of iodine released from reverse tri-
iodothyronine/min per mg protein
Thyroidal activity Hepatic activity













ND. not detectable ; —. not determined.
gel electrophoresis (SDS-PAGE) with molecular mass
markers and affinity-labelled proteins visualized using
autoradiography.
RESULTS
Effect of TSH and KI concentration on T3 and T4
secreted by human and sheep thyrocytes
T3 and T4 production by sheep thyrocytes showed
clear dose-dependence on both TSH and KI (Figs
1 a and 2a). The optimal concentration for TSH was
1 mU/ml. In the case of KI. T3 and T4 production
rose to a plateau in some experiments, but decreased
with levels of KI beyond 10 pmol/1 in others. Accord¬
ingly, 10 pmol/1 was used as the optimum KI concen¬
tration. In human thyrocytes T4 production was low
and failed to be stimulated by TSH or iodide. In fact.
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at a dose of TSH of 1 mU/ml, T4 in the media was
significantly reduced (Fig. 1 b). Although T3 produc¬
tion was stimulated by TSH (optimum 1 mU/ml), no
effect of K1 addition could be seen (Fig. 2b). Human
thyrocytes secreted approximately 25% of the amount
of T3 and T4 secreted by the sheep thyrocytes when
under TSH stimulation.
Effect of inhibitors on T3 and T4 production by human
and sheep thyrocytes
In sheep thyrocytes, methimazole and PTU produced
a dose-dependent inhibition of both T3 and T4 accu¬
mulation, with a maximal effect for both compounds
at 1 mmol/1 (Figs 3a and 4a respectively). At this
dose, methimazole caused 35% decreases in T3 and
T4, while PTU caused 50% decreases in both T3 and
T4. IPA had no significant effect on T3 and T4 accu¬
mulation (Fig. 5a).
In human thyrocytes, methimazole caused no large
changes in T3 and T4 secretion (Fig. 3b). In contrast
to the sheep thyrocytes, PTU and IPA caused a sig¬
nificant increase in T4 and a corresponding decrease
in T3 accumulation (Figs 4b and 5b). Maximal effects
occurred at lOmmol PTU/1 which caused a 50%
increase in T4 and an 80% decrease in T3. In the case
of IPA, maximal effects occurred at lOOpmol IPA/1
and consisted of an 80% increase in T4 and a 70%
decrease in T3.
Incorporation of l2SI into T3 and T4 by human and
sheep thyrocytes
In the presence of TSH, incorporation of l2>I into T3
and T4 occurred in sheep thyrocytes, with no detect¬
able incorporation occurring when TSH was absent
(Fig. 6). With human thyrocytes no l2T incorporation
into T3 and T4 could be detected irrespective of the
presence or absence of TSH.
ID-I activity in thyroid and liver homogenates from
various species
There was a large variation in the activity of ID-I
measured in the different livers, but all showed sub¬
stantial levels of activity ranging from 119 to
1066 fmol/min per mg (Table 1). Only in the thyroid
tissue from rat, man, mouse and guinea-pig could sig¬
nificant activity be demonstrated, with the rat having
the highest specific activity (1296 fmol/min per mg).
All other species had very low specific activities
(0-3-3-6 fmol/min per mg).
Affinity labelling of thyroid and liver homogenates
from various species
Liver homogenates from all species showed an ID-I
band in the region of 27-3 to 29-0 kDa but there were
small but clear differences in the molecular mass of
this band between species. A second band was also
apparent in the liver of all species which had a consist¬
ent molecular mass of 53-2 kDa. When thyroid homo¬
genates were subjected to SDS-PAGE, rat and human
exhibited a band corresponding in molecular mass to
the ID-I demonstrated in the liver of the correspond¬
ing species (Fig. 7; Table 2). For thyroid tissue of
the other species studied in Fig. 7, although bands
were found with molecular masses in the region
30-5-33 kDa, no band was found with the lower
kDa kDa
1 2 3 4 5 6 7 8
figure 7. Autoradiograph of an SDS-PAGE gel of thyroid homogenates from
various species labelled with bromoacetyl [i:4]rT-,. Tracks 1 8 show sheep,
llama, human, cattle, deer. pig. goat and rat respectively. The mobility of
molecular mass markers is shown.
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molecular mass band corresponding to that of ID-I
in the liver of the same species. The presence of the
ID-I band in the thyroid of the various species thus
correlated well with ID-1 activity, indicating that the
very low enzyme activities were due to a lack of
expression of the enzyme, rather than inhibition of
activity. All the thyroid glands from these species had
selenium-containing glutathione peroxidase activity,
confirming that the lack of ID-I activity was not due
to selenium deficiency (data not shown).
DISCUSSION
In sheep thyrocytes, the production of T3 and T4 was
dependent on TSH and KI and was inhibited by
methimazole and PTU, substances which inhibit de-
novo synthesis. In addition was incorporated into
both T, and T4 in the presence of TSH. These data
clearly established that sheep thyrocytes were able to
produce both T3 and T4 by de-novo synthesis under
these culture conditions. In the sheep, ID-I can play
no role in thyroidal T3 production as the thyroid does
not express significant levels of this enzyme in this
species. In support of this. IPA (which inhibits ID-I)
had no effect on T3 production in sheep thyrocytes.
In contrast, T3 production in human thyrocytes was
inhibited by IPA or PTU. but not by methimazole.
We also observed that T3 production was independent
of iodide and that no 125I was incorporated into T3 or
T4, even under TSH stimulation. These observations
are consistent with T3 production arising from deiodi-
nation of endogenous T4 present within the thyrocytes
following their isolation, with little or no T3 being
produced in a de-novo fashion. Unlike sheep thyro¬
cytes. human thyrocytes expressed ID-I activity and
therefore the TSH-dependence of T3 production in the
isolated cell system could be attributed to the TSH-
responsive nature of ID-I in human thyroid tissue.
High levels of TSH have been shown to stimulate the
activity of the enzyme, probably in a cyclic AMP-
dependent manner (Murakami el al. 1990).
These results obtained with the human thyrocytes
(Figs 3 5) differ from those of Kraeim et al. (1988),
who proposed that T3 production in isolated human
thyrocytes arises from de-novo synthesis. These work¬
ers based their conclusions on the observation that
PTU inhibited T3 production, an observation con¬
firmed by our work. However, since PTU inhibits
both T3 synthesis and deiodination of T4, the inhibi¬
tory effect of PTU cannot distinguish between these
two sources of T3. Kraeim et al. (1988), also reported
(but did not publish any supportive data) that
methimazole inhibited T3 production, while the effects
table 2. Molecular mass of hepatic iodothyronine
deiodinase type I (ID-I) from various species as
determined by autoradiography of an SDS-PAGE gel of
bromoacetyl [' :I]rT-.-labelled homogenate. Using thyroid
tissue, bands observed within the molecular mass region
of hepatic ID-I in the corresponding species are also
shown. Only rat and human thyroid tissue had a band













of IPA were not studied. We found no evidence of
inhibition of T3 production, even at methimazole con¬
centrations as high as 10 mmol/1. Differences between
our study and that of Kraeim et al. (1988) may lie in
the culture system since Kraeim et al. (1988) used cells
cyro-preserved in medium 199/10% fetal calf
serum/10% DMSO with Hepes (25 mmol/1).
Sato et al. (1988) using a culture system of isolated
human follicles were able to demonstrate de-novo
synthesis of T3 and T4 in the presence of DMSO
(1-7%) and low concentrations of fetal calf serum
(1%). They postulated that synthesis occurred by
DMSO preventing dedifferentiation and that high
levels of fetal calf serum led to deterioration of thyroid
function.
Our studies show that, although all the species
investigated contained an active ID-I in their liver,
the thyroidal ID-I activity showed a high degree of
species variation. As previously reported (Toyoda et
al. 1992), we found that human thyroid expresses ID-
I. We have also demonstrated that ID-I is expressed
in the thyroids of other omnivores (mouse, guinea-
pig and rat). In contrast, the thyroids of herbivores
and the pig seem to lack ID-I activity, but why this
should be is unclear. In cattle, pigs, sheep, goats, rab¬
bits. deer and llamas, thyroidal ID-I is not signifi¬
cantly expressed and cannot therefore provide a
source of thyroidal T3 in cases of iodine deficiency.
Man. mice, guinea-pigs and rats have significant levels
of thyroidal ID and hence this could prove to be a
useful secondary system for maintaining plasma T3
under conditions of hypothyroid stress, such as in
iodine depletion, where increased TSH leads to stimu¬
lation of ID-I synthesis.
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SELENIUM STATUS AND THYROIDAL IODOTHYRONINE DEIODINASE ACTIVITY
IN RAT AND HUMAN THYROCYTES
S.G. Beech, S.W. Walker, J.R. Arthur*, F. Nicof and G.J. Beckett
Department of Clinical Biochemistry, Royal Infirmary, Edinburgh EH3 9YW, U.K, and
the 'Rowett Research Institute, Bucksburn, Aberdeen AB2 9SB, U.K.
Introduction
Approximately 80% of plasma 3',5',5-triiodothyronine (T3) is derived from
5'monodeiodination of thyroxine (TJ, a reaction catalysed by the selenoenzyme type-l
iodothyronine deiodinase (ID-I) (1-3) in non-thyroidal tissues such as liver, kidney and
muscle. Cloning of the gene for the enzyme and site directed mutagenesis have
confirmed the presence of a selenocysteine residue at the active site, coded for by a
UGA triplet. The thyroid of some, but not all species (4), also express ID-I. However
unlike hepatic ID-I, thyroidal ID-I can be stimulated by thyrotropin (TSH) (5-7). In
selenium deficiency the activity of hepatic ID-I is often decreased to less than 10% of
the activity found in selenium-supplemented rats and the activity of hepatic glutathione
peroxidase (GPx), a selenoenzyme involved in the protection of tissue from
peroxidative damage, is decreased to levels of < 1.0% of activities found in selenium-
supplemented animals (8). There is good evidence to suggest that in selenium
deficiency the brain, endocrine and reproductive tissues retain selenium more efficiently
than the liver, and that within a tissue there is a hierarchy for selenium supply to the
various selenoproteins (9).
In this paper we present data on the effects of selenium deficiency on thyroidal ID-I
activity in rat and man. We also show that selenium uptake and retention by cultured
thyrocytes is a temperature dependent process.
Methods and Results
Effect of TSH and selenite on ID-I activity in cultured human thyrocytes
Human thyrocytes were isolated from normal and colloid goitre tissue from patients
undergoing thyroid surgery using a modified version of the dog thyroid cell culture
method of Rapoport (10) as described previously (4).
After 24 h, the medium was removed from the thyrocytes and the cells washed twice
with 1ml Earle's balanced salt solution (EBS) before fresh Dulbecco's modified Eagle's
medium (DMEM) was added (no fetal calf serum). Selenite was added (50nmol/L or
1000nmol/L), in the presence or absence of 1U/L TSH. After a further 24 h, the
medium was removed and the cells washed and treated with selenite and TSH as on
the first medium change. The thyrocytes were then cultured for a further 4 days before
being washed twice with EBS and detached from the plate in potassium phosphate
(100mmol/L) buffer containing 1mmol/L EDTA (pH 7.4) using a rubber policeman. The
thyrocyte suspensions were sonicated and the ID-I activity assayed by measuring the
release of 125l from 125l-rT3l as described previously (11).
In the absence of TSH and selenite the activity of ID-I was very low (table 1) and a
small but significant increase in activity was observed when selenite was added to the
culture medium. In the absence of selenite the activity of ID-I was increased 20 fold on
addition of TSH. On addition of selenite a further 3 fold increase in ID-I activity was
found with a plateau of ID-I activity occurring at a selenite concentration of between 50







No TSH 22.8 ± 19.0 136.3 ± 48.2 102.3 ± 43.2
1 U/L TSH 406.7 ± 70.3 1251 ±111 1340 ± 284
The effect of dietary selenium and iodine on the activity of ID-I and GPx in the rat
Male, Hooded Lister, weanling rats of the Rowett Institute strain were divided into 4
groups and offered one of the following diets for 10 weeks : 1) selenium and iodine
supplemented control (Se+I+), 2) selenium deficient (Se-I+), 3) iodine deficient
(Se+I-), and 4) selenium and iodine deficient (Se-I-). The basal diet (Se-I-) was
prepared as described previously (12). Where appropriate, the basal diet was
supplemented with 0.1 mg Se/kg as selenite, and/or 1.0mg l/kg as potassium iodate.
Distilled water and food were available ad libitum. After 10 weeks the liver and thyroids
of the animals were removed into liquid nitrogen and kept at -70°C prior to assay of
ID-I and GPx activities in tissue homogenates. (11, 13).
In both groups of Se- animals, thyroidal GPx activity was decreased to approximately
50% of the activity found in the Se+ groups; in the livers of the same animals GPx
activity was reduced by selenium deficiency to approximately 1% of the control values.
Hepatic ID-I activity was reduced by selenium deficiency to 10% of control values but










Se+ 1+ 1054 ± 69 0.072 ± 0.0034 3915 ± 105 0.931 ± 0.0638
Se-1+ 1539 ± 134 0.035 ± 0.0024 396 ± 34 Not Detectable
Se+ 1- 1567 ± 101 0.114 ± 0.0093 3553 ± 151 1.087 ± 0.0630
Se-1- 2712 ± 196 0.055 ± 0.0027 380 ± 26 Not Detectable
Selenium uptake by cultured human thyrocytes in suspension culture
Human thyrocytes were isolated as above and allowed to recover overnight after which
time Na2(75Se03) (Amersham, Bucks, U.K.) was added to the cells (74kBq/million
cells/ml). The cells were incubated at 37°C and 400/jI aliquots were removed at
defined times. The samples were centrifuged (3500g, 5 mins) and the pellet washed
3 times with isotonic saline before counting for 75Se. In a further incubation of
thyrocytes from the same preparation, cells were incubated for 18h at 4°C after which
time a further 9h incubation was performed at 37°C.
Figure 1 shows the temperature dependence of 75Se uptake by the human thyrocytes.
Very little 75Se uptake occured at 4°C, but at 37°C the amount of 75Se associated with



















These results show that in culture, human thyroidal ID-I expression appears to be
dependent on both TSH and selenium supply. However, TSH was able to produce a
marked stimulation of ID-I activity in the absence of an extracellular supply of selenium
(table 1). In the rat the level of thyroidal ID-I activity appears to be related to the level
of plasma TSH (12) and not the selenium status of the animal (table 2). We have also
shown in the rat that the loss of GPx activity is noticeably less marked in the thyroid
than in the liver. These observations are consistent with the view that the thyroid, but
not the liver is able to retain selenium in situations where the supply of the trace
element is limited. In addition these data are also in keeping with the suggestion of
Behne that in selenium deficiency, selenium supply is diverted preferentially to
selenoproteins other than GPx (9). We have now demonstrated that ID-I is one of
these proteins.
The mechanism by which the thyroid retains selenium in situations where the supply
of the trace element is insufficient is unclear, but our observation that selenium uptake
and retention is temperature dependent (figure 1) suggests that an energy dependent
process may be involved.
This work was supported by the Wellcome Trust.
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Species Differences in Thyroidal Iodothyronine Deiodinase Expression
and the Effect of Selenium Deficiency on its Activity
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Thyroxine (T4) is commonly regarded as a prohormone
requiring 5' monodeiodination to produce the biologi¬
cally-active hormone triiodothyronine (T3). The mono¬
deiodination of T4 occurs in most tissues and is cataly¬
sed by the iodothyronine deiodinases (ID). Liver, kid¬
ney and muscle contain a type I ID (IDI) whilst brain,
pituitary and brown adipose tissue express a type II
enzyme. IDI is a selenoenzyme and synthesis of the
enzyme in liver and kidney does not occur in selenium
deficiency (1). In contrast to the type I enzyme, type II
ID is not a selenoenzyme but its expression is decrea¬
sed in selenium deficiency as a consequence of the
increased plasma T4 concentrations (2).
Under normal circumstances more than 80% of plasma
T, is derived from the action of IDI on T4 in non-thyro-
idal tissue and less than 20% of T3 is derived by de
novo synthesis in the thyroid. In iodine deficiency and
in selenium deficiency (3) the thyroid may provide an
important source of plasma Tv Thyroidal production
of T, may arise either by de novo synthesis on thyro-
globulin or by intra-thyroid deiodination of T4 (rat thy¬
roid expresses high activities of IDI) but the relative
quantitative importance of these two pathways of T.
production is unclear.
We have investigated the role that thyroidal ID may
play in T3 production in rats with normal or low seleni¬
um status and in primary culture of sheep and human
thyrocytes.
We determine IDI activity in the thyroid and liver
obtained from a number of species by using [l2:>I]
reverse T, as substrate and determining [125I] release
(Table 1). Whilst all species studied expressed IDI
activity in the liver, the activity was very low or unde¬
tectable in goat, cattle, rabbit, sheep, pig, llama and
deer with the highest activities being found in mice,
rats, guinea pigs and man. These observations were
confirmed using affinity labelling experiments with
[l25I] bromoacetyl reverse T, and were carried out as
described in (1).
In sheep thyrocytes grown in the presence or absence
of inhibitors of IDI (iopanoic acid 10~4 M) or de novo
thyroid hormone synthesis (methimazole lO-3 M) T3
production was unaffected by iopanoic acid addition
but was inhibited to 60% of control values.
Methimazole had no effect on T3 production in human
thyrocytes whilst iopanoic acid decreased the rate of T3
production to 27% of control values. These data sug¬
gest that in cultured sheep thyrocytes T3 production
arises from de novo synthesis on thyroglobulin whilst
in human thyrocytes T, production arises from deiodi¬
nation of T4 within the thyrocyte. Thus we found that
when sheep thyrocytes were grown in the presence of
Na[l25I], l25I incorporation into T3 and T4 occurred
whilst no [125I] incorporation was found in the human
system. We have, as yet, been unable to demonstrate
any effect of selenium status on T3 production in cultu¬
red human thyrocytes.
Table 1. Thyroidal IDI Activity in Various Species.





Goat, cattle, rabbit, sheep, pig, llama and deer each had activities
less than 4 fmol 1/min/mg protein.
Table 2. Effect of Se Status on Thyroid IDI and glutathione
peroxidase activity.
Se + Se -
Deiodinase 1907 ±615 1903 ±501
(fmol 1/min/mg protein)
Glutathione Peroxidase 0.184 ±0.0680 0.076 ±0.0248
IU/min protein)
Activities are shown as the mean ± SD ot' rats (fourteen per group)
fed a selenium deficient (Se-) or selenium supplemented (Se+) diet
for six weeks as described in reference 2.
J. Trace Elem. Electrolytes Health Dis. /Vol. 7 / 1993 / No. 2
Copyright © 1993 Walter de Gruvter • Berlin • New York
124 Beckett ei al.\ Thyroidal Iodothyronine Deiodinase Expression and Selenium Deficiency
Selenium deficiency in rats for six weeks from wea¬
ning had no significant effect on thyroidal IDI activity
(Table 1) whilst in the liver IDI activity was reduced to
approximately 5% of values in selenium-sufficient
rats. Similarly, selenium deficiency decreased thyro¬
idal glutathione peroxidase activity to approximately
50% of control values (Table 2) whereas in the liver the
activity was decreased to < 1% of control values.
Thus there are marked species differences in the
expression of thyroidal IDI. Consequently, in species
such as the sheep which only poorly express the thyro¬
idal IDI thyroidal deiodination of T4 cannot play an
important role in T, production. In man and the rat the
activity of thyroidal ID appears largely resistant to
changes in selenium status. This ability of the thyroid
to maintain the expression of IDI in selenium deficien¬
cy allows T4 to be produced by both de novo synthesis
and intrathyroidal deiodination of T4. In addition, the
maintenance of glutathione peroxidase activity in the
presence of selenium deficiency provides continued
protection of the thyroid from the high intracellular
levels of hydrogen peroxide which are produced by the
gland during hormone synthesis.
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INTRODUCTION
At least five selenoproteins have been identified and cloned, indicating multiple
functions for selenium in the maintenance of normal cell biochemistry (reviewed 1).
Mechanisms for the incorporation of selenocysteine into proteins have also been
recognised, further supporting the idea of specific biological and biochemical
functions for selenium (2). In addition to the functional selenoproteins already
identified, there are other selenium-containing proteins with, as yet, no recognised
function (3) These proteins have been detected by SDS-polyacrylamide gel
electrophoresis, after in vivo treatment of rats or mice with ^Se (4,5). The
identification of several selenoproteins is consistent with diverse biological functions
for the trace element and thus the multiple effects of selenium deficiency in animals
and humans.
The ability of the selenium-containing glutathione peroxidases to destroy hydrogen
peroxide and lipid peroxides in the cell is essential in the prevention of the formation
of potentially injurious-free radicals. Thus the effects of selenium deficiency which
are reversed by either selenium or vitamin E supplementation are probably related to
the antioxidant functions of the glutathione peroxidases in plasma or cell membranes
or cytosol (1,3). Such disorders include skeletal and cardiac muscle myopathies and
liver necrosis, which occur in many animal species (6). In selenium deficiency
decreases in the glutathione peroxidases at specific sites in the cell might explain
some of the diverse responses to the deficiency. However, despite this potential for
variable responses, changes in glutathione peroxidase activity cannot explain all the
effects of selenium deficiency (7-9). This has provided the impetus for the
characterisation of other biochemical functions for selenium in other metabolic
processes, and the discovery of an essential role for selenium in maintaining normal
thyroid hormone and iodine metabolism (10-13). This function is exerted via control
of the deiodinase enzymes which regulate the conversion of thyroxine (T4) to the
more metabolicaily active 3,3',5-triiodothyronine (T3). Type I iodothyronine 5'-
deiodinase (IDI) is a selenoprotein and its expression is regulated by dietary
selenium supply (10-15). Although type II iodothyronine 5'-deiodinase (IDII) is not a
selenoprotein, its activity is regulated in selenium deficiency by changes in plasma T4
concentrations (16).
SELENIUM AND THYROID HORMONES
The effects of selenium deficiency on thyroid hormone and iodine metabolism have
been reviewed in detail (12,13,17). Figure 1 gives a summary of some of these
findings which are derived mainly from experiments with rats. The left side of the
Figure 1: The effects of selenium deficiency on hyroid hormone metabolism.
Key: T2, diiodothyronine; TSH, thyroid stimulating hormone; rTs, reverse
triiodothyronine; GH, growth hormone; I, iodine.
diagram, shows the effects of selenium deficiency mediated through decreases in IDI
activity. There is decreased hepatic and renal T3 production from T4, which
contributes to increased plasma T4 and decreased plasma T3 concentrations, both
characteristic of selenium deficiency. IDI also degrades T3 to T2 and reverse T3 to T2.
This reaction is also inhibited in selenium deficiency which helps to maintain plasma
T3 concentrations (18). Increased T4 concentrations and decreased T3
concentrations may cause changes in hepatic enzyme activities which are observed
in selenium deficiency, such as the increase glutathione S-transferase levels.
However, further research is required to confirm an association between thyroid
hormones and these changes. As illustrated at the right-hand side of Figure 1,
inhibition of IDII activity decreases T3 production in the pituitary and the brain.
Selenium deficiency also decreases IDII activity in brown adipose tissue (not shown
in the diagram). Impaired T3 production in the pituitary influences the mechanisms
which control TSH production and release; thus there are increased plasma TSH
concentrations in selenium deficiency. This increase in TSH is consistent with
decreased levels of T4, Ts and iodine in the thyroid gland of selenium-deficient rats.
Additionally, the decrease in T3 formation may cause lower growth hormone
concentrations in the pituitary and thus impaired growth in selenium deficiency.
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Figure 2: The effect of dietary selenium supply on renal IDI activity in the rat.
Animals were fed semisynthetic diets (10,11) for six weeks from weaning.
Flesults are mean ± SEM, 6 animals/ group.
The data summarised in figure I were obtained with rats of a very low selenium
status; for example hepatic GSHPx activity was less than 1% of normal values. As
this severity of deficiency is rarely encountered in animals or humans, we have also
investigated the effects of more "biologically relevant" dietary selenium
concentrations on thyroid hormone metabolism. In rats, hepatic IDI activity,
determined as deiodination of rT3, increased with dietary selenium concentration
throughout the range from severely deficient (0.005 mg Se/kg diet) to adequate (0.1
mg Se/kg diet). There was no further increase in activity as dietary selenium was
increased to 0.4 mg Se/kg. IDI protein, detected by affinity labelling with 125l-
bromoacetyl-rT3 or 125!-bromoacetyl-T4, reflected the changes in IDI activity in
response to the different selenium intakes. Additionally, decreasing dietary selenium
Se in diet (mg/kg)
Figure 3: the effect of dietary selenium supply on plasma 7*3 concentrations in the
rat. Animals were fed semisynthetic diets (10,11) for six weeks from weaning.
Results are mean ± SEM, 6 animals/ group.
intake from 0.1 mg/kg diet to 0.005 mg/kg diet caused inhibition of renai IDI activity
(Figure 2) and IDII activity in both brain and brown adipose tissue . The decreases in
IDI activity caused increases in plasma T4 concentrations and lower hepatic
catabolism of T3to T2 (18 and J.R. Arthur, F. Nicol, B. Gill, Y. Guo and G.J. Beckett,
unpublished observations). As well as decreased Ts catabolism by hepatic IDI,
induction of thyroidal IDI also helps to maintain plasma T3 concentrations (13,14).
Thus plasma T3 concentrations are only decreased by 5 to 10% at very low dietary
selenium intakes (Figure3; 10,13,14), which is less than would be predicted if the
concentrations were only controlled by hepatic or renal IDI activity (see Figure 2)
CONCLUSIONS
Despite compensatory mechanisms which tend to maintain Ts production, thyroid
hormone concentrations are abnormal in plasma and organs of selenium-deficient
rats and may contribute to adverse effects of the deficiency, especially when free
radical activity is supressed by adequate vitamin E concentrations (12,13,18). As
well as in the rat thyroid, significant IDI activity occurs in the thyroids of mice, guinea
pigs and humans. Thus all these species have a potential mechanism for
maintaining plasma T3 concentrations in selenium deficiency and in hypothyroid
stress (19). However, cattle, sheep, pigs, llamas, goats, deer and rabbits have no
significant activity in the gland which cannot therefore provide T3 by deiodination
(19). If no other mechanisms exist to maintain plasma and tissue Ts concentrations
in these latter species, they may be more susceptible to thyroid-related effects of
selenium deficiency.
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Effects of combined iodine and selenium deficiency
on thyroid hormone metabolism in rats1,2
Geoffrey J Beckett, Fergus Nicol, Peter WH Rae, Stuart Beech, Yuming Guo, and John R Arthur
ABSTRACT This paper compares the effects of combined
iodine and selenium deficiency, of single deficiencies of these
trace elements, and of no deficiency on thyroid hormone me¬
tabolism in rats. In rats deficient in both trace elements, thyroidal
triiodothyronine (T3), thyroidal thyroxin (T4), thyroidal total
iodine, hepatic T4, and plasma T4 were significantly lower, and
plasma thyroid-stimulating hormone (TSH) and thyroid weight
were significantly higher than in rats deficient in iodine alone.
Plasma and hepatic T3 concentrations were similar in the dietary
groups. Hepatic type I iodothyronine deiodinase (ID-I) activity
was inhibited by selenium deficiency irrespective of the iodine
status. Type II deiodinase (ID-II) activity in the brain was sig¬
nificantly higher and in pituitary, significantly lower in combined
deficiency than in iodine deficiency alone. These data show
that selenium can play an important role in determining the
severity of the hypothyroidism associated with iodine deficiency.
Am J Clin Nutr Suppl 1993;57:240S-3S.
KEY WORDS Selenium deficiency, iodine deficiency, io¬
dothyronine deiodinase, thyroid hormones, glutathione perox¬
idase
Introduction
Iodine deficiency has profound effects on the mental and
physical development of the fetus and the child; severe iodine
deficiency may result in cretinism (1). Several adaptive processes
can protect people from the harmful effects of iodine deficiency.
The trapping of iodide is increased and intrathyroidal iodine
metabolism is modified to increase 3,3',5-triiodothyronine (T3)
production at the expense of thyroxin (T4) synthesis. These
changes in thyroid hormone metabolism are thought to be con¬
trolled by thyroid-stimulating hormone (TSH), the release of
which is triggered by a decrease in plasma T4. The result of these
modifications in thyroid hormone synthesis in iodine deficiency
is that although plasma T4 may fall to subnormal concentrations,
-plasma T3 is maintained (2).
Approximately 80% of plasma T3 is normally derived from
5'-deiodination of T4 in nonthyroidal tissues such as the liver,
"kidney, and muscle. These tissues contain a type I iodothyronine
deiodinase enzyme (ID-I) that can catalyse both 5- and 5'-mono-
deiodination of T4 and other iodothyronines (3). We demon¬
strated that ID-I is a selenoenzyme (4-7) and Berry et al (8)
cloned the enzyme, confirming the presence of selenium as a
selenocysteine residue, coded for by a uracil-guanine-adenine
(UGA) triplet, at the active site (8). The cloning data and the
results of Behne et al show that only one selenium residue is
present in the enzyme (9).
The pituitary, central nervous system, brown adipose tissue,
and brain contain a type II deiodinase (ID-II) that can perform
only 5'-deiodination (3). This enzyme is probably not a seleno¬
enzyme (10) but its expression is suppressed by high plasma
concentrations of T4 such as are found in hyperthyroidism or
selenium deficiency (3-5, 10). It has been suggested that selenium
deficiency as well as iodine deficiency may be involved in the
pathogenesis of endemic cretinism (11, 12), and that selenium
deficiency exacerbates some aspects of the hypothyroidism as¬
sociated with iodine deficiency in rats (13). This paper describes
comprehensive studies of the effects of combined iodine and
selenium deficiencies on thyroid hormone metabolism in rats.
Methods
Animals and diets
Male, Hooded Lister, weanling rats of the Rowett Institute
strain were divided into four groups and offered one of the fol¬
lowing diets for 7 wk; 1) selenium- and iodine-supplemented
control (Se+I+), 2) selenium-deficient (Se—IT-), 2) iodine-defi¬
cient (Se+I—), and 4) selenium- and iodine-deficient (Se—I—).
The basal diet (Se—I—) was prepared as described previously
with the omission of potassium iodate from the mineral mix
(4); it contained < 0.005 mg Se/kg diet and < 0.1 mg I/kg. Where
appropriate, the basal diet was supplemented with 0.1 mg Se/
kg as selenite and/or 1.0 mg I/kg as potassium iodate. Distilled
water and food were available ad libitum; food intake was re¬
corded daily and animals were weighed weekly. At the end of
the experiment, rats were anesthetized with diethyl ether, and
blood was taken into heparinized tubes by cardiac puncture.
Livers were perfused with 0.15 mol KC1/L at 4 °C, removed,
and immediately frozen in liquid nitrogen. The thyroid gland,
brain, kidney, and brown adipose tissue were also removed and
frozen immediately in liquid nitrogen.
Hormone assays
Plasma and organ T4 and T3 concentrations were measured
by radioimmunoassay (4). Free T4 was determined using a mi-
1 From the University Department of Clinical Chemistry, Royal In¬
firmary, Edinburgh, and the Division of Biochemical Sciences, Rowett
Research Institute, Aberdeen, Scotland.
2 Address reprint requests to GJ Beckett. University Department of
Clinical Chemistry, Royal Infirmary, Edinburgh EH3 9YW, UK.
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croencapsulated-antibody method (IDS Ltd, Wallsend, Tyne and
Wear, UK). Plasma TSH was assayed by radioimmunoassay by
using reagents provided by the National Institute of Arthritis,
Diabetes, and Digestive and Kidney Diseases, National Institutes
of Health, Bethesda. MD, and the Scottish Antibody Production
Unit, Carluke, Lanarkshire, UK.
Deiodinase assays
5-ID-I activity in liver was measured as the production of T3
from T4 as substrate (4). The 5-ID-I activity in liver homogenates
was determined as [,25I]-diiothyronine production from [,25I]T3
[0.37 MBq (1 yd); specific activity > 44 TBq/g > 1200 mCi/
mg); substrate and product were separated by thin-layer chro¬
matography. The 5' deiodinase activity in brain, pituitary, and
brown adipose tissue was measured by using [125I]-reverse T3 as
substrate (14).
Tissue Tj and T4 concentrations
Liver homogenates were extracted with ammoniacal meth¬
anol; thereafter, T3 and T4 were assayed in the extracts by ra¬
dioimmunoassay. The T3, T4, and iodine contents of rat thyroid
were determined as described previously (15).
Glutathione peroxidase
This was measured as described previously (16).
Statistics
Results were analyzed by ANOVA, and the residual standard
error was used to calculate the significance of the difference be¬
tween group-mean values.
Results
There were no significant differences in final body weight
among the dietary groups, nor was the food intake different (re¬
sults not shown). Iodine deficiency produced a significant in¬
crease in thyroid size and weight, but the heaviest and largest
glands were found in selenium- and iodine-deficient rats (Ta¬
ble 1).
Rats receiving either of the selenium-deficient diets had sig¬
nificantly lower hepatic glutathione peroxidase activities than
did animals receiving the diets supplemented with selenite. Iodine
deficiency had no significant effect on glutathione peroxidase
activity (Table 1).
Selenium deficiency alone caused a significant decrease in
plasma T3, but in iodine-deficient or selenium- and iodine-de¬
ficient rats, plasma T3 concentration were not significantly
changed.
Plasma total and free T4 concentrations were increased by
selenium deficiency and were decreased by iodine deficiency
compared with values in Se+I+ rats. The lowest plasma total T4
concentrations occurred in Se"I~ rats whereas free T4 was below
the detection limit of the assay in all iodine-deficient rats irre¬
spective of selenium status (Table 1).
Selenium deficiency alone had no significant effect on plasma
TSH despite the increase and decrease in plasma T4 and T3
concentrations, respectively. Iodine deficiency produced a sig¬
nificant increase in plasma TSH with concentrations as 100%
greater than that found in control animals. The highest TSH
concentrations occurred in the rats deficient in both selenium
and iodine; their concentrations were 250% greater than those
in rats deficient in iodine alone.
Hepatic 5- and 5'-ID-I activity was inhibited by selenium de¬
ficiency irrespective of the iodine status. Iodine deficiency had
no effect on hepatic 5-ID-I activity (Table 2). Selenium deficiency
significantly decreased ID-II activity in the pituitary. In iodine
deficiency, ID-II was increased in the brain but not the pituitary.
In selenium-and-iodine-deficient rats, brain ID-II activity
increased to significantly higher levels than it did in iodine
deficiency, but ID-II activity in the pituitary was decreased
(Table 2).
Hepatic T4 and T3 concentrations reflected the plasma hor¬
mone concentrations. Hepatic T4 was increased in selenium de¬
ficiency and decreased in iodine deficiency. The lowest hepatic
T4 concentrations occurred in combined selenium and iodine
deficiency. Hepatic T3 was slightly decreased in selenium defi¬
ciency, but in iodine deficiency and combined selenium and
iodine deficiency, hepatic T3 was slightly increased (Table 1).
TABLE 1
Plasma and tissue hormone concentrations and thyroid weights in selenium and iodine deficiency*
Se+I+ Se-I+ Se+I- Se-I—
Plasma
Total T4 (nmol/L) 67.20 ± 2.870 88.75 ± 1.658f 39.8 ± 2.164 33.4 ± 4.77f
Total T3 (nmol/L) 1.24 ±0.32 0.96 ±0.21 1.29 ±0.18 1.04 ±0.21
Free T4 (pmol/L) 2.56 ± 0.52 6.93 ± 0.58f ND ND
TSH (Mg/L) 0.93 + 0.11 1.28 ± 0.15t 2.69 ± 0.40f 4.35 ± 0.52f
Liver
Total T4 (ng/g liver) 14.8 ± 1.3 25.7 ± 3.2t 5.9 ± 0.54§ 2.26 ± 0.3f
Total T3 (ng/g liver) 1.80 + 0.06 1.40 ± 0.04+ 2.1 ±0.104 2.14 ± 0.154
Thyroid
Total T4 (nmol/g protein) 2545 ± 108 1905 ± 1914 228 ± 45f 6.7 ± 2.0f
Total T3 (nmol/g protein) 330 ± 16 243 ± 154 56 ± 9.7f 20 ± 3.9f
Total I (/xmol/g protein) 58.7 ± 4.9 47.9 ± 3.It 6.82 ± 0.82f 0.82 ± 0.28f
Thyroid weight (mg) 21.81 ± 1.37 22.24 ± 0.74 34.85 ± 1.774 54.13 ± 41.034
* x ± SEM. Se+I+, control; Se+I—, iodine deficient; Se—1+, selenium deficient; Se—I—, selenium and iodine deficient; ND, not detected.
+t§ Significantly different from control; tP < 0.001, %P < 0.05, §P <0.01.
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TABLE 2
Type 1 and type II deiodinase and glutathione peroxidase activity in selenium and iodine deficiency*
Se+I+ Se-I+ Se+I- Se~I—
Liver
5-ID-I (pmol T3-min~'-g protein"') 113 ±7.6 8 ± 0.8f 104 ±8.4 6 ± 3.It
5-ID-I (%)t 20.2 ±4.4 5.6 ± 2.3§ 16.6 ±2.1 7.8 ± 2.3§
Glutathione peroxidase (U/g protein) 1.44 ±0.43 0.003 ± 0.002t 1.58 ±0.13 0.004 ± 0.002f
Pituitary
ID-II (pmol Tj-min '-g protein"1) 18.04 ± 2.38 10.78 ± 1.381| 19.22 ± 3.21 13.39 ± 1.37§
Brain
ID-II (pmol r • min"1 -g protein"1) 0.678 ± 0.034 0.498 ±0.100 1.148 ± 0.172|| 1.614 ± 0.085f
x± SEM. Se+I+: control; Se+I-: iodine deficient; Se-I+: selenium deficient; Se-I-: selenium and iodine deficient.
+§|| Significantly different from control: fP < 0.001, §P < 0.05, ||P < 0.01.
% T3-to-T2 conversion.
In the thyroid of the selenium-deficient rats, there was a sig¬
nificant, « 15% decrease in T3, T4, and iodine content. Iodine
deficiency caused a > 75% decrease in iodine and hormone con¬
centrations, and combined selenium and iodine deficiency pro¬
duced the greatest decreases in thyroidal T4, T3, and iodine con¬
tent (Table 1).
Discussion
Concurrent selenium deficiency can exacerbate the goiter and
hypothyroidism associated with iodine deficiency (Table 1).
Thyroid weight, gland size, and plasma TSH were all significantly
increased in rats fed the diet deficient in both trace elements
when compared with iodine-deficient rats. Concurrent selenium
deficiency also caused a further reduction in thyroidal T3, T4,
and iodine content and plasma and hepatic T4, when compared
with iodine deficiency (P < 0.05).
In both iodine and combined iodine and selenium deficiency,
plasma and hepatic T3 concentrations did not decrease, and in
the liver, T3 concentrations slightly increased. The increases in
T3 were not reflected in hepatic malic enzyme activity, which
was decreased in iodine-deficient rats and unchanged in com¬
bined selenium and iodine deficiency. The ability of the rats
with combined iodine and selenium deficiency to maintain
plasma and tissue concentrations of T3 when hepatic ID-1 is
markedly inhibited can be explained by compensatory mecha¬
nisms. In iodine deficiency, plasma T3 concentrations are main¬
tained as a result of increased thyroidal T3 synthesis, driven by
increased plasma TSH. It has been suggested that in iodine de¬
ficiency, the major part of circulating T3 is in fact derived from
the thyroid (17). Our data support this view because when iodine
deficiency is accompanied by selenium deficiency, there is a
marked decrease in hepatic conversion of T4 to T3 but thyroidal
T4, T3, and iodine are diminished as a result of the thyroidal
hormone synthesis being stimulated by increased TSH. The
ability to maintain normal T3 concentrations in combined se¬
lenium and iodine deficiencies would be potentiated by an in¬
hibition of 5-ID-I activity because it is this reaction that is re¬
sponsible for catabolism of T3.
Thyroidal ID-I may have a role in generating the increased
production of T3 in conditions that increase plasma TSH (18).
Other data supporting this view are elevations of thyroidal ID-
I in the groups with elevated TSH (JR Arthur, GJ Beckett, S
Beech, F Nicol. and PWH Rae, unpublished observations). This
increase in thyroidal ID-I in the rats deficient in both iodine and
selenium is of interest because these data suggest that the thyroid
gland is able to retain adequate amounts of selenium for ID-I
production when the liver cannot achieve this. In selenium-de¬
ficient rats, thyroidal glutathione peroxidase activity was de¬
creased by 50% whereas hepatic glutathione peroxidase activity
was decreased to < 1% of control values (14).
Although hepatic thyroid hormone status is maintained in
combined iodine and selenium deficiency, this is not the case
for the pituitary (Table 2) and brown adipose tissue (19). In rats
with combined deficiency, plasma TSH was highest as a result
of very low plasma total and free T4 and also of a decrease in
pituitary ID-II. Similarly, the decreased concentrations of mi¬
tochondrial uncoupling protein in brown adipose tissue caused
by combined selenium and iodine deficiency in rats probably
results from decreased ID-II activity. Such deficient animals are
likely to have a diminished capacity for thermogenesis.
We did not measure an end-organ marker of function in the
brain, but in rats with combined selenium and iodine deficiencies
there was a large stimulation in brain ID-II activity. This indicates
that the brain is under a greater hypothyroid stress than in iodine
deficiency alone. The crucial question is whether this increase
in cerebral ID-II can compensate for the very low plasma T4
concentrations of combined selenium and iodine deficiency,
particularly because the brain utilizes plasma T3 very ineffec¬
tively. The mechanism behind the differential tissue effects of
combined selenium and iodine deficiencies on ID-II remains to
be resolved. ID-II is not a selenoenzyme but its expression can
be controlled by plasma T4 concentrations (10). Thus, when
plasma T4 is low, such as in iodine deficiency or combined iodine
and selenium deficiency, ID-II would be expected to increase,
and indeed this occurs in the brain; in pituitary (Table 2) and
brown adipose tissue, however, ID-II decreased.
In conclusion, our data suggest that selenium deficiency can
increase the hypothyroid stress associated with iodine deficiency
alone. Rats are able to compensate for this in tissues containing
ID-I. These tissues utilize plasma T3, and by increasing thyroidal
T3 production and decreasing peripheral catabolic 5-deiodina-
tion, T3 concentrations are maintained. Pituitary and brown
adipose tissue, which contain ID-II and require plasma T4, can¬
not compensate for the decreased plasma T4 that occurs in com¬
bined deficiencies. In contrast, in the brain, ID-II is induced by
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combined selenium and iodine deficiency, which may ameliorate
some of the potentially damaging effects of impaired thyroid
hormone metabolism. E3
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